0001520138-23-000473.txt : 20231108 0001520138-23-000473.hdr.sgml : 20231108 20231108163031 ACCESSION NUMBER: 0001520138-23-000473 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 231388362 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20230930_10q.htm FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2023
false --06-30 2023 Q1 0001580149 0001580149 2023-07-01 2023-09-30 0001580149 2023-11-06 0001580149 2023-09-30 0001580149 2023-06-30 0001580149 2022-07-01 2022-09-30 0001580149 2022-06-30 0001580149 2022-09-30 0001580149 us-gaap:CommonStockMember 2022-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001580149 bivi:TreasuryStocksMember 2022-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001580149 us-gaap:RetainedEarningsMember 2022-06-30 0001580149 us-gaap:CommonStockMember 2023-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001580149 bivi:TreasuryStocksMember 2023-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001580149 us-gaap:RetainedEarningsMember 2023-06-30 0001580149 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001580149 bivi:TreasuryStocksMember 2022-07-01 2022-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001580149 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001580149 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001580149 bivi:TreasuryStocksMember 2023-07-01 2023-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001580149 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001580149 us-gaap:CommonStockMember 2022-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001580149 bivi:TreasuryStocksMember 2022-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001580149 us-gaap:RetainedEarningsMember 2022-09-30 0001580149 us-gaap:CommonStockMember 2023-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001580149 bivi:TreasuryStocksMember 2023-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001580149 us-gaap:RetainedEarningsMember 2023-09-30 0001580149 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001580149 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001580149 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001580149 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001580149 2022-07-01 2023-06-30 0001580149 bivi:AcuitasGroupHoldingsLLCMember 2022-07-15 0001580149 us-gaap:PrimeRateMember 2023-07-01 2023-09-30 0001580149 bivi:UnearnedDiscountMember 2023-09-30 0001580149 us-gaap:FinanceReceivablesMember 2023-09-30 0001580149 bivi:LoanAccretionPremiumMember 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 us-gaap:CashMember 2023-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:USTreasuryBillSecurities1Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 us-gaap:CashMember 2023-06-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 bivi:USTreasuryBillSecurities1Member us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:USTreasuryBillSecurities1Member 2023-06-30 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2023-07-01 2023-09-30 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2022-07-01 2022-09-30 0001580149 bivi:StockOptionsMember 2023-07-01 2023-09-30 0001580149 bivi:StockOptionsMember 2022-07-01 2022-09-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember bivi:N2019OmnibusIncentiveEquityPlanMember bivi:FourDirectorsMember 2022-11-01 2022-11-23 0001580149 us-gaap:RestrictedStockUnitsRSUMember bivi:FourDirectorsMember 2022-11-01 2022-11-23 0001580149 us-gaap:RestrictedStockUnitsRSUMember bivi:N2019OmnibusIncentiveEquityPlanMember bivi:ThreeDirectorsMember 2022-11-01 2022-11-23 0001580149 us-gaap:RestrictedStockUnitsRSUMember bivi:ThreeDirectorsMember 2022-11-01 2022-11-23 0001580149 2022-11-23 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-08-01 2023-08-09 0001580149 us-gaap:SubsequentEventMember us-gaap:StockOptionMember bivi:NewEmployeeMember 2023-10-01 2023-10-03 0001580149 us-gaap:SubsequentEventMember us-gaap:StockOptionMember bivi:NewEmployeeMember srt:MinimumMember 2023-10-01 2023-10-03 0001580149 us-gaap:SubsequentEventMember us-gaap:StockOptionMember bivi:NewEmployeeMember srt:MaximumMember 2023-10-01 2023-10-03 0001580149 bivi:StockOptionsMember 2023-06-30 0001580149 bivi:StockOptionsMember 2022-07-01 2023-06-30 0001580149 bivi:StockOptionsMember 2023-09-30 0001580149 us-gaap:WarrantMember 2023-06-30 0001580149 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001580149 us-gaap:WarrantMember 2023-09-30 0001580149 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001580149 us-gaap:SubsequentEventMember bivi:SalesAgreementMember bivi:AgentMember 2023-11-01 2023-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________to _____________

 

Commission File Number: 001-39015

 

BIOVIE INC.

(Exact name of registrant as specified in its charter)

 

Nevada   46-2510769
(State or other jurisdiction of 
incorporation or organization)
  (I.R.S. Empl. Ident. No.)

 

680 W Nye Lane Suite 204
Carson City, NV 89703
(Address of principal executive offices, Zip Code)
 
(775) 888-3162
(Registrant’s telephone number, including area code)

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes                                           No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes                                           No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes                                           No

 

There were 37,742,695 shares of the Registrant’s $0.0001 par value Class A common stock outstanding as of November 6, 2023.

 

 

 

 

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION  
     
Item 1. Unaudited Financial Statements  
  Condensed Balance Sheets at September 30, 2023 and June 30, 2023 3
  Condensed Statements of Operations and Comprehensive Loss - for the three months ended September 30, 2023 and 2022 4
  Condensed Statements of Cash Flows - for the three months ended September 30, 2023 and 2022 5
  Condensed Statements of Changes in Stockholders’ Equity - for the periods from July 1, 2023 through September 30, 2023 and July 1, 2022 through September 30, 2022 6
  Notes to Unaudited Condensed Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
Item 4. Controls and Procedures 24
     
PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 25
Item 1A. Risk Factors 25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28
Item 3. Defaults Upon Senior Securities 28
Item 4. Mine Safety Disclosures 28
Item 5. Other Information 28
Item 6. Exhibits 29
     
SIGNATURES 30

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include, among others: our research and development activities and distributor channel; compliance with regulatory requirements; and our ability to satisfy our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

You are cautioned not to place undue reliance on the forward-looking statements in this report, which speak only as of the date of this report. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments, except as required by law. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

 

When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

 

2 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

BioVie Inc.

Condensed Balance Sheets

 

           
   September 30,   June 30, 
   2023   2023 
   (Unaudited)     
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents  $21,214,670   $19,460,883 
Investments in U.S. Treasury Bills   -    14,477,726 
Prepaids and other assets   1,549,287    102,526 
Total current assets   22,763,957    34,041,135 
           
Operating lease right-of-use assets, net   70,748    80,789 
Intangible assets, net   579,751    637,095 
Goodwill   345,711    345,711 
           
TOTAL ASSETS  $23,760,167   $35,104,730 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $2,714,760   $3,476,259 
Other current liabilities   -    48,385 
Current portion of operating lease liabilities   46,548    44,909 
Current portion of note payable, net of financing cost, unearned premium and discount of $661,467 at September 30, 2023 and $894,926 at June 30, 2023   9,338,533    9,105,074 
Warrant liabilities   622,397    894,280 
Embedded derivative liability   489,843    925,762 
Total current liabilities   13,212,081    14,494,669 
           
Operating lease liabilities, net of current portion   30,221    42,505 
Note payable, net of current portion, financing cost, unearned premium and  discount of $469,937 at September 30, 2023 and $227,270 at June 30, 2023   2,969,937    5,227,270 
TOTAL LIABILITIES   16,212,239    19,764,444 
           
Commitments and contingencies (Note 12)          
           
STOCKHOLDERS’ EQUITY:          
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding   -    - 
Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2023 and June 30, 2023, respectively; 36,922,760 shares issued of which 36,899,880 shares are outstanding at September 30, 2023; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023;   3,690    3,643 
Additional paid in capital   319,480,409    316,385,759 
Accumulated other comprehensive income   -    176,591 
Accumulated deficit   (311,936,169)   (301,225,705)
Treasury stock   (2)   (2)
Total stockholders’ equity   7,547,928    15,340,286 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $23,760,167   $35,104,730 

 

See accompanying notes to unaudited condensed financial statements

 

3 

 

BioVie Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

 

         
   Three Months Ended   Three Months Ended 
   September 30, 2023   September 30, 2022 
         
OPERATING EXPENSES:          
Amortization  $57,344   $57,344 
Research and development expenses   8,875,659    6,769,932 
Selling, general and administrative expenses   1,942,818    2,007,062 
TOTAL OPERATING EXPENSES   10,875,821    8,834,338 
           
LOSS FROM OPERATIONS   (10,875,821)   (8,834,338)
           
OTHER EXPENSE (INCOME):          
Change in fair value of derivative liabilities   (707,802)   566,542 
Interest expense   1,004,668    1,056,416 
Interest income   (462,223)   (41,585)
TOTAL OTHER (INCOME) EXPENSE, NET   (165,357)   1,581,373 
           
NET LOSS  $(10,710,464)  $(10,415,711)
           
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS  $(10,710,464)  $(10,415,711)
           
NET LOSS PER COMMON SHARE          
- Basic  $(0.29)  $(0.38)
- Diluted  $(0.29)  $(0.38)
           
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING          
- Basic   36,742,812    27,212,445 
- Diluted   36,742,812    27,212,445 
           
NET LOSS  $(10,710,464)  $(10,415,711)
           
Other comprehensive loss          
Reclassification of unrealized gains on available-for-sale investments upon settlement   (176,591)   - 
Total other comprehensive loss   (176,591)   - 
Comprehensive loss  $(10,887,055)  $(10,415,711)

 

See accompanying notes to unaudited condensed financial statements

 

4 

 

BioVie Inc.

Condensed Statements of Cash Flows

(Unaudited) 

 

           
   Three Months Ended   Three Months Ended 
   September 30, 2023   September 30, 2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(10,710,464)  $(10,415,711)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of intangible assets   57,344    57,344 
Stock based compensation - restricted stock units   380,834    17,537 
Stock based compensation expense - stock options   808,027    878,640 
Amortization of financing costs   37,825    42,554 
Accretion of unearned loan discount   355,877    400,361 
Accretion of loan premium   82,424    143,813 
Realized gain on maturity of available-for sale   (223,865)     
Change in operating lease right-of-use assets   10,041    8,983 
Change in fair value of derivative liabilities   (707,802)   566,542 
Changes in operating assets and liabilities:          
Prepaids and other assets   (1,446,761)   (221,244)
Accounts payable and accrued expenses   (761,499)   179,530 
Operating lease liabilities   (10,645)   (9,213)
Other liabilities   (48,385)   (869,456)
Net cash used in operating activities   (12,177,049)   (9,220,320)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Maturity of U.S. Treasury Bills   14,525,000    - 
Net cash provided by investing activities   14,525,000    - 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Net proceeds from issuance of common stock   1,905,836    5,903,682 
Payment of note payable   (2,500,000)   - 
Net proceeds from issuance of common stock - Related Party   -    5,905,840 
Net cash (used in) provided by financing activities   (594,164)   11,809,522 
           
Net increase in cash and cash equivalents   1,753,787    2,589,202 
           
Cash and cash equivalents, beginning of period   19,460,883    18,641,716 
           
Cash and cash equivalents, end of period  $21,214,670   $21,230,918 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $528,541   $469,687 
           
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:           
Reclassification of unrealized gains on available-for-sale investments upon settlement  $176,591   $-  

 

See accompanying notes to unaudited condensed financial statements

 

5 

 

BioVie Inc.

Condensed Statements of Changes in Stockholders’ Equity

(Unaudited)

 

                                         
                       Accumulated         
           Additional           Other       Total 
   Common Stock   Common Stock   Paid in   Treasury Stock   Treasury Stock   Comprehensive   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Shares   Amount   Income   Deficit   Equity 
                                 
Balance, June 30, 2022   24,984,083   $2,496   $254,638,329    -   $-   $-   $(250,969,890)  $3,670,935 
                                         
Stock option based compensation   -    -    878,640    -    -    -    -    878,640 
                                         
Stock-based compensation - restricted stock units   -    -    17,537    -    -    -    -    17,537 
                                         
Proceeds from issuance of common stock, net of costs of $368,370   1,544,872    155    5,903,527    -    -    -    -    5,903,682 
                                         
Proceeds from issuance of common stock, net of costs of $94,160 - Related Party   3,636,364    364    5,905,476    -    -    -    -    5,905,840 
                                         
Net loss   -    -    -    -    -    -    (10,415,711)   (10,415,711)
                                         
Balance, September 30, 2022   30,165,319   $3,015   $267,343,509    -    -    -   $(261,385,601)  $5,960,923 
                                         
Balance, June 30, 2023   36,451,829   $3,643  $316,385,759    (22,880)  $(2)  $176,591   $(301,225,705)  $15,340,286 
                                         
Stock - based compensation - stock options   -    -    808,027    -    -    -    -    808,027 
                                         
Stock-based compensation - restricted stock units   -    -    380,834    -    -    -    -   380,834 
                                         
Proceeds from issuance of common stock, net of costs of $118,891   432,201    43    1,905,793    -    -    -    -   1,905,836 
                                         
Issuance of common stock from vesting of - restricted stock units   38,730    4    (4)   -    -    -    -   - 
                                         
Net loss   -    -    -    -    -    -    (10,710,464)  (10,710,464)
                                         
Reclassification of unrealized gains on available for sale investments upon settlement   -    -    -    -    -    (176,591)   -   (176,591)
                                         
Balance, September 30, 2023   36,922,760   $3,690   $319,480,409    (22,880)  $(2)  $-   $(311,936,169)  $7,547,928 

 

See accompanying notes to unaudited condensed financial statements

 

6 

 

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2023 and 2022

(unaudited)

 

1. Background Information

 

BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. 

 

The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), from a related party privately held clinical-stage pharmaceutical company, in June 2021. The acquired assets included NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase (“ERK”) signaling that, based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), and NE3107 could, if approved represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD.

 

Late in September 2023, the final patient completed the last treatment at week 30 in the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients who have mild to moderate Alzheimer’s disease. The database cleaning process remains underway, with the clinical team resolving outstanding queries and entering final data into the electronic data system. Final database lock, unblinding and subsequent release of topline results is anticipated to occur during the fourth quarter of calendar year 2023.

 

The Company completed its Phase 2 study assessing NE3107 in PD patients in the fourth quarter of calendar year 2022. The NM201 study (NCT05083260) was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. The study was primarily designed to assess safety (general safety in the patient population and potential for drug-drug interactions of NE3107 with levodopa); and secondary, to look for indications of promotoric activity akin to promotoric activity and apparent enhancement of levodopa activity observed in preclinical models. Both the safety and efficacy objectives of the study were met.

 

Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD frontotemporal lobar dementia, and Amyotrophic lateral sclerosis (ALS). NE3107 is an orally bioavailable, blood-brain permeable, small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea.  

 

The Company’s Orphan Drug candidate BIV201 (continuous infusion terlipressin), has been granted Fast Track designation status by the U.S. Food and Drug Administration (“FDA”), is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The Phase 2b study was closed before full enrollment, without clinically meaningful adverse effects associated with BIV201 treatment. While the active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, treatment of ascites is not included in these authorizations. Patients with refractory ascites suffer from frequent life-threatening complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The FDA has not approved any drug to treat refractory ascites.

 

The BIV201 development program was initiated by LAT Pharma LLC (“LAT Pharma”). On April 11, 2016, the Company acquired LAT Pharma and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin), if approved, to be shared by the members of LAT Pharma, PharmaIn Corporation and The Barrett Edge, Inc.

 

7 

 

2. Liquidity

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2023, the Company had working capital of approximately $9.6 million, cash and cash equivalents totaling of approximately $21.2 million, stockholders’ equity of approximately $7.5 million, and an accumulated deficit of approximately $311.9 million. The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Although our cash balance may possibly sustain operations over the next 12 months from the balance sheet date if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company’s development of next phase clinical programs, the Company’s current planned operations to meet certain goals and objectives, project cash flows to be depleted within that period of time.

 

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.

 

Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

 

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2023 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2023 and 2022 in our Annual Report on Form 10-K filed with the SEC on August 16, 2023 (the “2023 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2023 Form 10-K.

 

8 

 

Net loss per Common Share

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, par value $0.0001 per share (“common stock”), outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and restricted stock units. For the three months ended September 30, 2023 and 2022, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods.

 

The table below shows the number of outstanding stock options, warrants and restricted stock units as of September 30, 2023 and 2022:

 

          
   September 30, 2023   September 30, 2022 
   Number of Shares   Number of Shares 
Stock Options   3,952,864    3,348,330 
Warrants   7,770,285    7,779,194 
Restricted Stock Units   557,727    124,520 
Total   12,280,876    11,252,044 

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations and comprehensive loss since the 2023 Form 10-K.

 

Cash and cash equivalents

 

Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.

 

Investments in U.S. Treasury Bills

 

Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gain were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Upon the maturity and settlement of these investments, realized gains were recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.

 

Concentration of Credit Risk in the Financial Service Industry

 

As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.

 

Fair value measurement of assets and liabilities

 

We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:

 

9 

 

Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2 – Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

 

Level 3 – Inputs are unobservable inputs based on our assumptions.

 

The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities, notes payable and other derivative liabilities (see Note 9). The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.

 

4.Investments in U.S. Treasury Bills Available for Sale

 

The following is a summary of the U.S. Treasury Bills held at June 30, 2023:

 

                
   Amortized Cost
Basis
   Gross Unrealized
Gain
   Fair Value   Total Accumulated
Other
Comprehensive
Income
 
U.S. Treasury Bills due is 3 - 6 months  $14,301,136   $176,591   $14,477,726   $176,591 

 

During the fiscal year ended June 30, 2023, the Company purchased a total of approximately $46 million of U.S. Treasury Bills during the year ended June 30, 2023. All outstanding investments in U.S. Treasury Bills available for sale held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $223,865 recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.

 

5.Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma and are amortized over their estimated useful lives.

 

The following is a summary of the Company’s intangible assets:

 

        
   September 30, 2023   June 30, 2023 
         
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,714,019)   (1,656,675)
Intellectual Property, Net  $579,751   $637,095 

 

Amortization expense was $57,344 in each of the three-month periods ended September 30, 2023 and 2022. The Company amortizes intellectual property over the expected, original useful lives of 10 years.

 

Estimated future amortization expense is as follows:

 

     
Year ending June 30, 2024 (Remaining 9 months)  $172,033 
2025   229,377 
2026   178,341 
   $        579,751 

 

10 

 

6. Related Party Transactions

 

Equity Transactions with Acuitas

 

On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 3,636,364 shares of the Company’s Common Stock, at a price of $1.65 per share (the “PIPE Shares”), and (ii) a warrant to purchase 7,272,728 shares of Common Stock (“PIPE Warrant Shares”), at an exercise price of $1.82, with a term of exercise of five years. The warrant has a down round feature that reduces the exercise price of the warrant if the Company sells stock at a price lower than the exercise price of the warrant. On August 15, 2022, the Company received net proceeds of approximately $5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the “Existing Registration Rights Agreement”), to amend the definition of “Registrable Securities” in the Existing Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.

 

7. Other Liabilities

 

The current portion of other liabilities at June 30, 2023 was approximately $48,000 and represented the remaining balance of a retention bonus payable for arrangements with certain employees, which was paid in July 2023. 

 

8. Notes Payable

 

On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan provided for an additional $5 million to be available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.00% plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at September 30, 2023 was 8.50%. The Loan is secured by a lien upon and security interest in all of the Company’s assets, including intellectual property, subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.

 

The Loan Agreement required monthly interest-only payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and Tranche 2.

 

The Loan Agreement includes a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $6.98 per share.

 

On the Closing Date, the Company issued to Avenue warrants to purchase 361,002 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $5.82. The Avenue Warrants are exercisable until November 30, 2026.

 

The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes; approximately $1.4 million to the fair value of the Avenue Warrants and approximately $2.2 million to the fair value of the embedded conversion option. Accordingly, the total amount of unearned discount of approximately $3.6 million, the total direct financing cost of approximately $390,000 and premium of $850,000 are recognized on an effective interest method over the term of the Loan. The adjusted effective interest rate is 25%. The total interest expense of approximately $1 million for the three months ended September 30, 2023, was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest only payments totaling approximately $525,000, the amortization of financing costs of approximately $38,000, unearned discount of approximately $356,000 and the accretion of loan premium of approximately $82,000.

 

The total interest expense of approximately $1.1 million for the three months ended September 30, 2022; was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest payments totaling approximately $470,000, the amortization of financing costs of approximately $43,000, unearned discount of approximately $400,000 and the accretion of loan premium totaled of approximately $144,000.

 

As of September 30, 2023, the remaining principal balance of $12.5 million under the Loan is payable in 15 monthly equal installments. For the three months ended September 30, 2023, the Company paid back $2.5 million of the original loan of $15 million.

 

11 

 

The following is a summary of the Notes Payable as of September 30, 2023 and June 30, 2023:

 

Current portion of Notes Payable

 

          
   September 30, 2023   June 30, 2023 
         
Current portion of Notes Payable  $10,000,000   $10,000,000 
Less debt financing costs   (80,381)   (108,751)
Less unearned discount   (756,238)   (1,023,145)
Plus accretion of loan premium   175,152    236,970 
Current portion of Notes Payable, net of financing costs, unearned premiums and discount  $9,338,533   $9,105,074 

 

Non-current portion of Notes Payable

 

   September 30, 2023   June 30, 2023 
         
Notes Payable  $2,500,000   $5,000,000 
Less debt financing costs   (2,365)   (11,820)
Less unearned discount   (22,242)   (111,212)
Plus accretion of loan premium   494,544    350,302 
Notes Payable, net of the current portion financing costs, unearned premiums and discount  $2,969,937   $5,227,270 

 

Estimated future amortization expense and accretion of premium is as follows:

 

            
   Unearned Discount   Debt Financing
Costs
   Loan accretion
Premium
 
             
Year ending June 30, 2024 (Remaining 9 months)  $667,268   $70,926   $154,546 
2025   111,212    11,820    25,758 
Total  $778,480   $82,746   $180,304 

 

12 

 

9.Fair Value Measurements

 

At September 30, 2023 and June 30, 2023, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

 

                 
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $622,397   $622,397 
Derivative liability - Conversion option on notes payable   -    -    489,843    489,843 
Total derivatives  $         -   $        -   $1,112,240   $1,112,240 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $894,280   $894,280 
Derivative liability - Conversion option on note payable           -          -    925,762    925,762 
Total derivatives  $-   $-   $1,820,042   $1,820,042 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2023: 

 

          
   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2023  $894,280   $925,762 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   (271,883)   (435,919)
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2023  $622,397   $489,843 

 

13 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2022:

 

   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2022  $194,531   $188,030 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   248,061    318,481 
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2022  $442,592   $506,511 

  

The fair values of derivative liabilities for the Avenue Warrants and the conversion option at September 30, 2023 in the accompanying condensed balance sheet, were approximately $622,000 and approximately $490,000, respectively. The total change in the fair value of the derivative liabilities totaled approximately $708,000 for the three months ended September 30, 2023; and accordingly, was recorded in the accompanying condensed statement of operations and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at September 30, 2023 included the closing stock price of $3.41 per share; for the Avenue Warrants, the exercise price of $5.82, remaining term 3.2 years, risk free rate of 4.8% and volatility of 92.0%; and for the embedded derivative liability of the conversion option, the conversion price of $6.98; remaining term 1.17 years, risk free rate of 5.39% and volatility of 93.0%.

 

Derivative liability – Avenue Warrants

 

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet and anti-dilution provisions or adjustments to the strike price due to an occurrence of a future event are accounted for as derivative financial instruments. The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompany condensed balance sheet at September 30, 2023.

 

The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at their fair values at the date of issuance and remeasured at September 30, 2023.

 

Embedded derivative liability – Conversion Option

 

The embedded derivative liability represents the optional conversion feature of up to $5.0 million of the outstanding Loan, which meets the definition of a derivative and requires bifurcation from the loan amount.

 

The Black Scholes model was used to calculate the fair value of the embedded derivative to bifurcate the embedded derivative amount representing the conversion option from the Avenue Loan amount funded.

 

Financial assets

 

As of September 30, 2023, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1.

 

14 

 

The following table presents information about our assets that are measured at fair value on a recurring basis.

 

                
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $7,764,886   $-   $-   $7,764,886 
U.S. Treasury Bills due in 3 months or less at purchase   13,449,784        -         -    13,449,784 
U.S. Treasury Bills due in 3 - 6 months at purchase   -    -    -    - 
Total  $21,214,670   $-   $-   $21,214,670 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $6,304,543   $-   $-   $6,304,543 
U.S. Treasury Bills due in 3 months or less at purchase   13,156,340            -            -   13,156,340 
U.S. Treasury Bills due in 3 - 6 months at purchase   14,477,726    -    -   14,477,726 
Total  $33,938,609   $-   $-   $33,938,609 

 

15 

 

10. Equity Transactions

 

 

Issuance of common stock for cash

 

On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the three months ended September 30, 2023, the Company sold 432,201 shares of common stock under the Sales Agreement for total net proceeds of $1.9 million after 3% commissions and expenses of approximately $119,000. During the three months ended September 30, 2022, the Company sold 1,544,872 shares of common stock under the Sales Agreement for total net proceeds of $5.9 million after 3% commissions and expenses of approximately $400,000.

 

Stock Options

 

The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2023:

 

                    
   Options   Weighed-
Average
Exercise
Price
   Weighted
Remaining
Average
Contractual
Term
   Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2023   3,952,864   7.10    6.3   1,067,966 
Outstanding at September 30, 2023   3,952,864   7.10    6.0   477,247 
Exercisable at September 30, 2023   1,689,339   $7.64    5.5   $154,404 

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. No stock options were issued, expired, canceled or exercised during the three months ended September 30, 2023.

 

The total stock option-based compensation expense for three-months ended September 30, 2023 and 2022 was of $808,027 and $878,640, respectively.

 

16 

 

Issuance of restricted stock units and options :

 

On November 23, 2022, the Company issued equity awards for the board of directors’ annual compensation. Four directors received restricted stick units (“RSUs”) to purchase a total of 155,636 shares of common stock at the grant date fair value of $6.12 per share, a total cost of $952,492 recognized as stock compensation in the three months ended December 31, 2022. Three directors received stock options to purchase 195,000 shares of common stock at an exercise price of $6.12 per share, the grant date fair value. The total stock compensation cost of stock options of $791,700 was recognized in the three months ended December 31, 2022. The equity awards vest every three months beginning from the last annual shareholders’ meeting on November 9, 2022, on February 9, 2023, May 9, 2023, August 9, 2023 and earlier of November 9, 2023 or the next annual shareholders’ meeting. While the agreements contain certain contractual vesting terms, there are circumstances where the vesting can be accelerated that is not within the Company’s control and as a result, for accounting purposes, the awards are assumed to have been fully vested on the grant date, accordingly, the Company recognized the total compensation cost of $1,744,192 on November 23, 2022. On August 9, 2023, the Company delivered the vested portion and issued 38,730 shares of common stock.

 

The following table summarizes vesting of restricted common stock:

 

        
   Number of
Shares
   Weighted
Average
Grant
Date Fair
Value
Per
Share
 
         
Unvested at June 30, 2023   596,457   $5.24 
Vested   (38,730)   6.12 
Unvested at September 30, 2023   557,727   $5.40 

 

The total stock based compensation – restricted stock expense for three-months ended September 30, 2023 and 2022 was of $380,834 and $17,537, respectively.

 

Issuance of Stock Options under the 2019 Omnibus Plan.

 

On October 3, 2023, the Company granted stock options to purchase 211,167 shares of Common Stock to new hire employees. 20% of the shares underlying the options awarded vest on the one-year anniversary of the grant date, and the remaining 80% will vest in equal monthly installments over 48 months each month thereafter. The exercise price of the options is $3.41 per share and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are fully exercised.

 

17 

 

Stock Warrants

 

The following table summarizes warrant activity during the three months ended September 30, 2023:

 

                    
   Number of
Shares
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding and exercisable at June 30, 2023   7,770,285   $2.06    4.0   $18,318,954 
Outstanding and exercisable at September 30, 2023   7,770,285   $2.06    3.8   $11,682,257 

 

Of the above warrants, 101,380 expire in the fiscal year ending June 30, 2025, 35,175 expire in the fiscal year ending June 30, 2026, and 7,633,730 expire in the fiscal year ending June 30, 2027. No warrants were granted, expired, or were exercised during the three months ended September 30, 2023.

 

18 

 

11. Leases

 

Office Lease

 

The Company pays an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 897603. The rental agreement was for a one-year term and commenced on October 1, 2022 and has been subsequently renewed for another year at the same rate.

 

On February 26, 2022, the Company’s San Diego office relocated to 5090 Shoreham Place, San Diego, CA 92122. The term for the office lease is 38 months and commenced on March 1, 2022. The monthly base rate currently is $4,300, with annual increases of three percent.

 

Total operating lease expense of approximately $13,000 and $13,000 for the three months ended September 30, 2023 and 2022, respectively; were included in the accompanying condensed statements of operations and comprehensive loss as a component of selling, general and administrative expenses.

 

The right-of-use asset, net and current and non current portion of the operating lease liabilities included in the accompany condensed balance sheets are as follows:

 

          
   September 30, 2023   June 30, 2023 
Assets          
Operating lease, right-of-use asset, net  $70,748   $80,789 
           
Liabilities          
Current portion of operating lease liabilities  $46,548   $44,909 
Operating lease liabilities, net of current portion   30,221    42,505 
Total operating lease liabilities  $76,769   $87,414 

 

At September 30, 2023, the future estimated minimum lease payments under non-cancelable operating leases are as follows:

 

      
Year ending June 30, 2024 (Remaining 9 months)  $39,256 
2025  44,636 
Total minimum lease payments   83,892 
      
Less amount representing interest   (7,123)
Present value of future minimum lease payments   76,769 
      
Less current portion of operating lease liabilities   (46,548)
Operating lease liabilities, net of current portion  $30,221 

 

Total cash paid for amounts included in the measurement of lease liabilities were $12,900 and $12,525 for the three months ended September 30, 2023 and 2022, respectively.

 

19 

 

The weighted average remaining lease term and discount rate as of September 30, 2023 and June 30, 2023 were as follows:

 

        
   September 30, 2023   June 30, 2023 
         
Weighted average remaining lease term (Years)          
Operating leases   1.5    1.8 
Weighted average discount rate          
Operating leases   10.75%   10.75%

 

12. Commitments and Contingencies

 

Royalty Agreements

 

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

 

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year.

 

13. Employee Benefit Plan

 

On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate.

 

Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan., The Company made contributions of approximately $30,900 and $45,500, for the three months ended September 30, 2023 and 2022, respectively.

 

14. Subsequent Events

 

Subsequent to September 30, 2023, the Company sold 819,935 shares of common stock for net proceeds of $3.5 million net of 3% commission and expenses totaling approximately $105,000 under the Sales Agreement with the Agent.

 

20 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include, among others: our research and development activities and distributor channel; compliance with regulatory requirements; and our ability to satisfy our capital needs Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. 

 

You are cautioned not to place undue reliance on the forward-looking statements in this report, which speak only as of the date of this report. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments, except as required by law. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission (the “SEC”) that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. 

 

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this report. 

 

Management’s Discussion

 

BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. 

 

The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), a privately held clinical-stage pharmaceutical company, in June 2021. The acquired assets included NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase (ERK) signaling that, based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), and NE3107 could, if approved represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD. Late in September 2023, the last patient completed the last treatment at week 30 in the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients who have mild to moderate Alzheimer’s disease. The database cleaning process remains underway, with the clinical team resolving outstanding queries and entering final data into the electronic data system. Final database lock, unblinding, and subsequent release of topline results is anticipated to occur during the fourth quarter of calendar year 2023.

 

The Phase 2 study of NE3107 in Parkinson’s disease (“PD”) (NCT05083260), completed in December 2022 was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. Forty-five patients with a defined L-dopa “off state” were randomized 1:1 to placebo:NE3107 20 mg twice daily for 28 days. This trial was launched with two design objectives: 1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to demonstrate the absence of adverse interactions of NE3107 with levodopa; and 2) the secondary objective is to determine if preclinical indications of promotoric activity and apparent enhancement of levodopa activity can be seen in humans. Both objectives were met. The Company continues to process its findings from its completed study as it prepares for the next round of clinical studies in PD.  

 

Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and Amyotrophic lateral sclerosis (ALS). NE3107 is an oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea. 

 

The Company’s Orphan Drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track designation status, is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The Phase 2b study was closed before full enrollment, without clinically meaningful adverse effects associated with BIV201 treatment. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. 

 

21 

 

Comparison of the three months ended September 30, 2023 to the three months ended September 30, 2022

 

Net loss

 

The net loss for the three months ended September 30, 2023, was approximately $10.7 million and was comparable to the net loss of $10.4 million for the three months ended September 30, 2022. The increase in net loss was comprised of increased research and development expenses of $2.1 million offset from a decrease in selling, general and administrative expenses of approximately $64,000, an increase in interest income of approximately $420,000 and the change in the fair value of derivative liabilities of $1.3 million for the three months ended September 30, 2023 from the three months ended September 30, 2022.

 

Total operating expenses for the three months ended September 30, 2023, were approximately $10.9 million as compared to $8.8 million for the three months ended September 30, 2022. The net increase of approximately $2.1 million for the three months ended September 30, 2023 was comprised of increased research and development expenses of approximately $2.1 million offset by a decrease in selling general and administrative expenses of approximately $64,000.

 

Research and Development Expenses

 

Research and development expenses were approximately $8.9 million and $6.8 million for the three months ended September 30, 2023, and 2022, respectively. The net increase of approximately $2.1 million, represented an approximate decline of $1.4 million in expenses from the completion of the PD Phase 2 and Ascites Phase 2b studies and the near completion of the AD Phase 3, offset by increased expenditures of $1.7 million related to development of next clinical studies and other research; increased expenses attributed to publication of our abstracts and posters presented at various conferences totaling approximately $172,000, and increased expenses in Chemistry, Manufacturing and Control of approximately $46,000 and the Clinical Teams compensation of approximately $1.5 million. The total clinical team employee and outside consultants’ compensation increased by approximately $780,000 and $712,000, respectively; for the three months ended September 30 2023; representing an increase in the employee headcount by 7 to 15 and the expanded use in the number of outside consultants.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were approximately $1.9 million and $2.0 million for the three months ended September 30, 2023, and 2022, respectively. The net decrease of approximately $64,000 was primarily attributed to decline in directors stock compensation of approximately $313,000,and other professional and advisory fees of $37,000 offset by general administrative compensations of $31,000, increased legal fees of $155,000, other consultants of approximately $58,000 and insurance expenses of approximately $41,000.

 

Other Income and Expense

 

Other income, net was approximately $165,000 compared to other expense, net of $1.6 million, for the three months ended September 30, 2023 and 2022, respectively. The net increase in other income of approximately $1.8 million represented change in fair value of the related derivative liabilities of approximately $1.3 million, and increase in interest income of approximately $420,000 which was primarily comprised of $223,865 realized gain on settlement of investments in U.S. Treasury Bills.

 

22 

 

Capital Resources and Liquidity

 

As of September 30, 2023 the Company had working capital of approximately $9.6 million, cash and cash equivalents totaling approximately $21.2 million, stockholders’ equity of approximately $7.5 million, and an accumulated deficit of approximately $311.9 million.

 

During the three months ended September 30, 2023, the Company sold approximately 432,000 shares of its Common Stock under its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co for total net proceeds of approximately $1.9 million after 3% commissions and offering costs totaling approximately $119,000.

 

The Company has not generated any revenue and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.

 

Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Critical Accounting Policies and Estimates

 

For the three-month period ended September 30, 2023, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2023.  

 

23 

 

New Accounting Pronouncements

 

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations and comprehensive loss.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable to smaller reporting companies.

 

Item 4. Controls and Procedures

 

We maintain “disclosure controls and procedures.” Such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also are based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

24 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

To our knowledge, neither the Company nor any of its officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

 

Item 1A. Risk Factors

 

Except as described below, there have been no material changes to the Risk Factors previously disclosed in our Form 10-K. The risks described in our Form 10-K and below are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results.

 

Risks Relating to Our Business and Industry

 

We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or do not successfully perform and comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize our product candidates.

 

We depend, and will continue to depend, on contract research organizations (“CROs”), clinical trial sites and clinical trial principal investigators, contract laboratories, and other third parties to conduct our clinical trials. We rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the protocol and applicable legal, regulatory, and scientific standards and regulations, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with current good clinical practices (“cGCPs”), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for the conduct of clinical trials on product candidates in clinical development. Regulatory authorities enforce cGCPs through periodic inspections and for-cause inspections of clinical trial principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs or fail to enroll a sufficient number of patients, we may be required to conduct additional clinical trials to support our marketing applications, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal, state, or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, or provide us or government agencies with inaccurate, misleading, or incomplete data. For example, during routine monitoring of blinded data from our Phase 3 study (NCT04669028) of NE3107, we uncovered what appears to be potential scientific misconduct and significant non-compliance with GCPs and regulation at six sites. We have alerted the FDA’s Office of Scientific Integrity (“OSI”) about these issues and believe OSI will perform a thorough, competent, objective and fair research of any potential scientific misconduct and non-compliance of GCPs and regulation. Sensitivity analysis excluding data from these six problematic sites has been performed and accounted for in the statistical analysis plan for the study (NCT04669028). Nonetheless, these findings of potential scientific misconduct and significant GCP violations may call into question the rigor, robustness and validity of the entire data set for this study (NCT04669028) and may require additional clinical studies to confirm the final results of the study.

 

Although we design the clinical trials for our product candidates, our CROs are tasked with facilitating and monitoring our clinical trials. As a result, many important aspects of our clinical development programs, including site and investigator selection, and the conduct and timing and monitoring of the study, will be partly or completely outside our direct control. Our reliance on third parties to conduct clinical trials also results in less direct control over the collection, management, and quality of data developed through clinical trials than would be the case if we were relying entirely upon our own employees. Communicating with third parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities.

 

Successful development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control.

 

Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons. Pre-clinical study results may show the product candidate to be less effective than desired (e.g., the study failed to meet its primary endpoints) or to have harmful or problematic side effects. Product candidates may fail to receive the necessary regulatory approvals or may be delayed in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies; length of time to achieve study endpoints; additional time requirements for data analysis; IND and later NDA preparation; discussions with the FDA; an FDA request for additional pre-clinical or clinical data; unexpected safety or manufacturing issues; manufacturing costs; pricing or reimbursement issues; clinical sites deviating from the trial protocol, committing scientific misconduct, or other violations of regulatory requirements – which can render data from those sites unusable in support of regulatory approval; or other factors that make the product not economical. Proprietary rights of others and their competing products and technologies may also prevent the product from being commercialized.

 

25 

 

Success in pre-clinical and early clinical studies does not ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product to the next, and may be difficult to predict. There can be no assurance that any of our products will develop successfully, and the failure to develop our products will have a materially adverse effect on our business and will cause you to lose all of your investment.

 

Adverse Developments Affecting the Financial Services Industry and Concentration of Risk

 

As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.

 

26 

 

Risks Relating To Our Common Stock

 

You may experience future dilution as a result of future equity offerings or if we issue shares subject to options, warrants, stock awards or other arrangements.

 

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock, including under the Controlled Equity Offering Sales Agreement (the “Sales Agreement”), dated as of August 31, 2022, with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may issue and sell from time to time shares of common stock through the Agent. We may sell shares or other securities in any other offering at a price per share that is less than the current market price of our securities, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The sale of additional shares of common stock or other securities convertible into or exchangeable for our common stock would dilute all of our stockholders, and if such sales of convertible securities into or exchangeable into our common stock occur at a deemed issuance price that is lower than the current exercise price of our outstanding warrants sold to Acuitas Group Holdings, LLC (“Acuitas”) in August 2022, the exercise price for those warrants would adjust downward to the deemed issuance price pursuant to price adjustment protection contained within those warrants.

 

In addition, as of September 30, 2023, there were warrants outstanding to purchase an aggregate of 7,770,285 shares of common stock at exercise prices ranging from $1.82 to $12.50 per share and 3,952,864 shares issuable upon exercise of outstanding options at exercise prices ranging from $1.69 to $42.09 per share and restricted stock units totaling 557,727. Our Loan Agreement entered into on November 30, 2021 contains a conversion feature whereby at the option of lender, up to $5 million of the outstanding loan amount may be converted into shares of common stock at a conversion price of $6.98 per share. We may grant additional options, warrants or equity awards. To the extent such shares are issued, the interest of holders of our common stock will be diluted.

 

Moreover, we are obligated to issue shares of common stock upon achievement of certain clinical, regulatory and commercial milestones with respect to certain of our drug candidates (i.e., NE3107, NE3291, NE3413, and NE3789) pursuant to the asset purchase agreement, dated April 27, 2021, by and among the Company, NeurMedix, Inc. and Acuitas, as amended on May 9, 2021. The achievement of these milestones could result in the issuance of up to 18 million shares of our common stock, further diluting the interest of holders of our common stock.

 

Certain stockholders who are also officers and directors of the Company may have significant control over our management.

 

As of September 30, 2023, our directors and executive officers and affiliates currently own aggregate 23,587,296 shares of our Common Stock, which currently constitutes 64.0% of our issued and outstanding Common Stock. As a result, directors and executive officers and affiliates may have a significant influence on our affairs and management, as well as on all matters requiring member approval, including electing and removing members of our Board of Directors, causing us to engage in transactions with affiliates entities, causing or restricting our sale or merger, and certain other matters. Our majority shareholder, Mr. Terren Peizer, may be deemed to beneficially own the 23,166,210 shares of Common Stock held by Acuitas, which constitutes 63.0% of our issued and outstanding Common Stock Such concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even when such a change of control would be in the best interests of our stockholders. 

 

27 

 

We may, in the future, issue additional common stock, which would reduce investors’ percent of ownership and may dilute our share value.

 

As of September 30, 2023, our Articles of Incorporation, as amended, authorize the issuance of 800,000,000 shares of Common Stock, and we had 36,922,760 shares of Common Stock issued and 36,899,880 issued and outstanding. Accordingly, we may issue up to an additional 763,100,120 shares of Common Stock. The future issuance of Common Stock may result in substantial dilution in the percentage of our Common Stock held by our then existing stockholders. We may value any Common Stock in the future on an arbitrary basis. The issuance of Common Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors, might have an adverse effect on any trading market for our Common Stock and could impair our ability to raise capital in the future through the sale of equity securities.

 

Item 2. Unregistered sales of equity securities

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information

 

None 

28 

 

Item 6. Exhibits

 

(a) Exhibit index

 

Exhibit

 

31.1*   Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
     
31.2*   Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
     
32.1**   Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2**   Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document

 

* Filed herewith.
   
** Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

29 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioVie Inc.,

 

Signature   Titles   Date
         
/s/ Cuong V Do        
Cuong V Do   Chairman and Chief Executive Officer (Principal Executive Officer)   November 8, 2023
         
/s/ Joanne Wendy Kim        
Joanne Wendy Kim   Chief Financial Officer (Principal Financial and Accounting Officer)   November 8, 2023

 

30 

 

EX-31.1 2 bivi-20230930_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Cuong V Do, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 8, 2023

                /s/ Cuong V Do
               
Cuong V Do
Chief Executive Officer
(Principal Executive Officer)
 
EX-31.2 3 bivi-20230930_10qex31z2.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

     

I, Joanne Wendy Kim, certify that:
     
1. I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:
   
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 8, 2023

                /s/ Joanne Wendy Kim
               

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 
EX-32.1 4 bivi-20230930_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cuong V Do, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 8, 2023

                /s/ Cuong V Do
                Cuong V Do
Chief Executive Officer
(Principal Executive Officer)

 

 
EX-32.2 5 bivi-20230930_10qex32z2.htm EXHIBIT 32.2

Exhibit 32.2

 

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 8, 2023

                  /s/ Joanne Wendy Kim
                 

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

 
EX-101.SCH 6 bivi-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investments in U.S. Treasury Bills Available for Sale link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Other Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Investments in U.S. Treasury Bills available for sale (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Other Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Notes Payable (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Equity Transactions (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Employee Benefit Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bivi-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bivi-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bivi-20230930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stocks [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Restricted Stock Units (RSUs) [Member] Investment Type [Axis] US Treasury Bill Securities [Member] Related Party, Type [Axis] Acuitas Group Holdings L L C [Member] Variable Rate [Axis] Prime Rate [Member] Receivable Type [Axis] Unearned Discount [Member] Financing Receivable [Member] Loan Accretion Premium [Member] Concentration Risk Benchmark [Axis] Derivative Liability Warrants [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Derivative Liability Conversion Option On Note Payable [Member] Derivative Liability Conversion Option On Convertible Debenture [Member] Cash and Cash Equivalents [Axis] Cash [Member] U S Treasury Bill Securities 1 [Member] Class of Stock [Axis] Common Class A [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Sales Agreement [Member] Derivative Instrument [Axis] Stock Options [Member] Award Type [Axis] Plan Name [Axis] N 2019 Omnibus Incentive Equity Plan [Member] Title of Individual [Axis] Four Directors [Member] Three Directors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] New Employee [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Transaction Type [Axis] Counterparty Name [Axis] Agent [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Investments in U.S. Treasury Bills Prepaids and other assets Total current assets Operating lease right-of-use assets, net Intangible assets, net Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses Other current liabilities Current portion of operating lease liabilities Current portion of note payable, net of financing cost, unearned premium and discount of $661,467 at September 30, 2023 and $894,926 at June 30, 2023 Warrant liabilities Embedded derivative liability Total current liabilities Operating lease liabilities, net of current portion Note payable, net of current portion, financing cost, unearned premium and  discount of $469,937 at September 30, 2023 and $227,270 at June 30, 2023 TOTAL LIABILITIES Commitments and contingencies (Note 12) STOCKHOLDERS’ EQUITY: Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2023 and June 30, 2023, respectively; 36,922,760 shares issued of which 36,899,880 shares are outstanding at September 30, 2023; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023; Additional paid in capital Accumulated other comprehensive income Accumulated deficit Treasury stock Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Unearned premium and discount current Unearned premium and discount Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES: Amortization Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME): Change in fair value of derivative liabilities Interest expense Interest income TOTAL OTHER (INCOME) EXPENSE, NET NET LOSS NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS NET LOSS PER COMMON SHARE - Basic - Diluted WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING - Basic - Diluted NET LOSS Other comprehensive loss Reclassification of unrealized gains on available-for-sale investments upon settlement Total other comprehensive loss Comprehensive loss Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization of intangible assets Stock based compensation - restricted stock units Stock based compensation expense - stock options Amortization of financing costs Accretion of unearned loan discount Accretion of loan premium Realized gain on maturity of available-for sale Change in operating lease right-of-use assets Change in fair value of derivative liabilities Changes in operating assets and liabilities: Prepaids and other assets Accounts payable and accrued expenses Operating lease liabilities Other liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Maturity of U.S. Treasury Bills Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common stock Payment of note payable Net proceeds from issuance of common stock - Related Party Net cash (used in) provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES: Reclassification of unrealized gains on available-for-sale investments upon settlement Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Stock - based compensation - stock options Stock-based compensation - restricted stock units Proceeds from issuance of common stock, net of costs of $118,891 Proceeds from issuance of common stock, shares Issuance of common stock from vesting of - restricted stock units Issuance of common stock from vesting of - restricted stock units, shares Proceeds from issuance of common stock, net of costs of $94,160 - Related Party Proceeds from issuance of common stock related party, shares Net loss Reclassification of unrealized gains on available for sale investments upon settlement Ending balance, value Ending balance, shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Background Information Liquidity Accounting Policies [Abstract] Significant Accounting Policies Investments In U.s. Treasury Bills Available For Sale Investments in U.S. Treasury Bills Available for Sale Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Related Party Transactions [Abstract] Related Party Transactions Other Liabilities Disclosure [Abstract] Other Liabilities Debt Disclosure [Abstract] Notes Payable Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Equity Transactions Leases Leases Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Employee Benefit Plan Employee Benefit Plan Subsequent Events [Abstract] Subsequent Events Basis of Presentation – Interim Financial Information Net loss per Common Share Recent Accounting Pronouncements Cash and cash equivalents Investments in U.S. Treasury Bills Concentration of Credit Risk in the Financial Service Industry Fair value measurement of assets and liabilities Schedule of dilutive securities were excluded from the computation of diluted loss per share Schedule of U.S. treasury bills held Schedule of intangible assets Schedule of future amortization expense Schedule of note payable Schedule of estimated future amortization expense and accretion of premium Schedule of derivative liabilities at fair value Fair value, liabilities measured on recurring basis Measured at fair value on a recurring basis Schedule of summarizes the activity relating to the Company’s stock options Schedule of vesting of restricted common stock Summary of warrants activity Schedule of deferred tax assets Schedule of future estimated minimum lease payments under non-cancelable operating leases Schedule of weighted average remaining lease term and discount rate Working capital Cash and cash equivalent Stockholders' equity Accumulated deficit Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Schedule of Investments [Table] Schedule of Investments [Line Items] Amortized Cost Basis Gross Unrealized Gain Fair Value Total Accumulated Other Comprehensive Income Number of stock purchased Realized gain on maturity of available-for sale Intellectual Property Less Accumulated Amortization Intellectual Property, Net Year ending June 30, 2024 (Remaining 9 months) 2025 2026 Finite lived intangible assets, net Amortization expenses Useful Life Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Common Stock, shares issued Other liabilities Current portion of Notes Payable Less debt financing costs Less unearned discount Plus accretion of loan premium Current portion of Notes Payable, net of financing costs, unearned premiums and discount Notes Payable Less debt financing costs Less unearned discount Plus accretion of loan premium Notes Payable, net of the current portion financing costs, unearned premiums and discount Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts, Notes, Loans and Financing Receivable [Line Items] Year ending June 30, 2024 (Remaining 9 months) 2025 Total Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Interest rate Fair value of warrants Fair value of embedded conversion option Unearned discount Direct financing cost Unamortized premium recognized Interest expense Interest payment Amortization of financing costs Accretion of loan premium Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total derivatives Balance at beginning Additions to level 3 liabilities Change in in fair value of level 3 liability Transfer in and/or out of Level 3 Balance at ending Total Share Price Exercise Price Term Risk Free Interest Rate Volatility Rate Offsetting Assets [Table] Offsetting Assets [Line Items] Options outstanding at beginning Weighted average exercise price, Options outstanding at beginning Weighted Remaining Average Contractual Term, Ending Balance Aggregate Intrinsic Value, Outstanding at beginning of period Options Exercisable Weighted Average Exercise Price, Options Exercisable Weighted Average Remaining Contractual Term, Options Exercisable Aggregate Intrinsic Value, Options Exercisable Number of shares unvested at beginning Weighted average grant date fair value per share unvested at beginning Number of shares, Vested Weighted average grant date fair value per share, Vested Number of shares unvested at ending Weighted average grant date fair value per share unvested at ending Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Warrant Outstanding Weighted average exercise price, warrants outstanding Weighted average remaining life (Years), warrants outstanding Aggregate intrinsic value, otstanding Schedule of Stock by Class [Table] Class of Stock [Line Items] Issuance of common stock for cash, shares Issuance of common stock for cash Commissions percentage Issuance costs Stock-based compensation expense Rsu granted Rsu granted, grant date fair value Total compensation cost Shares issued over the vesting period Stock option to purchase Awarded Vested rights, percentage Weighted Average Contractual Term, Granted (in Years) Weighted Average Exercise Price, Options Grants Operating lease, right-of-use asset, net Total operating lease liabilities Year ending June 30, 2024 (Remaining 9 months) 2025 Total minimum lease payments Less amount representing interest Present value of future minimum lease payments Less current portion of operating lease liabilities Weighted average remaining lease term (Years) Operating leases Weighted average discount rate Operating leases Operating lease cost Cash paid for amounts included in measurement of lease liabilities Employee Benefit Plan Subsequent Event [Table] Subsequent Event [Line Items] Number of common stock sold Value of common stock sold Commission and expenses Assets, Current Assets Liabilities, Current Liabilities Treasury Stock, Value Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Gain (Loss) on Sale of Derivatives Interest Income, Other TotalOtherExpenseIncome Income (Loss) Attributable to Parent, before Tax Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent InterestExpenseFromConvertibleDebenture Derivative, Gain (Loss) on Derivative, Net Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Net Cash Provided by (Used in) Operating Activities MaturityOfU.s.TreasuryBills Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Shares, Outstanding Net Income (Loss) Attributable to Parent Lessee, Operating Leases [Text Block] EmployeeBenefitPlanTextBlock Cash and Cash Equivalents, Policy [Policy Text Block] InvestmentsUSTreasuryBillsPolicyTextBlock AccumulatedDeficit Finite-Lived Intangible Assets, Accumulated Amortization Other Liabilities [Default Label] Deferred Discounts, Finance Charges and Interest Included in Receivables NotesPayableNoncurrent LongtermDebtFinancingCosts LongTermAccretionOfLoanPremiums AmortizationExpenseNextRollingTwelveMonths AmortizationExpenseNextRollingTwoYears AmortizationExpenseTotal Interest Expense, Debt Amortization of Debt Issuance Costs AccretionsOfLoanPremium Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment Defined Benefit Plan, Plan Assets, Contributions by Employer EX-101.PRE 10 bivi-20230930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
3 Months Ended
Sep. 30, 2023
Nov. 06, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --06-30  
Entity File Number 001-39015  
Entity Registrant Name BIOVIE INC.  
Entity Central Index Key 0001580149  
Entity Tax Identification Number 46-2510769  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 680 W Nye Lane  
Entity Address, Address Line Two Suite 204  
Entity Address, City or Town Carson City  
Entity Address, State or Province NV  
Entity Address, Postal Zip Code 89703  
City Area Code 775  
Local Phone Number 888-3162  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share  
Trading Symbol BIVI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   37,742,695
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 21,214,670 $ 19,460,883
Investments in U.S. Treasury Bills 14,477,726
Prepaids and other assets 1,549,287 102,526
Total current assets 22,763,957 34,041,135
Operating lease right-of-use assets, net 70,748 80,789
Intangible assets, net 579,751 637,095
Goodwill 345,711 345,711
TOTAL ASSETS 23,760,167 35,104,730
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 2,714,760 3,476,259
Other current liabilities 48,385
Current portion of operating lease liabilities 46,548 44,909
Current portion of note payable, net of financing cost, unearned premium and discount of $661,467 at September 30, 2023 and $894,926 at June 30, 2023 9,338,533 9,105,074
Warrant liabilities 622,397 894,280
Embedded derivative liability 489,843 925,762
Total current liabilities 13,212,081 14,494,669
Operating lease liabilities, net of current portion 30,221 42,505
Note payable, net of current portion, financing cost, unearned premium and  discount of $469,937 at September 30, 2023 and $227,270 at June 30, 2023 2,969,937 5,227,270
TOTAL LIABILITIES 16,212,239 19,764,444
STOCKHOLDERS’ EQUITY:    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2023 and June 30, 2023, respectively; 36,922,760 shares issued of which 36,899,880 shares are outstanding at September 30, 2023; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023; 3,690 3,643
Additional paid in capital 319,480,409 316,385,759
Accumulated other comprehensive income 176,591
Accumulated deficit (311,936,169) (301,225,705)
Treasury stock (2) (2)
Total stockholders’ equity 7,547,928 15,340,286
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 23,760,167 $ 35,104,730
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Unearned premium and discount current $ 661,467 $ 894,926
Unearned premium and discount $ 469,937 $ 227,270
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 800,000,000 800,000,000
Common stock, shares issued 36,922,760 36,451,829
Common stock, shares outstanding 36,899,880 36,428,949
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
OPERATING EXPENSES:    
Amortization $ 57,344 $ 57,344
Research and development expenses 8,875,659 6,769,932
Selling, general and administrative expenses 1,942,818 2,007,062
TOTAL OPERATING EXPENSES 10,875,821 8,834,338
LOSS FROM OPERATIONS (10,875,821) (8,834,338)
OTHER EXPENSE (INCOME):    
Change in fair value of derivative liabilities (707,802) 566,542
Interest expense 1,004,668 1,056,416
Interest income (462,223) (41,585)
TOTAL OTHER (INCOME) EXPENSE, NET (165,357) 1,581,373
NET LOSS (10,710,464) (10,415,711)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (10,710,464) $ (10,415,711)
NET LOSS PER COMMON SHARE    
- Basic $ (0.29) $ (0.38)
- Diluted $ (0.29) $ (0.38)
WEIGHTED AVERAGE NUMBER OF COMMON  SHARES OUTSTANDING    
- Basic 36,742,812 27,212,445
- Diluted 36,742,812 27,212,445
NET LOSS $ (10,710,464) $ (10,415,711)
Other comprehensive loss    
Reclassification of unrealized gains on available-for-sale investments upon settlement (176,591)
Total other comprehensive loss (176,591)
Comprehensive loss $ (10,887,055) $ (10,415,711)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (10,710,464) $ (10,415,711)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of intangible assets 57,344 57,344
Stock based compensation - restricted stock units 380,834 17,537
Stock based compensation expense - stock options 808,027 878,640
Amortization of financing costs 37,825 42,554
Accretion of unearned loan discount 355,877 400,361
Accretion of loan premium 82,424 143,813
Realized gain on maturity of available-for sale (223,865)  
Change in operating lease right-of-use assets 10,041 8,983
Change in fair value of derivative liabilities (707,802) 566,542
Changes in operating assets and liabilities:    
Prepaids and other assets (1,446,761) (221,244)
Accounts payable and accrued expenses (761,499) 179,530
Operating lease liabilities (10,645) (9,213)
Other liabilities (48,385) (869,456)
Net cash used in operating activities (12,177,049) (9,220,320)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Maturity of U.S. Treasury Bills 14,525,000
Net cash provided by investing activities 14,525,000
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from issuance of common stock 1,905,836 5,903,682
Payment of note payable (2,500,000)
Net proceeds from issuance of common stock - Related Party 5,905,840
Net cash (used in) provided by financing activities (594,164) 11,809,522
Net increase in cash and cash equivalents 1,753,787 2,589,202
Cash and cash equivalents, beginning of period 19,460,883 18,641,716
Cash and cash equivalents, end of period 21,214,670 21,230,918
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest 528,541 469,687
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:    
Reclassification of unrealized gains on available-for-sale investments upon settlement $ 176,591
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stocks [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Jun. 30, 2022 $ 2,496 $ 254,638,329 $ (250,969,890) $ 3,670,935
Beginning balance, shares at Jun. 30, 2022 24,984,083        
Stock - based compensation - stock options 878,640 878,640
Stock-based compensation - restricted stock units 17,537 17,537
Proceeds from issuance of common stock, net of costs of $118,891 $ 155 5,903,527 5,903,682
Proceeds from issuance of common stock, shares 1,544,872          
Proceeds from issuance of common stock, net of costs of $94,160 - Related Party $ 364 5,905,476 5,905,840
Proceeds from issuance of common stock related party, shares 3,636,364          
Net loss (10,415,711) (10,415,711)
Ending balance, value at Sep. 30, 2022 $ 3,015 267,343,509 (261,385,601) 5,960,923
Ending balance, shares at Sep. 30, 2022 30,165,319        
Beginning balance, value at Jun. 30, 2023 $ 3,643 316,385,759 $ (2) 176,591 (301,225,705) 15,340,286
Beginning balance, shares at Jun. 30, 2023 36,451,829   (22,880)      
Stock - based compensation - stock options 808,027 808,027
Stock-based compensation - restricted stock units 380,834 380,834
Proceeds from issuance of common stock, net of costs of $118,891 $ 43 1,905,793 1,905,836
Proceeds from issuance of common stock, shares 432,201          
Issuance of common stock from vesting of - restricted stock units $ 4 (4)
Issuance of common stock from vesting of - restricted stock units, shares 38,730          
Net loss (10,710,464) (10,710,464)
Reclassification of unrealized gains on available for sale investments upon settlement (176,591) (176,591)
Ending balance, value at Sep. 30, 2023 $ 3,690 $ 319,480,409 $ (2) $ (311,936,169) $ 7,547,928
Ending balance, shares at Sep. 30, 2023 36,922,760   (22,880)      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Background Information
3 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Background Information

 

1. Background Information

 

BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. 

 

The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), from a related party privately held clinical-stage pharmaceutical company, in June 2021. The acquired assets included NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase (“ERK”) signaling that, based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), and NE3107 could, if approved represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD.

 

Late in September 2023, the final patient completed the last treatment at week 30 in the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients who have mild to moderate Alzheimer’s disease. The database cleaning process remains underway, with the clinical team resolving outstanding queries and entering final data into the electronic data system. Final database lock, unblinding and subsequent release of topline results is anticipated to occur during the fourth quarter of calendar year 2023.

 

The Company completed its Phase 2 study assessing NE3107 in PD patients in the fourth quarter of calendar year 2022. The NM201 study (NCT05083260) was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. The study was primarily designed to assess safety (general safety in the patient population and potential for drug-drug interactions of NE3107 with levodopa); and secondary, to look for indications of promotoric activity akin to promotoric activity and apparent enhancement of levodopa activity observed in preclinical models. Both the safety and efficacy objectives of the study were met.

 

Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD frontotemporal lobar dementia, and Amyotrophic lateral sclerosis (ALS). NE3107 is an orally bioavailable, blood-brain permeable, small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea.  

 

The Company’s Orphan Drug candidate BIV201 (continuous infusion terlipressin), has been granted Fast Track designation status by the U.S. Food and Drug Administration (“FDA”), is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The Phase 2b study was closed before full enrollment, without clinically meaningful adverse effects associated with BIV201 treatment. While the active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, treatment of ascites is not included in these authorizations. Patients with refractory ascites suffer from frequent life-threatening complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The FDA has not approved any drug to treat refractory ascites.

 

The BIV201 development program was initiated by LAT Pharma LLC (“LAT Pharma”). On April 11, 2016, the Company acquired LAT Pharma and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin), if approved, to be shared by the members of LAT Pharma, PharmaIn Corporation and The Barrett Edge, Inc.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Liquidity
3 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity

 

2. Liquidity

 

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2023, the Company had working capital of approximately $9.6 million, cash and cash equivalents totaling of approximately $21.2 million, stockholders’ equity of approximately $7.5 million, and an accumulated deficit of approximately $311.9 million. The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Although our cash balance may possibly sustain operations over the next 12 months from the balance sheet date if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company’s development of next phase clinical programs, the Company’s current planned operations to meet certain goals and objectives, project cash flows to be depleted within that period of time.

 

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.

 

Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies
3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies

 

3. Significant Accounting Policies

 

Basis of Presentation – Interim Financial Information

 

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2023 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2023 and 2022 in our Annual Report on Form 10-K filed with the SEC on August 16, 2023 (the “2023 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2023 Form 10-K.

 

Net loss per Common Share

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, par value $0.0001 per share (“common stock”), outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and restricted stock units. For the three months ended September 30, 2023 and 2022, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods.

 

The table below shows the number of outstanding stock options, warrants and restricted stock units as of September 30, 2023 and 2022:

 

          
   September 30, 2023   September 30, 2022 
   Number of Shares   Number of Shares 
Stock Options   3,952,864    3,348,330 
Warrants   7,770,285    7,779,194 
Restricted Stock Units   557,727    124,520 
Total   12,280,876    11,252,044 

 

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations and comprehensive loss since the 2023 Form 10-K.

 

Cash and cash equivalents

 

Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.

 

Investments in U.S. Treasury Bills

 

Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gain were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Upon the maturity and settlement of these investments, realized gains were recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.

 

Concentration of Credit Risk in the Financial Service Industry

 

As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.

 

Fair value measurement of assets and liabilities

 

We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2 – Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

 

Level 3 – Inputs are unobservable inputs based on our assumptions.

 

The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities, notes payable and other derivative liabilities (see Note 9). The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in U.S. Treasury Bills Available for Sale
3 Months Ended
Sep. 30, 2023
Investments In U.s. Treasury Bills Available For Sale  
Investments in U.S. Treasury Bills Available for Sale

 

4.Investments in U.S. Treasury Bills Available for Sale

 

The following is a summary of the U.S. Treasury Bills held at June 30, 2023:

 

                
   Amortized Cost
Basis
   Gross Unrealized
Gain
   Fair Value   Total Accumulated
Other
Comprehensive
Income
 
U.S. Treasury Bills due is 3 - 6 months  $14,301,136   $176,591   $14,477,726   $176,591 

 

During the fiscal year ended June 30, 2023, the Company purchased a total of approximately $46 million of U.S. Treasury Bills during the year ended June 30, 2023. All outstanding investments in U.S. Treasury Bills available for sale held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $223,865 recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets
3 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

 

5.Intangible Assets

 

The Company’s intangible assets consist of intellectual property acquired from LAT Pharma and are amortized over their estimated useful lives.

 

The following is a summary of the Company’s intangible assets:

 

        
   September 30, 2023   June 30, 2023 
         
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,714,019)   (1,656,675)
Intellectual Property, Net  $579,751   $637,095 

 

Amortization expense was $57,344 in each of the three-month periods ended September 30, 2023 and 2022. The Company amortizes intellectual property over the expected, original useful lives of 10 years.

 

Estimated future amortization expense is as follows:

 

     
Year ending June 30, 2024 (Remaining 9 months)  $172,033 
2025   229,377 
2026   178,341 
   $        579,751 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
3 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

 

6. Related Party Transactions

 

Equity Transactions with Acuitas

 

On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of 3,636,364 shares of the Company’s Common Stock, at a price of $1.65 per share (the “PIPE Shares”), and (ii) a warrant to purchase 7,272,728 shares of Common Stock (“PIPE Warrant Shares”), at an exercise price of $1.82, with a term of exercise of five years. The warrant has a down round feature that reduces the exercise price of the warrant if the Company sells stock at a price lower than the exercise price of the warrant. On August 15, 2022, the Company received net proceeds of approximately $5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the “Existing Registration Rights Agreement”), to amend the definition of “Registrable Securities” in the Existing Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Other Liabilities
3 Months Ended
Sep. 30, 2023
Other Liabilities Disclosure [Abstract]  
Other Liabilities

 

7. Other Liabilities

 

The current portion of other liabilities at June 30, 2023 was approximately $48,000 and represented the remaining balance of a retention bonus payable for arrangements with certain employees, which was paid in July 2023. 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable
3 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Notes Payable

 

8. Notes Payable

 

On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan provided for an additional $5 million to be available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.00% plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at September 30, 2023 was 8.50%. The Loan is secured by a lien upon and security interest in all of the Company’s assets, including intellectual property, subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.

 

The Loan Agreement required monthly interest-only payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and Tranche 2.

 

The Loan Agreement includes a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $6.98 per share.

 

On the Closing Date, the Company issued to Avenue warrants to purchase 361,002 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $5.82. The Avenue Warrants are exercisable until November 30, 2026.

 

The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes; approximately $1.4 million to the fair value of the Avenue Warrants and approximately $2.2 million to the fair value of the embedded conversion option. Accordingly, the total amount of unearned discount of approximately $3.6 million, the total direct financing cost of approximately $390,000 and premium of $850,000 are recognized on an effective interest method over the term of the Loan. The adjusted effective interest rate is 25%. The total interest expense of approximately $1 million for the three months ended September 30, 2023, was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest only payments totaling approximately $525,000, the amortization of financing costs of approximately $38,000, unearned discount of approximately $356,000 and the accretion of loan premium of approximately $82,000.

 

The total interest expense of approximately $1.1 million for the three months ended September 30, 2022; was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest payments totaling approximately $470,000, the amortization of financing costs of approximately $43,000, unearned discount of approximately $400,000 and the accretion of loan premium totaled of approximately $144,000.

 

As of September 30, 2023, the remaining principal balance of $12.5 million under the Loan is payable in 15 monthly equal installments. For the three months ended September 30, 2023, the Company paid back $2.5 million of the original loan of $15 million.

 

The following is a summary of the Notes Payable as of September 30, 2023 and June 30, 2023:

 

Current portion of Notes Payable

 

          
   September 30, 2023   June 30, 2023 
         
Current portion of Notes Payable  $10,000,000   $10,000,000 
Less debt financing costs   (80,381)   (108,751)
Less unearned discount   (756,238)   (1,023,145)
Plus accretion of loan premium   175,152    236,970 
Current portion of Notes Payable, net of financing costs, unearned premiums and discount  $9,338,533   $9,105,074 

 

Non-current portion of Notes Payable

 

   September 30, 2023   June 30, 2023 
         
Notes Payable  $2,500,000   $5,000,000 
Less debt financing costs   (2,365)   (11,820)
Less unearned discount   (22,242)   (111,212)
Plus accretion of loan premium   494,544    350,302 
Notes Payable, net of the current portion financing costs, unearned premiums and discount  $2,969,937   $5,227,270 

 

Estimated future amortization expense and accretion of premium is as follows:

 

            
   Unearned Discount   Debt Financing
Costs
   Loan accretion
Premium
 
             
Year ending June 30, 2024 (Remaining 9 months)  $667,268   $70,926   $154,546 
2025   111,212    11,820    25,758 
Total  $778,480   $82,746   $180,304 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
3 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements

 

9.Fair Value Measurements

 

At September 30, 2023 and June 30, 2023, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

 

                 
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $622,397   $622,397 
Derivative liability - Conversion option on notes payable   -    -    489,843    489,843 
Total derivatives  $         -   $        -   $1,112,240   $1,112,240 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $894,280   $894,280 
Derivative liability - Conversion option on note payable           -          -    925,762    925,762 
Total derivatives  $-   $-   $1,820,042   $1,820,042 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2023: 

 

          
   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2023  $894,280   $925,762 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   (271,883)   (435,919)
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2023  $622,397   $489,843 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2022:

 

   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2022  $194,531   $188,030 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   248,061    318,481 
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2022  $442,592   $506,511 

  

The fair values of derivative liabilities for the Avenue Warrants and the conversion option at September 30, 2023 in the accompanying condensed balance sheet, were approximately $622,000 and approximately $490,000, respectively. The total change in the fair value of the derivative liabilities totaled approximately $708,000 for the three months ended September 30, 2023; and accordingly, was recorded in the accompanying condensed statement of operations and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at September 30, 2023 included the closing stock price of $3.41 per share; for the Avenue Warrants, the exercise price of $5.82, remaining term 3.2 years, risk free rate of 4.8% and volatility of 92.0%; and for the embedded derivative liability of the conversion option, the conversion price of $6.98; remaining term 1.17 years, risk free rate of 5.39% and volatility of 93.0%.

 

Derivative liability – Avenue Warrants

 

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet and anti-dilution provisions or adjustments to the strike price due to an occurrence of a future event are accounted for as derivative financial instruments. The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompany condensed balance sheet at September 30, 2023.

 

The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at their fair values at the date of issuance and remeasured at September 30, 2023.

 

Embedded derivative liability – Conversion Option

 

The embedded derivative liability represents the optional conversion feature of up to $5.0 million of the outstanding Loan, which meets the definition of a derivative and requires bifurcation from the loan amount.

 

The Black Scholes model was used to calculate the fair value of the embedded derivative to bifurcate the embedded derivative amount representing the conversion option from the Avenue Loan amount funded.

 

Financial assets

 

As of September 30, 2023, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1.

 

The following table presents information about our assets that are measured at fair value on a recurring basis.

 

                
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $7,764,886   $-   $-   $7,764,886 
U.S. Treasury Bills due in 3 months or less at purchase   13,449,784        -         -    13,449,784 
U.S. Treasury Bills due in 3 - 6 months at purchase   -    -    -    - 
Total  $21,214,670   $-   $-   $21,214,670 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $6,304,543   $-   $-   $6,304,543 
U.S. Treasury Bills due in 3 months or less at purchase   13,156,340            -            -   13,156,340 
U.S. Treasury Bills due in 3 - 6 months at purchase   14,477,726    -    -   14,477,726 
Total  $33,938,609   $-   $-   $33,938,609 

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions
3 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Equity Transactions

 

10. Equity Transactions

 

Issuance of common stock for cash

 

On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the three months ended September 30, 2023, the Company sold 432,201 shares of common stock under the Sales Agreement for total net proceeds of $1.9 million after 3% commissions and expenses of approximately $119,000. During the three months ended September 30, 2022, the Company sold 1,544,872 shares of common stock under the Sales Agreement for total net proceeds of $5.9 million after 3% commissions and expenses of approximately $400,000.

 

Stock Options

 

The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2023:

 

                    
   Options   Weighed-
Average
Exercise
Price
   Weighted
Remaining
Average
Contractual
Term
   Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2023   3,952,864   7.10    6.3   1,067,966 
Outstanding at September 30, 2023   3,952,864   7.10    6.0   477,247 
Exercisable at September 30, 2023   1,689,339   $7.64    5.5   $154,404 

 

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. No stock options were issued, expired, canceled or exercised during the three months ended September 30, 2023.

 

The total stock option-based compensation expense for three-months ended September 30, 2023 and 2022 was of $808,027 and $878,640, respectively.

 

Issuance of restricted stock units and options :

 

On November 23, 2022, the Company issued equity awards for the board of directors’ annual compensation. Four directors received restricted stick units (“RSUs”) to purchase a total of 155,636 shares of common stock at the grant date fair value of $6.12 per share, a total cost of $952,492 recognized as stock compensation in the three months ended December 31, 2022. Three directors received stock options to purchase 195,000 shares of common stock at an exercise price of $6.12 per share, the grant date fair value. The total stock compensation cost of stock options of $791,700 was recognized in the three months ended December 31, 2022. The equity awards vest every three months beginning from the last annual shareholders’ meeting on November 9, 2022, on February 9, 2023, May 9, 2023, August 9, 2023 and earlier of November 9, 2023 or the next annual shareholders’ meeting. While the agreements contain certain contractual vesting terms, there are circumstances where the vesting can be accelerated that is not within the Company’s control and as a result, for accounting purposes, the awards are assumed to have been fully vested on the grant date, accordingly, the Company recognized the total compensation cost of $1,744,192 on November 23, 2022. On August 9, 2023, the Company delivered the vested portion and issued 38,730 shares of common stock.

 

The following table summarizes vesting of restricted common stock:

 

        
   Number of
Shares
   Weighted
Average
Grant
Date Fair
Value
Per
Share
 
         
Unvested at June 30, 2023   596,457   $5.24 
Vested   (38,730)   6.12 
Unvested at September 30, 2023   557,727   $5.40 

 

The total stock based compensation – restricted stock expense for three-months ended September 30, 2023 and 2022 was of $380,834 and $17,537, respectively.

 

Issuance of Stock Options under the 2019 Omnibus Plan.

 

On October 3, 2023, the Company granted stock options to purchase 211,167 shares of Common Stock to new hire employees. 20% of the shares underlying the options awarded vest on the one-year anniversary of the grant date, and the remaining 80% will vest in equal monthly installments over 48 months each month thereafter. The exercise price of the options is $3.41 per share and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are fully exercised.

 

Stock Warrants

 

The following table summarizes warrant activity during the three months ended September 30, 2023:

 

                    
   Number of
Shares
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding and exercisable at June 30, 2023   7,770,285   $2.06    4.0   $18,318,954 
Outstanding and exercisable at September 30, 2023   7,770,285   $2.06    3.8   $11,682,257 

 

Of the above warrants, 101,380 expire in the fiscal year ending June 30, 2025, 35,175 expire in the fiscal year ending June 30, 2026, and 7,633,730 expire in the fiscal year ending June 30, 2027. No warrants were granted, expired, or were exercised during the three months ended September 30, 2023.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
3 Months Ended
Sep. 30, 2023
Leases  
Leases

 

11. Leases

 

Office Lease

 

The Company pays an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 897603. The rental agreement was for a one-year term and commenced on October 1, 2022 and has been subsequently renewed for another year at the same rate.

 

On February 26, 2022, the Company’s San Diego office relocated to 5090 Shoreham Place, San Diego, CA 92122. The term for the office lease is 38 months and commenced on March 1, 2022. The monthly base rate currently is $4,300, with annual increases of three percent.

 

Total operating lease expense of approximately $13,000 and $13,000 for the three months ended September 30, 2023 and 2022, respectively; were included in the accompanying condensed statements of operations and comprehensive loss as a component of selling, general and administrative expenses.

 

The right-of-use asset, net and current and non current portion of the operating lease liabilities included in the accompany condensed balance sheets are as follows:

 

          
   September 30, 2023   June 30, 2023 
Assets          
Operating lease, right-of-use asset, net  $70,748   $80,789 
           
Liabilities          
Current portion of operating lease liabilities  $46,548   $44,909 
Operating lease liabilities, net of current portion   30,221    42,505 
Total operating lease liabilities  $76,769   $87,414 

 

At September 30, 2023, the future estimated minimum lease payments under non-cancelable operating leases are as follows:

 

      
Year ending June 30, 2024 (Remaining 9 months)  $39,256 
2025  44,636 
Total minimum lease payments   83,892 
      
Less amount representing interest   (7,123)
Present value of future minimum lease payments   76,769 
      
Less current portion of operating lease liabilities   (46,548)
Operating lease liabilities, net of current portion  $30,221 

 

Total cash paid for amounts included in the measurement of lease liabilities were $12,900 and $12,525 for the three months ended September 30, 2023 and 2022, respectively.

 

The weighted average remaining lease term and discount rate as of September 30, 2023 and June 30, 2023 were as follows:

 

        
   September 30, 2023   June 30, 2023 
         
Weighted average remaining lease term (Years)          
Operating leases   1.5    1.8 
Weighted average discount rate          
Operating leases   10.75%   10.75%
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
3 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

12. Commitments and Contingencies

 

Royalty Agreements

 

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

 

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Employee Benefit Plan
3 Months Ended
Sep. 30, 2023
Employee Benefit Plan  
Employee Benefit Plan

 

13. Employee Benefit Plan

 

On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate.

 

Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan., The Company made contributions of approximately $30,900 and $45,500, for the three months ended September 30, 2023 and 2022, respectively.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
3 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

 

14. Subsequent Events

 

Subsequent to September 30, 2023, the Company sold 819,935 shares of common stock for net proceeds of $3.5 million net of 3% commission and expenses totaling approximately $105,000 under the Sales Agreement with the Agent.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Policies)
3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation – Interim Financial Information

Basis of Presentation – Interim Financial Information

 

These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2023 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2023 and 2022 in our Annual Report on Form 10-K filed with the SEC on August 16, 2023 (the “2023 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2023 Form 10-K.

 

Net loss per Common Share

Net loss per Common Share

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, par value $0.0001 per share (“common stock”), outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and restricted stock units. For the three months ended September 30, 2023 and 2022, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods.

 

The table below shows the number of outstanding stock options, warrants and restricted stock units as of September 30, 2023 and 2022:

 

          
   September 30, 2023   September 30, 2022 
   Number of Shares   Number of Shares 
Stock Options   3,952,864    3,348,330 
Warrants   7,770,285    7,779,194 
Restricted Stock Units   557,727    124,520 
Total   12,280,876    11,252,044 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations and comprehensive loss since the 2023 Form 10-K.

 

Cash and cash equivalents

Cash and cash equivalents

 

Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.

 

Investments in U.S. Treasury Bills

Investments in U.S. Treasury Bills

 

Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gain were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Upon the maturity and settlement of these investments, realized gains were recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.

 

Concentration of Credit Risk in the Financial Service Industry

Concentration of Credit Risk in the Financial Service Industry

 

As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.

 

Fair value measurement of assets and liabilities

Fair value measurement of assets and liabilities

 

We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2 – Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

 

Level 3 – Inputs are unobservable inputs based on our assumptions.

 

The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities, notes payable and other derivative liabilities (see Note 9). The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of dilutive securities were excluded from the computation of diluted loss per share
          
   September 30, 2023   September 30, 2022 
   Number of Shares   Number of Shares 
Stock Options   3,952,864    3,348,330 
Warrants   7,770,285    7,779,194 
Restricted Stock Units   557,727    124,520 
Total   12,280,876    11,252,044 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in U.S. Treasury Bills Available for Sale (Tables)
3 Months Ended
Sep. 30, 2023
Investments In U.s. Treasury Bills Available For Sale  
Schedule of U.S. treasury bills held
                
   Amortized Cost
Basis
   Gross Unrealized
Gain
   Fair Value   Total Accumulated
Other
Comprehensive
Income
 
U.S. Treasury Bills due is 3 - 6 months  $14,301,136   $176,591   $14,477,726   $176,591 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets (Tables)
3 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
        
   September 30, 2023   June 30, 2023 
         
Intellectual Property  $2,293,770   $2,293,770 
Less Accumulated Amortization   (1,714,019)   (1,656,675)
Intellectual Property, Net  $579,751   $637,095 
Schedule of future amortization expense
     
Year ending June 30, 2024 (Remaining 9 months)  $172,033 
2025   229,377 
2026   178,341 
   $        579,751 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable (Tables)
3 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of note payable
          
   September 30, 2023   June 30, 2023 
         
Current portion of Notes Payable  $10,000,000   $10,000,000 
Less debt financing costs   (80,381)   (108,751)
Less unearned discount   (756,238)   (1,023,145)
Plus accretion of loan premium   175,152    236,970 
Current portion of Notes Payable, net of financing costs, unearned premiums and discount  $9,338,533   $9,105,074 

 

Non-current portion of Notes Payable

 

   September 30, 2023   June 30, 2023 
         
Notes Payable  $2,500,000   $5,000,000 
Less debt financing costs   (2,365)   (11,820)
Less unearned discount   (22,242)   (111,212)
Plus accretion of loan premium   494,544    350,302 
Notes Payable, net of the current portion financing costs, unearned premiums and discount  $2,969,937   $5,227,270 
Schedule of estimated future amortization expense and accretion of premium
            
   Unearned Discount   Debt Financing
Costs
   Loan accretion
Premium
 
             
Year ending June 30, 2024 (Remaining 9 months)  $667,268   $70,926   $154,546 
2025   111,212    11,820    25,758 
Total  $778,480   $82,746   $180,304 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
3 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of derivative liabilities at fair value
                 
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $622,397   $622,397 
Derivative liability - Conversion option on notes payable   -    -    489,843    489,843 
Total derivatives  $         -   $        -   $1,112,240   $1,112,240 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Derivative liability - Warrants  $-   $-   $894,280   $894,280 
Derivative liability - Conversion option on note payable           -          -    925,762    925,762 
Total derivatives  $-   $-   $1,820,042   $1,820,042 
Fair value, liabilities measured on recurring basis
          
   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2023  $894,280   $925,762 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   (271,883)   (435,919)
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2023  $622,397   $489,843 

 

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2022:

 

   Derivative liabilities
- Warrants
   Derivative liability -
Conversion Option
on Convertible
Debenture
 
Balance at June 30, 2022  $194,531   $188,030 
Additions to level 3 liabilities   -    - 
Change in in fair value of level 3 liability   248,061    318,481 
Transfer in and/or out of Level 3   -    - 
Balance at September 30, 2022  $442,592   $506,511 
Measured at fair value on a recurring basis
                
   Fair Value Measurements at 
   September 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $7,764,886   $-   $-   $7,764,886 
U.S. Treasury Bills due in 3 months or less at purchase   13,449,784        -         -    13,449,784 
U.S. Treasury Bills due in 3 - 6 months at purchase   -    -    -    - 
Total  $21,214,670   $-   $-   $21,214,670 

 

   Fair Value Measurements at 
   June 30, 2023 
   Level 1   Level 2   Level 3   Total 
                 
Cash  $6,304,543   $-   $-   $6,304,543 
U.S. Treasury Bills due in 3 months or less at purchase   13,156,340            -            -   13,156,340 
U.S. Treasury Bills due in 3 - 6 months at purchase   14,477,726    -    -   14,477,726 
Total  $33,938,609   $-   $-   $33,938,609 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions (Tables)
3 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of summarizes the activity relating to the Company’s stock options
                    
   Options   Weighed-
Average
Exercise
Price
   Weighted
Remaining
Average
Contractual
Term
   Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2023   3,952,864   7.10    6.3   1,067,966 
Outstanding at September 30, 2023   3,952,864   7.10    6.0   477,247 
Exercisable at September 30, 2023   1,689,339   $7.64    5.5   $154,404 
Schedule of vesting of restricted common stock
        
   Number of
Shares
   Weighted
Average
Grant
Date Fair
Value
Per
Share
 
         
Unvested at June 30, 2023   596,457   $5.24 
Vested   (38,730)   6.12 
Unvested at September 30, 2023   557,727   $5.40 
Summary of warrants activity
                    
   Number of
Shares
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding and exercisable at June 30, 2023   7,770,285   $2.06    4.0   $18,318,954 
Outstanding and exercisable at September 30, 2023   7,770,285   $2.06    3.8   $11,682,257 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
3 Months Ended
Sep. 30, 2023
Leases  
Schedule of deferred tax assets
          
   September 30, 2023   June 30, 2023 
Assets          
Operating lease, right-of-use asset, net  $70,748   $80,789 
           
Liabilities          
Current portion of operating lease liabilities  $46,548   $44,909 
Operating lease liabilities, net of current portion   30,221    42,505 
Total operating lease liabilities  $76,769   $87,414 
Schedule of future estimated minimum lease payments under non-cancelable operating leases
      
Year ending June 30, 2024 (Remaining 9 months)  $39,256 
2025  44,636 
Total minimum lease payments   83,892 
      
Less amount representing interest   (7,123)
Present value of future minimum lease payments   76,769 
      
Less current portion of operating lease liabilities   (46,548)
Operating lease liabilities, net of current portion  $30,221 
Schedule of weighted average remaining lease term and discount rate
        
   September 30, 2023   June 30, 2023 
         
Weighted average remaining lease term (Years)          
Operating leases   1.5    1.8 
Weighted average discount rate          
Operating leases   10.75%   10.75%
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Liquidity (Details Narrative)
Sep. 30, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Working capital $ 9,600,000
Cash and cash equivalent 21,200,000
Stockholders' equity 7,500,000
Accumulated deficit $ 311,900,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Details) - shares
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 12,280,876 11,252,044
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 3,952,864 3,348,330
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 7,770,285 7,779,194
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 557,727 124,520
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Details Narrative) - $ / shares
Sep. 30, 2023
Jun. 30, 2023
Accounting Policies [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in U.S. Treasury Bills available for sale (Details) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Schedule of Investments [Line Items]    
Total Accumulated Other Comprehensive Income $ 176,591
US Treasury Bill Securities [Member]    
Schedule of Investments [Line Items]    
Amortized Cost Basis   14,301,136
Gross Unrealized Gain   176,591
Fair Value   14,477,726
Total Accumulated Other Comprehensive Income   $ 176,591
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in U.S. Treasury Bills Available for Sale (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Investments In U.s. Treasury Bills Available For Sale    
Number of stock purchased   $ 46,000,000
Realized gain on maturity of available-for sale $ 223,865  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets (Details) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Intellectual Property $ 2,293,770 $ 2,293,770
Less Accumulated Amortization (1,714,019) (1,656,675)
Intellectual Property, Net $ 579,751 $ 637,095
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets (Details 1) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Year ending June 30, 2024 (Remaining 9 months) $ 172,033  
2025 229,377  
2026 178,341  
Finite lived intangible assets, net $ 579,751 $ 637,095
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expenses $ 57,344 $ 57,344
Useful Life 10 years  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions (Details Narrative) - shares
Sep. 30, 2023
Jun. 30, 2023
Jul. 15, 2022
Related Party Transaction [Line Items]      
Common Stock, shares issued 36,922,760 36,451,829  
Acuitas Group Holdings L L C [Member]      
Related Party Transaction [Line Items]      
Common Stock, shares issued     3,636,364
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Other Liabilities (Details Narrative)
Sep. 30, 2023
USD ($)
Other Liabilities Disclosure [Abstract]  
Other liabilities $ 48,000
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable (Details) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Debt Disclosure [Abstract]    
Current portion of Notes Payable $ 10,000,000 $ 10,000,000
Less debt financing costs (80,381) (108,751)
Less unearned discount (756,238) (1,023,145)
Plus accretion of loan premium 175,152 236,970
Current portion of Notes Payable, net of financing costs, unearned premiums and discount 9,338,533 9,105,074
Notes Payable 2,500,000 5,000,000
Less debt financing costs (2,365) (11,820)
Less unearned discount (22,242) (111,212)
Plus accretion of loan premium 494,544 350,302
Notes Payable, net of the current portion financing costs, unearned premiums and discount $ 2,969,937 $ 5,227,270
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable (Details 1)
Sep. 30, 2023
USD ($)
Unearned Discount [Member]  
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Year ending June 30, 2024 (Remaining 9 months) $ 667,268
2025 111,212
Total 778,480
Financing Receivable [Member]  
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Year ending June 30, 2024 (Remaining 9 months) 70,926
2025 11,820
Total 82,746
Loan Accretion Premium [Member]  
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Year ending June 30, 2024 (Remaining 9 months) 154,546
2025 25,758
Total $ 180,304
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Notes Payable (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Debt Instrument [Line Items]      
Interest rate 8.50%    
Fair value of warrants $ 1,400,000    
Fair value of embedded conversion option 2,200,000    
Unearned discount 356,000 $ 400,000 $ 3,600,000
Direct financing cost 390,000    
Unamortized premium recognized 850,000    
Interest expense 1,000,000 1,100,000  
Interest payment 525,000 470,000  
Amortization of financing costs 38,000 43,000  
Accretion of loan premium $ 82,000 $ 144,000  
Prime Rate [Member]      
Debt Instrument [Line Items]      
Interest rate 7.00%    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives $ 1,112,240 $ 1,820,042    
Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives 1,112,240 1,820,042    
Derivative Liability Warrants [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives 622,397 894,280    
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives 622,397 894,280 $ 442,592 $ 194,531
Derivative Liability Conversion Option On Note Payable [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives 489,843 925,762    
Derivative Liability Conversion Option On Note Payable [Member] | Fair Value, Inputs, Level 1 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Derivative Liability Conversion Option On Note Payable [Member] | Fair Value, Inputs, Level 2 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives    
Derivative Liability Conversion Option On Note Payable [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total derivatives $ 489,843 $ 925,762    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details 1) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance at beginning $ 1,820,042  
Balance at ending 1,112,240  
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance at beginning 1,820,042  
Balance at ending 1,112,240  
Derivative Liability Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance at beginning 894,280  
Balance at ending 622,397  
Derivative Liability Warrants [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance at beginning 894,280 $ 194,531
Additions to level 3 liabilities
Change in in fair value of level 3 liability (271,883) 248,061
Transfer in and/or out of Level 3
Balance at ending 622,397 442,592
Derivative Liability Conversion Option On Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance at beginning 925,762 188,030
Additions to level 3 liabilities
Change in in fair value of level 3 liability (435,919) 318,481
Transfer in and/or out of Level 3
Balance at ending $ 489,843 $ 506,511
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details 2) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total $ 21,214,670 $ 33,938,609
US Treasury Bill Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 13,449,784 13,156,340
U S Treasury Bill Securities 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 14,477,726
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 21,214,670 33,938,609
Fair Value, Inputs, Level 1 [Member] | US Treasury Bill Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 13,449,784 13,156,340
Fair Value, Inputs, Level 1 [Member] | U S Treasury Bill Securities 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 14,477,726
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Bill Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Fair Value, Inputs, Level 2 [Member] | U S Treasury Bill Securities 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Bill Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Fair Value, Inputs, Level 3 [Member] | U S Treasury Bill Securities 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Cash [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 7,764,886 6,304,543
Cash [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 7,764,886 6,304,543
Cash [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
Cash [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details Narrative) - Fair Value, Inputs, Level 3 [Member]
3 Months Ended
Sep. 30, 2023
$ / shares
Derivative Liability Warrants [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Share Price $ 3.41
Exercise Price $ 5.82
Term 3 years 2 months 12 days
Risk Free Interest Rate 4.80%
Volatility Rate 92.00%
Derivative Liability Conversion Option On Convertible Debenture [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Share Price $ 6.98
Term 1 year 2 months 1 day
Risk Free Interest Rate 5.39%
Volatility Rate 93.00%
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions (Details) - Stock Options [Member] - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Offsetting Assets [Line Items]    
Options outstanding at beginning 3,952,864 3,952,864
Weighted average exercise price, Options outstanding at beginning $ 7.10 $ 7.10
Weighted Remaining Average Contractual Term, Ending Balance 6 years 6 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding at beginning of period $ 477,247 $ 1,067,966
Options Exercisable 1,689,339  
Weighted Average Exercise Price, Options Exercisable $ 7.64  
Weighted Average Remaining Contractual Term, Options Exercisable 5 years 6 months  
Aggregate Intrinsic Value, Options Exercisable $ 154,404  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions (Details 1)
3 Months Ended
Sep. 30, 2023
$ / shares
shares
Equity [Abstract]  
Number of shares unvested at beginning | shares 596,457
Weighted average grant date fair value per share unvested at beginning | $ / shares $ 5.24
Number of shares, Vested | shares (38,730)
Weighted average grant date fair value per share, Vested | $ / shares $ 6.12
Number of shares unvested at ending | shares 557,727
Weighted average grant date fair value per share unvested at ending | $ / shares $ 5.40
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions (Details 2) - Warrant [Member] - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Warrant Outstanding 7,770,285 7,770,285
Weighted average exercise price, warrants outstanding $ 2.06 $ 2.06
Weighted average remaining life (Years), warrants outstanding 3 years 9 months 18 days 4 years
Aggregate intrinsic value, otstanding $ 11,682,257 $ 18,318,954
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Equity Transactions (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Oct. 03, 2023
Aug. 09, 2023
Nov. 23, 2022
Sep. 30, 2023
Sep. 30, 2022
Class of Stock [Line Items]          
Stock-based compensation expense       $ 808,027 $ 878,640
Total compensation cost     $ 1,744,192    
Stock based compensation - restricted stock units       380,834 17,537
Restricted Stock Units (RSUs) [Member]          
Class of Stock [Line Items]          
Shares issued over the vesting period   38,730      
Restricted Stock Units (RSUs) [Member] | Four Directors [Member]          
Class of Stock [Line Items]          
Stock-based compensation expense     952,492    
Restricted Stock Units (RSUs) [Member] | Three Directors [Member]          
Class of Stock [Line Items]          
Stock-based compensation expense     $ 791,700    
Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member] | Four Directors [Member]          
Class of Stock [Line Items]          
Rsu granted     155,636    
Rsu granted, grant date fair value     $ 6.12    
Restricted Stock Units (RSUs) [Member] | N 2019 Omnibus Incentive Equity Plan [Member] | Three Directors [Member]          
Class of Stock [Line Items]          
Rsu granted     195,000    
Rsu granted, grant date fair value     $ 6.12    
Stock Options [Member]          
Class of Stock [Line Items]          
Stock-based compensation expense       $ 808,027 $ 878,640
Equity Option [Member] | New Employee [Member] | Subsequent Event [Member]          
Class of Stock [Line Items]          
Stock option to purchase 211,167        
Weighted Average Contractual Term, Granted (in Years) 48 months        
Weighted Average Exercise Price, Options Grants $ 3.41        
Equity Option [Member] | New Employee [Member] | Subsequent Event [Member] | Minimum [Member]          
Class of Stock [Line Items]          
Awarded Vested rights, percentage 20.00%        
Equity Option [Member] | New Employee [Member] | Subsequent Event [Member] | Maximum [Member]          
Class of Stock [Line Items]          
Awarded Vested rights, percentage 80.00%        
Common Class A [Member] | Sales Agreement [Member]          
Class of Stock [Line Items]          
Issuance of common stock for cash, shares       432,201 1,544,872
Issuance of common stock for cash       $ 1,900,000 $ 5,900,000
Commissions percentage       3.00% 3.00%
Issuance costs       $ 119,000 $ 400,000
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Leases    
Operating lease, right-of-use asset, net $ 70,748 $ 80,789
Current portion of operating lease liabilities 46,548 44,909
Operating lease liabilities, net of current portion 30,221 42,505
Total operating lease liabilities $ 76,769 $ 87,414
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details 1) - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Leases    
Year ending June 30, 2024 (Remaining 9 months) $ 39,256  
2025 44,636  
Total minimum lease payments 83,892  
Less amount representing interest (7,123)  
Present value of future minimum lease payments 76,769 $ 87,414
Less current portion of operating lease liabilities (46,548) (44,909)
Operating lease liabilities, net of current portion $ 30,221 $ 42,505
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details 2)
Sep. 30, 2023
Jun. 30, 2023
Leases    
Weighted average remaining lease term (Years) Operating leases 1 year 6 months 1 year 9 months 18 days
Weighted average discount rate Operating leases 10.75% 10.75%
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Leases    
Operating lease cost $ 13,000 $ 13,000
Cash paid for amounts included in measurement of lease liabilities $ 12,900 $ 12,525
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Employee Benefit Plan (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Employee Benefit Plan    
Employee Benefit Plan $ 30,900 $ 45,500
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details Narrative) - Subsequent Event [Member] - Sales Agreement [Member] - Agent [Member]
Nov. 14, 2023
USD ($)
shares
Subsequent Event [Line Items]  
Number of common stock sold | shares 819,935
Value of common stock sold $ 3,500,000
Commission and expenses $ 105,000
XML 66 bivi-20230930_10q_htm.xml IDEA: XBRL DOCUMENT 0001580149 2023-07-01 2023-09-30 0001580149 2023-11-06 0001580149 2023-09-30 0001580149 2023-06-30 0001580149 2022-07-01 2022-09-30 0001580149 2022-06-30 0001580149 2022-09-30 0001580149 us-gaap:CommonStockMember 2022-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001580149 bivi:TreasuryStocksMember 2022-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001580149 us-gaap:RetainedEarningsMember 2022-06-30 0001580149 us-gaap:CommonStockMember 2023-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001580149 bivi:TreasuryStocksMember 2023-06-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001580149 us-gaap:RetainedEarningsMember 2023-06-30 0001580149 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001580149 bivi:TreasuryStocksMember 2022-07-01 2022-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001580149 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001580149 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001580149 bivi:TreasuryStocksMember 2023-07-01 2023-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001580149 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001580149 us-gaap:CommonStockMember 2022-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001580149 bivi:TreasuryStocksMember 2022-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001580149 us-gaap:RetainedEarningsMember 2022-09-30 0001580149 us-gaap:CommonStockMember 2023-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001580149 bivi:TreasuryStocksMember 2023-09-30 0001580149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001580149 us-gaap:RetainedEarningsMember 2023-09-30 0001580149 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001580149 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0001580149 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001580149 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001580149 2022-07-01 2023-06-30 0001580149 bivi:AcuitasGroupHoldingsLLCMember 2022-07-15 0001580149 us-gaap:PrimeRateMember 2023-07-01 2023-09-30 0001580149 bivi:UnearnedDiscountMember 2023-09-30 0001580149 us-gaap:FinanceReceivablesMember 2023-09-30 0001580149 bivi:LoanAccretionPremiumMember 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnNotePayableMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-07-01 2023-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001580149 us-gaap:CashMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0001580149 us-gaap:USTreasuryBillSecuritiesMember 2023-09-30 0001580149 us-gaap:FairValueInputsLevel1Member bivi:USTreasuryBillSecurities1Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel2Member bivi:USTreasuryBillSecurities1Member 2023-09-30 0001580149 us-gaap:FairValueInputsLevel3Member bivi:USTreasuryBillSecurities1Member 2023-09-30 0001580149 bivi:USTreasuryBillSecurities1Member 2023-09-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001580149 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001580149 us-gaap:CashMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2023-06-30 0001580149 us-gaap:FairValueInputsLevel1Member bivi:USTreasuryBillSecurities1Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel2Member bivi:USTreasuryBillSecurities1Member 2023-06-30 0001580149 us-gaap:FairValueInputsLevel3Member bivi:USTreasuryBillSecurities1Member 2023-06-30 0001580149 bivi:USTreasuryBillSecurities1Member 2023-06-30 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2023-07-01 2023-09-30 0001580149 us-gaap:CommonClassAMember bivi:SalesAgreementMember 2022-07-01 2022-09-30 0001580149 bivi:StockOptionsMember 2023-07-01 2023-09-30 0001580149 bivi:StockOptionsMember 2022-07-01 2022-09-30 0001580149 bivi:FourDirectorsMember us-gaap:RestrictedStockUnitsRSUMember bivi:N2019OmnibusIncentiveEquityPlanMember 2022-11-01 2022-11-23 0001580149 bivi:FourDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2022-11-01 2022-11-23 0001580149 bivi:ThreeDirectorsMember us-gaap:RestrictedStockUnitsRSUMember bivi:N2019OmnibusIncentiveEquityPlanMember 2022-11-01 2022-11-23 0001580149 bivi:ThreeDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2022-11-01 2022-11-23 0001580149 2022-11-23 0001580149 us-gaap:RestrictedStockUnitsRSUMember 2023-08-01 2023-08-09 0001580149 bivi:NewEmployeeMember us-gaap:StockOptionMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-03 0001580149 srt:MinimumMember bivi:NewEmployeeMember us-gaap:StockOptionMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-03 0001580149 srt:MaximumMember bivi:NewEmployeeMember us-gaap:StockOptionMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-03 0001580149 bivi:StockOptionsMember 2023-06-30 0001580149 bivi:StockOptionsMember 2022-07-01 2023-06-30 0001580149 bivi:StockOptionsMember 2023-09-30 0001580149 us-gaap:WarrantMember 2023-06-30 0001580149 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001580149 us-gaap:WarrantMember 2023-09-30 0001580149 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001580149 bivi:AgentMember us-gaap:SubsequentEventMember bivi:SalesAgreementMember 2023-11-01 2023-11-14 iso4217:USD shares iso4217:USD shares pure false --06-30 2023 Q1 0001580149 10-Q true 2023-09-30 false 001-39015 BIOVIE INC. NV 46-2510769 680 W Nye Lane Suite 204 Carson City NV 89703 775 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ Yes Yes Non-accelerated Filer true false false 37742695 21214670 19460883 14477726 1549287 102526 22763957 34041135 70748 80789 579751 637095 345711 345711 23760167 35104730 2714760 3476259 48385 46548 44909 661467 894926 9338533 9105074 622397 894280 489843 925762 13212081 14494669 30221 42505 469937 227270 2969937 5227270 16212239 19764444 0.001 0.001 10000000 10000000 0 0 0 0 0.0001 0.0001 800000000 800000000 36922760 36899880 36451829 36428949 3690 3643 319480409 316385759 176591 -311936169 -301225705 2 2 7547928 15340286 23760167 35104730 57344 57344 8875659 6769932 1942818 2007062 10875821 8834338 -10875821 -8834338 707802 -566542 1004668 1056416 462223 41585 -165357 1581373 -10710464 -10415711 -10710464 -10415711 -0.29 -0.38 -0.29 -0.38 36742812 27212445 36742812 27212445 -10710464 -10415711 -176591 -176591 -10887055 -10415711 -10710464 -10415711 57344 57344 380834 17537 808027 878640 37825 42554 -355877 -400361 82424 143813 223865 10041 8983 707802 -566542 1446761 221244 -761499 179530 -10645 -9213 -48385 -869456 -12177049 -9220320 -14525000 14525000 1905836 5903682 2500000 5905840 -594164 11809522 1753787 2589202 19460883 18641716 21214670 21230918 528541 469687 -176591 24984083 2496 254638329 -250969890 3670935 878640 878640 17537 17537 1544872 155 5903527 5903682 3636364 364 5905476 5905840 -10415711 -10415711 30165319 3015 267343509 -261385601 5960923 36451829 3643 316385759 -22880 -2 176591 -301225705 15340286 808027 808027 380834 380834 432201 43 1905793 1905836 38730 4 -4 -10710464 -10710464 -176591 -176591 36922760 3690 319480409 -22880 -2 -311936169 7547928 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zlPYDfM4y742" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>1.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_828_zLYsDPpnOwl9">Background Information</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”), from a related party privately held clinical-stage pharmaceutical company, in June 2021. The acquired assets included NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase (“ERK”) signaling that, based on animal studies, is believed to reduce neuroinflammation. NE3107 is a novel orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), and NE3107 could, if approved represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Late in September 2023, the final patient completed the last treatment at week 30 in the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients who have mild to moderate Alzheimer’s disease. The database cleaning process remains underway, with the clinical team resolving outstanding queries and entering final data into the electronic data system. Final database lock, unblinding and subsequent release of topline results is anticipated to occur during the fourth quarter of calendar year 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed its Phase 2 study assessing NE3107 in PD patients in the fourth quarter of calendar year 2022. The NM201 study (NCT05083260) was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in PD participants treated with carbidopa/levodopa and NE3107. The study was primarily designed to assess safety (general safety in the patient population and potential for drug-drug interactions of NE3107 with levodopa); and secondary, to look for indications of promotoric activity akin to promotoric activity and apparent enhancement of levodopa activity observed in preclinical models. Both the safety and efficacy objectives of the study were met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD frontotemporal lobar dementia, and Amyotrophic lateral sclerosis (ALS). NE3107 is an orally bioavailable, blood-brain permeable, small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company’s work testing the molecule in AD and PD patients. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s Orphan Drug candidate BIV201 (continuous infusion terlipressin), has been granted Fast Track designation status by the U.S. Food and Drug Administration (“FDA”), is being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The Phase 2b study was closed before full enrollment, without clinically meaningful adverse effects associated with BIV201 treatment. While the active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, treatment of ascites is not included in these authorizations. Patients with refractory ascites suffer from frequent life-threatening complications, generate more than $5 billion in annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The FDA has not approved any drug to treat refractory ascites.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BIV201 development program was initiated by LAT Pharma LLC (“LAT Pharma”). On April 11, 2016, the Company acquired LAT Pharma and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin), if approved, to be shared by the members of LAT Pharma, PharmaIn Corporation and The Barrett Edge, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80F_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zbIqd31oYYdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>2.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_82F_z1SULUqooZo5">Liquidity</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2023, the Company had working capital of approximately $<span id="xdx_90B_ecustom--WorkingCapital_iI_pp0n3_dm_c20230930_zEBPOqfobemi" title="Working capital">9.6</span> million, cash and cash equivalents totaling of approximately $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n3_dm_c20230930_zdeexPnFOR0d" title="Cash and cash equivalent">21.2</span> million, stockholders’ equity of approximately $<span id="xdx_908_ecustom--StockholderEquities_iI_pp0n3_dm_c20230930_zQKlROfPDEdl" title="Stockholders' equity">7.5</span> million, and an accumulated deficit of approximately $<span id="xdx_908_ecustom--AccumulatedDeficit_iI_pp0n3_dm_c20230930_zgtXswgu1umh" title="Accumulated deficit">311.9</span> million. The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Although our cash balance may possibly sustain operations over the next 12 months from the balance sheet date if measures are taken to delay planned expenditures in our research protocols and slow the progress in the Company’s development of next phase clinical programs, the Company’s current planned operations to meet certain goals and objectives, project cash flows to be depleted within that period of time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> 9600000 21200000 7500000 311900000 <p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zXsiOYn5LGXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>3.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_82D_z0ulH0S2cc5h">Significant Accounting Policies</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJQDZYByLIA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_863_zF3xapuGb4f4">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2023 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2023 and 2022 in our Annual Report on Form 10-K filed with the SEC on August 16, 2023 (the “2023 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zTx5JCURoAq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_865_zBreUU77S4ge">Net loss per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930_zedeATKxk9Gk" title="Common stock, par value">0.0001</span> per share (“common stock”), outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and restricted stock units. For the three months ended September 30, 2023 and 2022, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the number of outstanding stock options, warrants and restricted stock units as of September 30, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z21oJmff2Ux8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B6_zd3GH2jBSF6d" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,952,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,348,330</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,770,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,779,194</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Restricted Stock Units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">557,727</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">124,520</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">12,280,876</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">11,252,044</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcu9jSdYime6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_868_zdf50lu9OUEe">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations and comprehensive loss since the 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLwYXwLNcoOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zhFgTCPHahZ8">Cash and cash equivalents</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_zIoluPi0vKCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_863_zz6urecVAurj">Investments in U.S. Treasury Bills</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gain were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Upon the maturity and settlement of these investments, realized gains were recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zHpTbPbfs5B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zyLG5q4C9DDj">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ze8HUBmlBN31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zkQOvUGge1z1">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 – Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 – Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities, notes payable and other derivative liabilities (see Note 9). The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJQDZYByLIA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_863_zF3xapuGb4f4">Basis of Presentation – Interim Financial Information</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”) for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2023 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. These unaudited interim condensed financial statements should be read in conjunction with the Company’s audited financial statements for the fiscal years ended June 30, 2023 and 2022 in our Annual Report on Form 10-K filed with the SEC on August 16, 2023 (the “2023 Form 10-K”). A summary of significant accounting policies can also be found in those audited financial statements in the 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zTx5JCURoAq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_865_zBreUU77S4ge">Net loss per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930_zedeATKxk9Gk" title="Common stock, par value">0.0001</span> per share (“common stock”), outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, and restricted stock units. For the three months ended September 30, 2023 and 2022, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for the periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the number of outstanding stock options, warrants and restricted stock units as of September 30, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z21oJmff2Ux8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B6_zd3GH2jBSF6d" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,952,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,348,330</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,770,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,779,194</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Restricted Stock Units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">557,727</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">124,520</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">12,280,876</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">11,252,044</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 0.0001 <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z21oJmff2Ux8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B6_zd3GH2jBSF6d" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Stock Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,952,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 10%; text-align: right" title="Total">3,348,330</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,770,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">7,779,194</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Restricted Stock Units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">557,727</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Total">124,520</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20230930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">12,280,876</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930_pdd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">11,252,044</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 3952864 3348330 7770285 7779194 557727 124520 12280876 11252044 <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcu9jSdYime6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_868_zdf50lu9OUEe">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”). There have been no recent ASUs that are expected to have a material impact on the Company’s balance sheets or statements of operations and comprehensive loss since the 2023 Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLwYXwLNcoOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_861_zhFgTCPHahZ8">Cash and cash equivalents</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consisted of cash deposits and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S. Treasury Bills with original maturities of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_zIoluPi0vKCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_863_zz6urecVAurj">Investments in U.S. Treasury Bills</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in U.S. Treasury Bills with maturities greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gain were included in other comprehensive income in the accompanying statements of operations and comprehensive loss. Upon the maturity and settlement of these investments, realized gains were recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zHpTbPbfs5B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_866_zyLG5q4C9DDj">Concentration of Credit Risk in the Financial Service Industry</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company’s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ze8HUBmlBN31" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zkQOvUGge1z1">Fair value measurement of assets and liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 – Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 – Inputs are unobservable inputs based on our assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments include cash, accounts payable, the carrying value of the operating lease liabilities, notes payable and other derivative liabilities (see Note 9). The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p> <p id="xdx_803_ecustom--InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_zyD4fgWavAYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_824_zwqcOlbO0zjj">Investments in U.S. Treasury Bills Available for Sale</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the U.S. Treasury Bills held at June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zCcnNMvhESr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills available for sale (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BD_zyXNw4dnNHeg" style="display: none">Schedule of U.S. treasury bills held</span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amortized Cost<br/> Basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Unrealized <br/> Gain</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Accumulated <br/> Other <br/> Comprehensive <br/> Income</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">U.S. Treasury Bills due is 3 - 6 months</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCostBasis_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zAPhfOR7mZjd" style="width: 10%; text-align: right" title="Amortized Cost Basis">14,301,136</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--GrossUnrealizedGain_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zmYHol4JWonb" style="width: 10%; text-align: right" title="Gross Unrealized Gain">176,591</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentOwnedUnrecognizedUnrealizedDepreciation_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zndR5DXnbZVd" style="width: 10%; text-align: right" title="Fair Value">14,477,726</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zVq8afNvoG1e" style="width: 10%; text-align: right" title="Total Accumulated Other Comprehensive Income">176,591</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended June 30, 2023, the Company purchased a total of approximately $<span id="xdx_90B_ecustom--NumberOfStockPurchased_pp0n3_dm_c20220701__20230630_zHRg3bIkZ1o6" title="Number of stock purchased">46</span> million of U.S. Treasury Bills during the year ended June 30, 2023. All outstanding investments in U.S. Treasury Bills available for sale held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $<span id="xdx_90D_ecustom--RealizedGainOnMaturityOfAvailableforSale_pp0p0_c20230701__20230930_zeyyBHSNzWZk" title="Realized gain on maturity of available-for sale">223,865</span> recorded as a component of interest income on the accompanying condensed statement of operations and comprehensive loss.</p> <table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zCcnNMvhESr" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills available for sale (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BD_zyXNw4dnNHeg" style="display: none">Schedule of U.S. treasury bills held</span></td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amortized Cost<br/> Basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Unrealized <br/> Gain</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Accumulated <br/> Other <br/> Comprehensive <br/> Income</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">U.S. Treasury Bills due is 3 - 6 months</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AmortizedCostBasis_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zAPhfOR7mZjd" style="width: 10%; text-align: right" title="Amortized Cost Basis">14,301,136</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--GrossUnrealizedGain_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zmYHol4JWonb" style="width: 10%; text-align: right" title="Gross Unrealized Gain">176,591</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentOwnedUnrecognizedUnrealizedDepreciation_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zndR5DXnbZVd" style="width: 10%; text-align: right" title="Fair Value">14,477,726</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iI_pp0p0_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_zVq8afNvoG1e" style="width: 10%; text-align: right" title="Total Accumulated Other Comprehensive Income">176,591</td><td style="width: 1%; text-align: left"> </td></tr> </table> 14301136 176591 14477726 176591 46000000 223865 <p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_zy1LpU19XeNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_82F_z1EaMR7ghfmg">Intangible Assets</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s intangible assets consist of intellectual property acquired from LAT Pharma and are amortized over their estimated useful lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Company’s intangible assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zOo408uWCMR5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BB_zP9ompyH7c81" style="display: none"> Schedule of intangible assets</span></td><td> </td> <td colspan="2" id="xdx_495_20230930_zFyH74y8h871" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20230630_zDEcqYwuz7Yb" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzS8E_zfhfsg2T2uo" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzS8E_zqExTWpCvulk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,714,019</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,656,675</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzS8E_zJaFmOpdhUJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">579,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">637,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_z3vLB7tAoC8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20230930_pp0p0" title="Amortization expenses"><span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20220701__20220930_pp0p0" title="Amortization expenses">57,344</span></span> in each of the three-month periods ended September 30, 2023 and 2022. The Company amortizes intellectual property over the expected, original useful lives of <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230930_zxYYzXxrPwEa" title="Useful Life">10</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated future amortization expense is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2jk3C6tnbVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span id="xdx_8B5_z9NzW6bZ462e" style="display: none">Schedule of future amortization expense</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20230930_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">172,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20230930_pp0p0" style="text-align: right" title="2025">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20230930_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2026">178,341</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230930_znnAmSbWO8u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite lived intangible assets, net">        579,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zOxR000Tz27c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zOo408uWCMR5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BB_zP9ompyH7c81" style="display: none"> Schedule of intangible assets</span></td><td> </td> <td colspan="2" id="xdx_495_20230930_zFyH74y8h871" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49A_20230630_zDEcqYwuz7Yb" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzS8E_zfhfsg2T2uo" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Intellectual Property</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzS8E_zqExTWpCvulk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,714,019</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,656,675</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzS8E_zJaFmOpdhUJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">579,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">637,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2293770 2293770 1714019 1656675 579751 637095 57344 57344 P10Y <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z2jk3C6tnbVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span id="xdx_8B5_z9NzW6bZ462e" style="display: none">Schedule of future amortization expense</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20230930_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">172,033</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20230930_pp0p0" style="text-align: right" title="2025">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c20230930_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2026">178,341</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20230930_znnAmSbWO8u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite lived intangible assets, net">        579,751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 172033 229377 178341 579751 <p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zP2K5wdPZuW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>6.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_824_zYfrN42KW9y2">Related Party Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity Transactions with Acuitas</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_zvOWpESYqg57" title="Common Stock, shares issued">3,636,364</span> shares of the Company’s Common Stock, at a price of $1.65 per share (the “PIPE Shares”), and (ii) a warrant to purchase 7,272,728 shares of Common Stock (“PIPE Warrant Shares”), at an exercise price of $1.82, with a term of exercise of five years. The warrant has a down round feature that reduces the exercise price of the warrant if the Company sells stock at a price lower than the exercise price of the warrant. On August 15, 2022, the Company received net proceeds of approximately $5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the “Existing Registration Rights Agreement”), to amend the definition of “Registrable Securities” in the Existing Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.</p> 3636364 <p id="xdx_805_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z6iPUHdFfDM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>7.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_824_zgWB2gW45n85">Other Liabilities</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current portion of other liabilities at June 30, 2023 was approximately $<span id="xdx_904_eus-gaap--OtherLiabilities_c20230930_pp0p0" title="Other liabilities">48,000</span> and represented the remaining balance of a retention bonus payable for arrangements with certain employees, which was paid in July 2023. </p> 48000 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zznRQApbveF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>8.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_82D_zkkhZDtBsCH5">Notes Payable</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 30, 2021 (the “Closing Date”), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and Promissory Notes (together, the “Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (“AVOPI”) and Avenue Venture Opportunities Fund II, L.P. (“AVOPII,” and together with AVOPI, “Avenue”) for growth capital loans in an aggregate commitment amount of up to $20 million (the “Loan”). On the Closing Date, $15 million of the Loan was funded (“Tranche 1”). The Loan provided for an additional $5 million to be available to the Company on or prior to September 15, 2022, subject to the Company’s achievement of certain milestones with respect to certain of its ongoing clinical trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20230930__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_pdd" title="Interest rate">7.00%</span> plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at September 30, 2023 was <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20230930_pdd" title="Interest rate">8.50%</span>. The Loan is secured by a lien upon and security interest in all of the Company’s assets, including intellectual property, subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement required monthly interest-only payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays equal monthly payments of principal, plus accrued interest, until the Loan’s maturity date when all remaining principal and accrued interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal amount of the Loan that is prepaid after the interest-only period. At the Loan’s maturity date, or on the date of the prepayment of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and Tranche 2.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement includes a conversion option to convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company’s Common Stock at a conversion price of $6.98 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the Closing Date, the Company issued to Avenue warrants to purchase 361,002 shares of Common Stock of the Company (the “Avenue Warrants”) at an exercise price per share equal to $5.82. The Avenue Warrants are exercisable until November 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of the carrying value of the notes payable was determined by allocating portions of the outstanding principal of the notes; approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_pp0n3_dm_c20230701__20230930_zmjrJdqGDtR4" title="Fair value of warrants">1.4</span> million to the fair value of the Avenue Warrants and approximately $<span id="xdx_902_ecustom--FairValueOfEmbeddedConversionOption_pp0n3_dm_c20230701__20230930_z06amYCgW11i" title="Fair value of embedded conversion option">2.2</span> million to the fair value of the embedded conversion option. Accordingly, the total amount of unearned discount of approximately $<span id="xdx_902_ecustom--UnearnedDiscount_pp0n3_dm_c20220701__20230630_zdXI37aKBTm3" title="Unearned discount">3.6</span> million, the total direct financing cost of approximately $<span id="xdx_908_ecustom--DirectFinancingCost_pp0p0_c20230701__20230930_z4ZfTeAfGas3" title="Direct financing cost">390,000</span> and premium of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pp0p0_c20230930_zCx0xWgxRq2h" title="Unamortized premium recognized">850,000</span> are recognized on an effective interest method over the term of the Loan. The adjusted effective interest rate is 25%. The total interest expense of approximately $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20230701__20230930_zc04tFptqgy3" title="Interest expense">1</span> million for the three months ended September 30, 2023, was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest only payments totaling approximately $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0p0_c20230701__20230930_zl56kxOg91He" title="Interest payment">525,000</span>, the amortization of financing costs of approximately $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20230701__20230930_zQIHJSbTLU41" title="Amortization of financing costs">38,000</span>, unearned discount of approximately $<span id="xdx_901_ecustom--UnearnedDiscount_pp0p0_c20230701__20230930_zlC4Drwh7787" title="Unearned discount">356,000</span> and the accretion of loan premium of approximately $<span id="xdx_907_ecustom--AccretionsOfLoanPremium_pp0p0_c20230701__20230930_ziCOBFEOwhW1" title="Accretion of loan premium">82,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total interest expense of approximately $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20220701__20220930_zMZW2sGux6I3" title="Interest expense">1.1</span> million for the three months ended September 30, 2022; was recognized in the accompanying condensed statements of operations and comprehensive loss and included the interest payments totaling approximately $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0p0_c20220701__20220930_zIaQWmK4kuE6" title="Interest payment">470,000</span>, the amortization of financing costs of approximately $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_pp0p0_c20220701__20220930_z2wTt4GlOpoc" title="Amortization of financing costs">43,000</span>, unearned discount of approximately $<span id="xdx_900_ecustom--UnearnedDiscount_pp0p0_c20220701__20220930_zfheYhejm3ec" title="Unearned discount">400,000</span> and the accretion of loan premium totaled of approximately $<span id="xdx_909_ecustom--AccretionsOfLoanPremium_pp0p0_c20220701__20220930_zVROSe0xFbsi" title="Accretion of loan premium">144,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the remaining principal balance of $12.5 million under the Loan is payable in 15 monthly equal installments. For the three months ended September 30, 2023, the Company paid back $2.5 million of the original loan of $15 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Notes Payable as of September 30, 2023 and June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current portion of Notes Payable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZ9b9phk41Zd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_zb3HNSoZhzQl" style="display: none">Schedule of note payable</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20230930_zTsQlNeDzJMd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20230630_zKgp9l7zerA9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">September 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">June 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Current portion of Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80,381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(108,751</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zEeYfuDZjlpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(756,238</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,023,145</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus accretion of loan premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">175,152</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236,970</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of Notes Payable, net of financing costs, unearned premiums and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,338,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,105,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-current portion of Notes Payable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230930" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">September 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230630" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">June 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,820</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22,242</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111,212</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus accretion of loan premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">494,544</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,302</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes Payable, net of the current portion financing costs, unearned premiums and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,969,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,227,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zRx3bKaUV2b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated future amortization expense and accretion of premium is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zzGw5NQlUreb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"><span id="xdx_8B6_zvrDt4M8yxQ5" style="display: none"> Schedule of estimated future amortization expense and accretion of premium</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Unearned Discount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Debt Financing <br/> Costs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Loan accretion <br/> Premium</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">667,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">70,926</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">154,546</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">111,212</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">11,820</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">25,758</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">778,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">82,746</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">180,304</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zkeP8rtLPqZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 0.0700 0.0850 1400000 2200000 3600000 390000 850000 1000000 525000 38000 356000 82000 1100000 470000 43000 400000 144000 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zZ9b9phk41Zd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BB_zb3HNSoZhzQl" style="display: none">Schedule of note payable</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20230930_zTsQlNeDzJMd" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20230630_zKgp9l7zerA9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">September 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">June 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Current portion of Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80,381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(108,751</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zEeYfuDZjlpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(756,238</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,023,145</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus accretion of loan premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">175,152</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">236,970</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of Notes Payable, net of financing costs, unearned premiums and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,338,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,105,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-current portion of Notes Payable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230930" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">September 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230630" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">June 30, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Notes Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less debt financing costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,365</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,820</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less unearned discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(22,242</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111,212</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Plus accretion of loan premium</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">494,544</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,302</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes Payable, net of the current portion financing costs, unearned premiums and discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,969,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,227,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10000000 10000000 -80381 -108751 756238 1023145 175152 236970 9338533 9105074 2500000 5000000 -2365 -11820 -22242 -111212 494544 350302 2969937 5227270 <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zzGw5NQlUreb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"><span id="xdx_8B6_zvrDt4M8yxQ5" style="display: none"> Schedule of estimated future amortization expense and accretion of premium</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Unearned Discount</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Debt Financing <br/> Costs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-weight: bold">Loan accretion <br/> Premium</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">667,268</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">70,926</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--AmortizationExpenseNextRollingTwelveMonths_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="width: 10%; text-align: right" title="Year ending June 30, 2024 (Remaining 9 months)">154,546</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">111,212</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">11,820</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--AmortizationExpenseNextRollingTwoYears_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="2025">25,758</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">778,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">82,746</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--AmortizationExpenseTotal_c20230930__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">180,304</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 667268 70926 154546 111212 11820 25758 778480 82746 180304 <p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zVjjzzdSABt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_826_zOarHmDLgSyh">Fair Value Measurements</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2023 and June 30, 2023, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxqNtPCixNGa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span id="xdx_8BE_zN6wywzLJ0He" style="display: none">Schedule of derivative liabilities at fair value</span> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Derivative liability - Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">622,397</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">622,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability - Conversion option on notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">489,843</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">489,843</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivatives</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">         <span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">        <span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,112,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,112,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Derivative liability - Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability - Conversion option on note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">        <span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">      <span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">925,762</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember_z4mVWcAYuGUl" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">925,762</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivatives</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxDcIUl2a203" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIb6rNjwDCW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3XhWXtr0sxc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630_zPveX3IPdfz4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zQlE2WQUFKQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2023: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zwVrz0gQV4mj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B8_zMMvaAfVGOLh" style="display: none">Fair value, liabilities measured on recurring basis</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liabilities <br/> - Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liability - <br/> Conversion Option <br/> on Convertible <br/> Debenture</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Balance at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYC48dz8iUDi" style="width: 10%; text-align: right" title="Balance at beginning">894,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVjMn6B8QYo" style="width: 10%; text-align: right" title="Balance at beginning">925,762</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">(271,883</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">(435,919</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3Ml3zRooyWk" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">622,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTV44ETSotXc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">489,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liabilities <br/> - Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liability - <br/> Conversion Option <br/> on Convertible <br/> Debenture</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Balance at June 30, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwqJHE6OZhif" style="width: 10%; text-align: right" title="Balance at beginning">194,531</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmtAA2zjNDw4" style="width: 10%; text-align: right" title="Balance at beginning">188,030</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0748">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">248,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">318,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zB5w4dePQuv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">442,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4mgsavXOiX4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">506,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zoDwhWh3e1ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of derivative liabilities for the Avenue Warrants and the conversion option at September 30, 2023 in the accompanying condensed balance sheet, were approximately $622,000 and approximately $490,000, respectively. The total change in the fair value of the derivative liabilities totaled approximately $708,000 for the three months ended September 30, 2023; and accordingly, was recorded in the accompanying condensed statement of operations and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at September 30, 2023 included the closing stock price of $<span id="xdx_90A_eus-gaap--SharePrice_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price">3.41</span> per share; for the Avenue Warrants, the exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Exercise Price">5.82</span>, remaining term <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5CFDERxCljl" title="Term">3.2</span> years, risk free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate">4.8%</span> and volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate">92.0%</span>; and for the embedded derivative liability of the conversion option, the conversion price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9wWoF3kF5q7" title="Share Price">6.98</span>; remaining term <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zT9JJuSvZLIl" title="Term">1.17</span> years, risk free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate">5.39%</span> and volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate">93.0%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Derivative liability – Avenue Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet and anti-dilution provisions or adjustments to the strike price due to an occurrence of a future event are accounted for as derivative financial instruments. The Avenue Warrants were not considered to be indexed to the Company’s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompany condensed balance sheet at September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Black Scholes model was used to calculate the fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants are recorded at their fair values at the date of issuance and remeasured at September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Embedded derivative liability – Conversion Option</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The embedded derivative liability represents the optional conversion feature of up to $5.0 million of the outstanding Loan, which meets the definition of a derivative and requires bifurcation from the loan amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Black Scholes model was used to calculate the fair value of the embedded derivative to bifurcate the embedded derivative amount representing the conversion option from the Avenue Loan amount funded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financial assets</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, investments in U.S. Treasury Bills were valued through use of quoted prices and are classified as Level 1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information about our assets that are measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyTfpsUKkSe2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BE_zAMBdys4ETcf" style="display: none"> Measured at fair value on a recurring basis</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total">7,764,886</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 10%; text-align: right" title="Total">7,764,886</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,449,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total">    <span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total">     <span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,449,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0801">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,214,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,214,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total">6,304,543</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 10%; text-align: right" title="Total">6,304,543</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total">        <span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total">        <span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">14,477,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">14,477,726</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">33,938,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">33,938,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zcBEi8wVtlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxqNtPCixNGa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span id="xdx_8BE_zN6wywzLJ0He" style="display: none">Schedule of derivative liabilities at fair value</span> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Derivative liability - Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">622,397</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">622,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability - Conversion option on notes payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">489,843</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">489,843</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivatives</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">         <span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">        <span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,112,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20230930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,112,240</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Derivative liability - Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability - Conversion option on note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">        <span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">      <span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">925,762</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnNotePayableMember_z4mVWcAYuGUl" style="border-bottom: Black 1pt solid; text-align: right" title="Total derivatives">925,762</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivatives</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxDcIUl2a203" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIb6rNjwDCW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3XhWXtr0sxc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20230630_zPveX3IPdfz4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 622397 622397 489843 489843 1112240 1112240 894280 894280 925762 925762 1820042 1820042 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zwVrz0gQV4mj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B8_zMMvaAfVGOLh" style="display: none">Fair value, liabilities measured on recurring basis</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liabilities <br/> - Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liability - <br/> Conversion Option <br/> on Convertible <br/> Debenture</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Balance at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYC48dz8iUDi" style="width: 10%; text-align: right" title="Balance at beginning">894,280</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVjMn6B8QYo" style="width: 10%; text-align: right" title="Balance at beginning">925,762</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">(271,883</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">(435,919</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3Ml3zRooyWk" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">622,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTV44ETSotXc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">489,843</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liabilities <br/> - Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Derivative liability - <br/> Conversion Option <br/> on Convertible <br/> Debenture</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Balance at June 30, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwqJHE6OZhif" style="width: 10%; text-align: right" title="Balance at beginning">194,531</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmtAA2zjNDw4" style="width: 10%; text-align: right" title="Balance at beginning">188,030</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions to level 3 liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0748">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">248,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liability">318,481</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0756">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zB5w4dePQuv1" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">442,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4mgsavXOiX4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at ending">506,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 894280 925762 -271883 -435919 622397 489843 194531 188030 248061 318481 442592 506511 3.41 5.82 P3Y2M12D 0.048 0.920 6.98 P1Y2M1D 0.0539 0.930 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zyTfpsUKkSe2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BE_zAMBdys4ETcf" style="display: none"> Measured at fair value on a recurring basis</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total">7,764,886</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 10%; text-align: right" title="Total">7,764,886</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,449,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total">    <span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total">     <span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,449,784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0801">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,214,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">21,214,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total">6,304,543</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0821">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 10%; text-align: right" title="Total">6,304,543</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total">        <span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total">        <span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">14,477,726</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">14,477,726</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">33,938,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">33,938,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7764886 7764886 13449784 13449784 21214670 21214670 6304543 6304543 13156340 13156340 14477726 14477726 33938609 33938609 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxtzBj37kpBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>10.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_821_z5PJDNc9aG9">Equity Transactions</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance of common stock for cash</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (collectively, the “Agents”), pursuant to which the Company may issue and sell from time-to-time shares of the Company’s common stock through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities, Inc. mutually agreed to terminate B. Riley Securities, Inc.’s role as a sales agent under the Sales Agreement. During the three months ended September 30, 2023, the Company sold <span id="xdx_90E_ecustom--IssuanceOfCommonStockForCashShares_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares">432,201</span> shares of common stock under the Sales Agreement for total net proceeds of $<span id="xdx_906_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zGoPCktNFO5a" title="Issuance of common stock for cash">1.9</span> million after <span id="xdx_908_ecustom--CommissionsPercentage_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage">3%</span> commissions and expenses of approximately $<span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Issuance costs">119,000</span>. During the three months ended September 30, 2022, the Company sold <span id="xdx_90C_ecustom--IssuanceOfCommonStockForCashShares_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares">1,544,872</span> shares of common stock under the Sales Agreement for total net proceeds of $<span id="xdx_90A_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zVXtlQirLTXg" title="Issuance of common stock for cash">5.9</span> million after <span id="xdx_90E_ecustom--CommissionsPercentage_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage">3%</span> commissions and expenses of approximately $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Issuance costs">400,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zaKhldeMbUS3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span id="xdx_8BB_zeHJk0pdKoSb" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighed-<br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Remaining <br/> Average <br/> Contractual <br/> Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="width: 10%; text-align: right" title="Options outstanding at beginning">3,952,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$ </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">7.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zLiq9hlc9ulg" title="Weighted Average Remaining Contractual Term, Options outstanding">6.3</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$ </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">1,067,966</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at beginning">3,952,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">7.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zS76n9Sg7wqc" title="Weighted Remaining Average Contractual Term, Ending Balance">6.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">477,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">1,689,339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options Exercisable">7.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zs8Kep1hjScc" title="Weighted Average Remaining Contractual Term, Options Exercisable">5.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Options Exercisable">154,404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zzuKFpsWlTJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. No stock options were issued, expired, canceled or exercised during the three months ended September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total stock option-based compensation expense for three-months ended September 30, 2023 and 2022 was of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" title="Stock-based compensation expense">808,027</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" title="Stock-based compensation expense">878,640</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance of restricted stock units and options :</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 23, 2022, the Company issued equity awards for the board of directors’ annual compensation. Four directors received restricted stick units (“RSUs”) to purchase a total of <span id="xdx_90A_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted">155,636</span> shares of common stock at the grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted, grant date fair value">6.12</span> per share, a total cost of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pp0p0" title="Stock-based compensation expense">952,492</span> recognized as stock compensation in the three months ended December 31, 2022. Three directors received stock options to purchase <span id="xdx_90D_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted">195,000</span> shares of common stock at an exercise price of $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted, grant date fair value">6.12</span> per share, the grant date fair value. The total stock compensation cost of stock options of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pp0p0" title="Stock-based compensation expense">791,700</span> was recognized in the three months ended December 31, 2022. The equity awards vest every three months beginning from the last annual shareholders’ meeting on November 9, 2022, on February 9, 2023, May 9, 2023, August 9, 2023 and earlier of November 9, 2023 or the next annual shareholders’ meeting. While the agreements contain certain contractual vesting terms, there are circumstances where the vesting can be accelerated that is not within the Company’s control and as a result, for accounting purposes, the awards are assumed to have been fully vested on the grant date, accordingly, the Company recognized the total compensation cost of $<span id="xdx_90F_ecustom--TotalCompensationCost_c20221123_pp0p0" title="Total compensation cost">1,744,192</span> on November 23, 2022. On August 9, 2023, the Company delivered the vested portion and issued <span id="xdx_905_ecustom--SharesIssuedOverVestingPeriod_c20230801__20230809__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zns4ifbYTdGf" title="Shares issued over the vesting period">38,730</span> shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes vesting of restricted common stock:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zsHAkWCqQY45" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8B3_z4twMmUEINsa" style="display: none"> Schedule of vesting of restricted common stock</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Grant <br/> Date Fair <br/> Value <br/> Per <br/> Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Unvested at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20230930_zF96GeP8P8z7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning">596,457</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20230930_znzwctfC1gv2" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning">5.24</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20230930_zdViIgpCO6Zg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested">(38,730</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20230930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested">6.12</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20230930_zFYkpo82ky9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares unvested at ending">557,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20230930_zekkcuQD6p6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending">5.40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zu9SaMPdMBzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total stock based compensation – restricted stock expense for three-months ended September 30, 2023 and 2022 was of $<span id="xdx_901_ecustom--StockBasedCompensationRestrictedStock_c20230701__20230930_pp0p0" title="Stock based compensation - restricted stock units">380,834</span> and $<span id="xdx_907_ecustom--StockBasedCompensationRestrictedStock_c20220701__20220930_pp0p0" title="Stock based compensation - restricted stock units">17,537</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Issuance of Stock Options under the 2019 Omnibus Plan.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2023, the Company granted stock options to purchase <span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20231001__20231003__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Stock option to purchase">211,167</span> shares of Common Stock to new hire employees. <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage">20%</span> of the shares underlying the options awarded vest on the one-year anniversary of the grant date, and the remaining <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage">80%</span> will vest in equal monthly installments over <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtM_c20231001__20231003__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_zjmbe02Q6Wt9" title="Weighted Average Contractual Term, Granted (in Years)">48</span> months each month thereafter. The exercise price of the options is $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20231003__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Weighted Average Exercise Price, Options Grants">3.41</span> per share and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are fully exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes warrant activity during the three months ended September 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zbzk1d1xoxZ3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_znWto9brZzH9" style="display: none">Summary of warrants activity</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2023</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBYnNgA1CXGe" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Warrant Outstanding">7,770,285</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOgyOj3Z7Trh" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, warrants outstanding">2.06</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8PtpfcJx5Nk" title="Weighted average remaining life (Years), warrants outstanding">4.0</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWtslMxV7kn2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, otstanding">18,318,954</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Outstanding and exercisable at September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1pnU6rvwQU5" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant Outstanding">7,770,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMeWBZMrgA3e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding">2.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZCEaR7Hvuna" title="Weighted average remaining life (Years), warrants outstanding">3.8</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, otstanding">11,682,257</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zpXxVcGfxFwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the above warrants, 101,380 expire in the fiscal year ending June 30, 2025, 35,175 expire in the fiscal year ending June 30, 2026, and 7,633,730 expire in the fiscal year ending June 30, 2027. No warrants were granted, expired, or were exercised during the three months ended September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 432201 1900000 0.03 119000 1544872 5900000 0.03 400000 <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zaKhldeMbUS3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span id="xdx_8BB_zeHJk0pdKoSb" style="display: none">Schedule of summarizes the activity relating to the Company’s stock options</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighed-<br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Remaining <br/> Average <br/> Contractual <br/> Term</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Outstanding at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="width: 10%; text-align: right" title="Options outstanding at beginning">3,952,864</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$ </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">7.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zLiq9hlc9ulg" title="Weighted Average Remaining Contractual Term, Options outstanding">6.3</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$ </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">1,067,966</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding at beginning">3,952,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">7.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zS76n9Sg7wqc" title="Weighted Remaining Average Contractual Term, Ending Balance">6.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period">477,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">1,689,339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options Exercisable">7.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zs8Kep1hjScc" title="Weighted Average Remaining Contractual Term, Options Exercisable">5.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Options Exercisable">154,404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3952864 7.10 P6Y3M18D 1067966 3952864 7.10 P6Y 477247 1689339 7.64 P5Y6M 154404 808027 878640 155636 6.12 952492 195000 6.12 791700 1744192 38730 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zsHAkWCqQY45" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 1)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8B3_z4twMmUEINsa" style="display: none"> Schedule of vesting of restricted common stock</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Grant <br/> Date Fair <br/> Value <br/> Per <br/> Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%">Unvested at June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20230930_zF96GeP8P8z7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning">596,457</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20230930_znzwctfC1gv2" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning">5.24</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20230930_zdViIgpCO6Zg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested">(38,730</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20230930_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested">6.12</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20230930_zFYkpo82ky9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares unvested at ending">557,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20230930_zekkcuQD6p6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending">5.40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 596457 5.24 38730 6.12 557727 5.40 380834 17537 211167 0.20 0.80 P48M 3.41 <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zbzk1d1xoxZ3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_znWto9brZzH9" style="display: none">Summary of warrants activity</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Remaining <br/> Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2023</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBYnNgA1CXGe" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Warrant Outstanding">7,770,285</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOgyOj3Z7Trh" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, warrants outstanding">2.06</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8PtpfcJx5Nk" title="Weighted average remaining life (Years), warrants outstanding">4.0</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWtslMxV7kn2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, otstanding">18,318,954</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Outstanding and exercisable at September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1pnU6rvwQU5" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant Outstanding">7,770,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMeWBZMrgA3e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding">2.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZCEaR7Hvuna" title="Weighted average remaining life (Years), warrants outstanding">3.8</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, otstanding">11,682,257</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 7770285 2.06 P4Y 18318954 7770285 2.06 P3Y9M18D 11682257 <p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zX5MuaOrIe1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>11.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_823_zuKzav1VFFee">Leases</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Office Lease</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company pays an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 897603. The rental agreement was for a one-year term and commenced on October 1, 2022 and has been subsequently renewed for another year at the same rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On February 26, 2022, the Company’s San Diego office relocated to 5090 Shoreham Place, San Diego, CA 92122. The term for the office lease is 38 months and commenced on March 1, 2022. The monthly base rate currently is $4,300, with annual increases of three percent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Total operating lease expense of approximately $<span id="xdx_902_eus-gaap--OperatingLeaseCost_c20230701__20230930_pp0p0" title="Operating lease cost">13,000</span> and $<span id="xdx_900_eus-gaap--OperatingLeaseCost_c20220701__20220930_pp0p0" title="Operating lease cost">13,000</span> for the three months ended September 30, 2023 and 2022, respectively; were included in the accompanying condensed statements of operations and comprehensive loss as a component of selling, general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The right-of-use asset, net and current and non current portion of the operating lease liabilities included in the accompany condensed balance sheets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOoohp3nyfbg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span id="xdx_8BC_zO5yidgagTZg" style="display: none">Schedule of deferred tax assets</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230930_z9uktkppTC68" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_499_20230630_z7ZXvlu80Hu3" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; text-align: left; padding-bottom: 1pt">Operating lease, right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">70,748</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">80,789</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Current portion of operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">46,548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">44,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,221</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42,505</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">76,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,414</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zbB4pzk4x9Ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2023, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_z3Ukk6co57K1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> <span id="xdx_8BE_zQbI86v5TpG1" style="display: none">Schedule of future estimated minimum lease payments under non-cancelable operating leases</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230930_zHmX5wcpJIi1" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 87%">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">39,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">44,636</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,892</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment_iNI_pp0p0_di_zp7o4m4Ohzcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,123</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zoyt9mLcZoEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,769</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zlKihAIpICp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(46,548</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zXhfkiozsmS1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,221</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zgWf5cnC1pha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Total cash paid for amounts included in the measurement of lease liabilities were $<span id="xdx_908_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_c20230701__20230930_pp0p0" title="Cash paid for amounts included in measurement of lease liabilities">12,900</span> and $<span id="xdx_90A_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_c20220701__20220930_pp0p0" title="Cash paid for amounts included in measurement of lease liabilities">12,525</span> for the three months ended September 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average remaining lease term and discount rate as of September 30, 2023 and June 30, 2023 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zkDgsvicPGyk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BA_zBu9kdFA9m99" style="display: none"> Schedule of weighted average remaining lease term and discount rate</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zvWict3NtKUe" title="Weighted average remaining lease term (Years) Operating leases">1.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_ztxu5t5IX4N7" title="Weighted average remaining lease term (Years) Operating leases">1.8</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230930_zNSDLYgS1jWi" title="Weighted average discount rate Operating leases">10.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zXDWVJW7MK1j" title="Weighted average discount rate Operating leases">10.75</span></td><td style="text-align: left">%</td></tr> </table> 13000 13000 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOoohp3nyfbg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span id="xdx_8BC_zO5yidgagTZg" style="display: none">Schedule of deferred tax assets</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230930_z9uktkppTC68" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_499_20230630_z7ZXvlu80Hu3" style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; text-align: left; padding-bottom: 1pt">Operating lease, right-of-use asset, net</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">70,748</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">80,789</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Current portion of operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">46,548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">44,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30,221</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42,505</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">76,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,414</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 70748 80789 46548 44909 30221 42505 76769 87414 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_z3Ukk6co57K1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> <span id="xdx_8BE_zQbI86v5TpG1" style="display: none">Schedule of future estimated minimum lease payments under non-cancelable operating leases</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20230930_zHmX5wcpJIi1" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 87%">Year ending June 30, 2024 (Remaining 9 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">39,256</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">44,636</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,892</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment_iNI_pp0p0_di_zp7o4m4Ohzcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,123</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zoyt9mLcZoEg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,769</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zlKihAIpICp8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(46,548</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zXhfkiozsmS1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,221</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 39256 44636 83892 7123 76769 46548 30221 12900 12525 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zkDgsvicPGyk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span id="xdx_8BA_zBu9kdFA9m99" style="display: none"> Schedule of weighted average remaining lease term and discount rate</span></td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zvWict3NtKUe" title="Weighted average remaining lease term (Years) Operating leases">1.5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_ztxu5t5IX4N7" title="Weighted average remaining lease term (Years) Operating leases">1.8</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230930_zNSDLYgS1jWi" title="Weighted average discount rate Operating leases">10.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zXDWVJW7MK1j" title="Weighted average discount rate Operating leases">10.75</span></td><td style="text-align: left">%</td></tr> </table> P1Y6M P1Y9M18D 0.1075 0.1075 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zsZiUE5tP0Q5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>12.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_828_zX2AlPeNIJGi">Commitments and Contingencies</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Royalty Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year.</p> <p id="xdx_80F_ecustom--EmployeeBenefitPlanTextBlock_zHRNEAyiWyaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>13.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_827_zW1IQq63rUok">Employee Benefit Plan</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the “401K Plan”) pursuant to which, all employees meeting eligibility requirements are able to participate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the Internal Revenue Code, eligible employees are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5% of an employee’s contributions to the 401K Plan., The Company made contributions of approximately $<span id="xdx_90D_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230701__20230930_pp0p0" title="Employee Benefit Plan">30,900</span> and $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20220701__20220930_pp0p0" title="Employee Benefit Plan">45,500</span>, for the three months ended September 30, 2023 and 2022, respectively.</p> 30900 45500 <p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zXSufAsEc8Li" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><b>14.</b></td> <td style="font-size: 10pt; text-align: justify"><b><span id="xdx_823_zY6UX6Hvtzy5">Subsequent Events</span></b></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to September 30, 2023, the Company sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231101__20231114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TransactionTypeAxis__custom--SalesAgreementMember__srt--CounterpartyNameAxis__custom--AgentMember_zKP7sutjsYa2" title="Number of common stock sold">819,935</span> shares of common stock for net proceeds of $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn3n3_dm_c20231101__20231114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TransactionTypeAxis__custom--SalesAgreementMember__srt--CounterpartyNameAxis__custom--AgentMember_zaBimBeaABR1" title="Value of common stock sold">3.5</span> million net of 3% commission and expenses totaling approximately $<span id="xdx_90E_eus-gaap--PaymentsForCommissions_c20231101__20231114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TransactionTypeAxis__custom--SalesAgreementMember__srt--CounterpartyNameAxis__custom--AgentMember_zCXvRbXG3C57" title="Commission and expenses">105,000</span> under the Sales Agreement with the Agent.</p> 819935 3500000 105000 EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 126 243 1 false 37 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://bioviepharma.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://bioviepharma.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://bioviepharma.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://bioviepharma.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://bioviepharma.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://bioviepharma.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Investments in U.S. Treasury Bills Available for Sale Sheet http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale Investments in U.S. Treasury Bills Available for Sale Notes 10 false false R11.htm 00000011 - Disclosure - Intangible Assets Sheet http://bioviepharma.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://bioviepharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Other Liabilities Sheet http://bioviepharma.com/role/OtherLiabilities Other Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Notes Payable Notes http://bioviepharma.com/role/NotesPayable Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - Fair Value Measurements Sheet http://bioviepharma.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 00000016 - Disclosure - Equity Transactions Sheet http://bioviepharma.com/role/EquityTransactions Equity Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Leases Sheet http://bioviepharma.com/role/Leases Leases Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://bioviepharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Employee Benefit Plan Sheet http://bioviepharma.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://bioviepharma.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://bioviepharma.com/role/SignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Significant Accounting Policies (Tables) Sheet http://bioviepharma.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://bioviepharma.com/role/SignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Tables) Sheet http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables Investments in U.S. Treasury Bills Available for Sale (Tables) Tables http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale 23 false false R24.htm 00000024 - Disclosure - Intangible Assets (Tables) Sheet http://bioviepharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://bioviepharma.com/role/IntangibleAssets 24 false false R25.htm 00000025 - Disclosure - Notes Payable (Tables) Notes http://bioviepharma.com/role/NotesPayableTables Notes Payable (Tables) Tables http://bioviepharma.com/role/NotesPayable 25 false false R26.htm 00000026 - Disclosure - Fair Value Measurements (Tables) Sheet http://bioviepharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://bioviepharma.com/role/FairValueMeasurements 26 false false R27.htm 00000027 - Disclosure - Equity Transactions (Tables) Sheet http://bioviepharma.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://bioviepharma.com/role/EquityTransactions 27 false false R28.htm 00000028 - Disclosure - Leases (Tables) Sheet http://bioviepharma.com/role/LeasesTables Leases (Tables) Tables http://bioviepharma.com/role/Leases 28 false false R29.htm 00000029 - Disclosure - Liquidity (Details Narrative) Sheet http://bioviepharma.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://bioviepharma.com/role/Liquidity 29 false false R30.htm 00000030 - Disclosure - Significant Accounting Policies (Details) Sheet http://bioviepharma.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://bioviepharma.com/role/SignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://bioviepharma.com/role/SignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - Investments in U.S. Treasury Bills available for sale (Details) Sheet http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails Investments in U.S. Treasury Bills available for sale (Details) Details 32 false false R33.htm 00000033 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details Narrative) Sheet http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative Investments in U.S. Treasury Bills Available for Sale (Details Narrative) Details http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables 33 false false R34.htm 00000034 - Disclosure - Intangible Assets (Details) Sheet http://bioviepharma.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://bioviepharma.com/role/IntangibleAssetsTables 34 false false R35.htm 00000035 - Disclosure - Intangible Assets (Details 1) Sheet http://bioviepharma.com/role/IntangibleAssetsDetails1 Intangible Assets (Details 1) Details http://bioviepharma.com/role/IntangibleAssetsTables 35 false false R36.htm 00000036 - Disclosure - Intangible Assets (Details Narrative) Sheet http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://bioviepharma.com/role/IntangibleAssetsTables 36 false false R37.htm 00000037 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://bioviepharma.com/role/RelatedPartyTransactions 37 false false R38.htm 00000038 - Disclosure - Other Liabilities (Details Narrative) Sheet http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative Other Liabilities (Details Narrative) Details http://bioviepharma.com/role/OtherLiabilities 38 false false R39.htm 00000039 - Disclosure - Notes Payable (Details) Notes http://bioviepharma.com/role/NotesPayableDetails Notes Payable (Details) Details http://bioviepharma.com/role/NotesPayableTables 39 false false R40.htm 00000040 - Disclosure - Notes Payable (Details 1) Notes http://bioviepharma.com/role/NotesPayableDetails1 Notes Payable (Details 1) Details http://bioviepharma.com/role/NotesPayableTables 40 false false R41.htm 00000041 - Disclosure - Notes Payable (Details Narrative) Notes http://bioviepharma.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://bioviepharma.com/role/NotesPayableTables 41 false false R42.htm 00000042 - Disclosure - Fair Value Measurements (Details) Sheet http://bioviepharma.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://bioviepharma.com/role/FairValueMeasurementsTables 42 false false R43.htm 00000043 - Disclosure - Fair Value Measurements (Details 1) Sheet http://bioviepharma.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://bioviepharma.com/role/FairValueMeasurementsTables 43 false false R44.htm 00000044 - Disclosure - Fair Value Measurements (Details 2) Sheet http://bioviepharma.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://bioviepharma.com/role/FairValueMeasurementsTables 44 false false R45.htm 00000045 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://bioviepharma.com/role/FairValueMeasurementsTables 45 false false R46.htm 00000046 - Disclosure - Equity Transactions (Details) Sheet http://bioviepharma.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://bioviepharma.com/role/EquityTransactionsTables 46 false false R47.htm 00000047 - Disclosure - Equity Transactions (Details 1) Sheet http://bioviepharma.com/role/EquityTransactionsDetails1 Equity Transactions (Details 1) Details http://bioviepharma.com/role/EquityTransactionsTables 47 false false R48.htm 00000048 - Disclosure - Equity Transactions (Details 2) Sheet http://bioviepharma.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://bioviepharma.com/role/EquityTransactionsTables 48 false false R49.htm 00000049 - Disclosure - Equity Transactions (Details Narrative) Sheet http://bioviepharma.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://bioviepharma.com/role/EquityTransactionsTables 49 false false R50.htm 00000050 - Disclosure - Leases (Details) Sheet http://bioviepharma.com/role/LeasesDetails Leases (Details) Details http://bioviepharma.com/role/LeasesTables 50 false false R51.htm 00000051 - Disclosure - Leases (Details 1) Sheet http://bioviepharma.com/role/LeasesDetails1 Leases (Details 1) Details http://bioviepharma.com/role/LeasesTables 51 false false R52.htm 00000052 - Disclosure - Leases (Details 2) Sheet http://bioviepharma.com/role/LeasesDetails2 Leases (Details 2) Details http://bioviepharma.com/role/LeasesTables 52 false false R53.htm 00000053 - Disclosure - Leases (Details Narrative) Sheet http://bioviepharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://bioviepharma.com/role/LeasesTables 53 false false R54.htm 00000054 - Disclosure - Employee Benefit Plan (Details Narrative) Sheet http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative Employee Benefit Plan (Details Narrative) Details http://bioviepharma.com/role/EmployeeBenefitPlan 54 false false R55.htm 00000055 - Disclosure - Subsequent Events (Details Narrative) Sheet http://bioviepharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://bioviepharma.com/role/SubsequentEvents 55 false false All Reports Book All Reports bivi-20230930.xsd bivi-20230930_10q.htm bivi-20230930_cal.xml bivi-20230930_def.xml bivi-20230930_lab.xml bivi-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bivi-20230930_10q.htm": { "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20230930", "dts": { "schema": { "local": [ "bivi-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "inline": { "local": [ "bivi-20230930_10q.htm" ] }, "calculationLink": { "local": [ "bivi-20230930_cal.xml" ] }, "definitionLink": { "local": [ "bivi-20230930_def.xml" ] }, "labelLink": { "local": [ "bivi-20230930_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20230930_pre.xml" ] } }, "keyStandard": 186, "keyCustom": 57, "axisStandard": 19, "axisCustom": 0, "memberStandard": 18, "memberCustom": 15, "hidden": { "total": 103, "http://fasb.org/us-gaap/2023": 82, "http://bioviepharma.com/20230930": 16, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 126, "entityCount": 1, "segmentCount": 37, "elementCount": 400, "unitCount": 4, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30, "http://fasb.org/us-gaap/2023": 431 }, "report": { "R1": { "role": "http://bioviepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://bioviepharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://bioviepharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:UnearnedPremiumAnddiscountCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:UnearnedPremiumAnddiscountCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R5": { "role": "http://bioviepharma.com/role/StatementsOfCashFlows", "longName": "00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R6": { "role": "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity", "longName": "00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://bioviepharma.com/role/BackgroundInformation", "longName": "00000007 - Disclosure - Background Information", "shortName": "Background Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://bioviepharma.com/role/Liquidity", "longName": "00000008 - Disclosure - Liquidity", "shortName": "Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://bioviepharma.com/role/SignificantAccountingPolicies", "longName": "00000009 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale", "longName": "00000010 - Disclosure - Investments in U.S. Treasury Bills Available for Sale", "shortName": "Investments in U.S. Treasury Bills Available for Sale", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://bioviepharma.com/role/IntangibleAssets", "longName": "00000011 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://bioviepharma.com/role/RelatedPartyTransactions", "longName": "00000012 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://bioviepharma.com/role/OtherLiabilities", "longName": "00000013 - Disclosure - Other Liabilities", "shortName": "Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://bioviepharma.com/role/NotesPayable", "longName": "00000014 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://bioviepharma.com/role/FairValueMeasurements", "longName": "00000015 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://bioviepharma.com/role/EquityTransactions", "longName": "00000016 - Disclosure - Equity Transactions", "shortName": "Equity Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://bioviepharma.com/role/Leases", "longName": "00000017 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://bioviepharma.com/role/CommitmentsAndContingencies", "longName": "00000018 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://bioviepharma.com/role/EmployeeBenefitPlan", "longName": "00000019 - Disclosure - Employee Benefit Plan", "shortName": "Employee Benefit Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:EmployeeBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:EmployeeBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://bioviepharma.com/role/SubsequentEvents", "longName": "00000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies", "longName": "00000021 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesTables", "longName": "00000022 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables", "longName": "00000023 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Tables)", "shortName": "Investments in U.S. Treasury Bills Available for Sale (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://bioviepharma.com/role/IntangibleAssetsTables", "longName": "00000024 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://bioviepharma.com/role/NotesPayableTables", "longName": "00000025 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://bioviepharma.com/role/FairValueMeasurementsTables", "longName": "00000026 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://bioviepharma.com/role/EquityTransactionsTables", "longName": "00000027 - Disclosure - Equity Transactions (Tables)", "shortName": "Equity Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://bioviepharma.com/role/LeasesTables", "longName": "00000028 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://bioviepharma.com/role/LiquidityDetailsNarrative", "longName": "00000029 - Disclosure - Liquidity (Details Narrative)", "shortName": "Liquidity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails", "longName": "00000030 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "00000031 - Disclosure - Significant Accounting Policies (Details Narrative)", "shortName": "Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails", "longName": "00000032 - Disclosure - Investments in U.S. Treasury Bills available for sale (Details)", "shortName": "Investments in U.S. Treasury Bills available for sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember", "name": "bivi:AmortizedCostBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R33": { "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative", "longName": "00000033 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details Narrative)", "shortName": "Investments in U.S. Treasury Bills Available for Sale (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2022-07-012023-06-30", "name": "bivi:NumberOfStockPurchased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012023-06-30", "name": "bivi:NumberOfStockPurchased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://bioviepharma.com/role/IntangibleAssetsDetails", "longName": "00000034 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://bioviepharma.com/role/IntangibleAssetsDetails1", "longName": "00000035 - Disclosure - Intangible Assets (Details 1)", "shortName": "Intangible Assets (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative", "longName": "00000036 - Disclosure - Intangible Assets (Details Narrative)", "shortName": "Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R37": { "role": "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000037 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-07-15_custom_AcuitasGroupHoldingsLLCMember", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R38": { "role": "http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative", "longName": "00000038 - Disclosure - Other Liabilities (Details Narrative)", "shortName": "Other Liabilities (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OtherLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OtherLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://bioviepharma.com/role/NotesPayableDetails", "longName": "00000039 - Disclosure - Notes Payable (Details)", "shortName": "Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:CurrentPortionOfNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "bivi:CurrentPortionOfNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://bioviepharma.com/role/NotesPayableDetails1", "longName": "00000040 - Disclosure - Notes Payable (Details 1)", "shortName": "Notes Payable (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-09-30_custom_UnearnedDiscountMember", "name": "bivi:AmortizationExpenseNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_UnearnedDiscountMember", "name": "bivi:AmortizationExpenseNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://bioviepharma.com/role/NotesPayableDetailsNarrative", "longName": "00000041 - Disclosure - Notes Payable (Details Narrative)", "shortName": "Notes Payable (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails", "longName": "00000042 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_DerivativeLiabilityConversionOptionOnNotePayableMember", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R43": { "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "longName": "00000043 - Disclosure - Fair Value Measurements (Details 1)", "shortName": "Fair Value Measurements (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R44": { "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "longName": "00000044 - Disclosure - Fair Value Measurements (Details 2)", "shortName": "Fair Value Measurements (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative", "longName": "00000045 - Disclosure - Fair Value Measurements (Details Narrative)", "shortName": "Fair Value Measurements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://bioviepharma.com/role/EquityTransactionsDetails", "longName": "00000046 - Disclosure - Equity Transactions (Details)", "shortName": "Equity Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-09-30_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_StockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://bioviepharma.com/role/EquityTransactionsDetails1", "longName": "00000047 - Disclosure - Equity Transactions (Details 1)", "shortName": "Equity Transactions (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://bioviepharma.com/role/EquityTransactionsDetails2", "longName": "00000048 - Disclosure - Equity Transactions (Details 2)", "shortName": "Equity Transactions (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "longName": "00000049 - Disclosure - Equity Transactions (Details Narrative)", "shortName": "Equity Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-11-23", "name": "bivi:TotalCompensationCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "unique": true } }, "R50": { "role": "http://bioviepharma.com/role/LeasesDetails", "longName": "00000050 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://bioviepharma.com/role/LeasesDetails1", "longName": "00000051 - Disclosure - Leases (Details 1)", "shortName": "Leases (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://bioviepharma.com/role/LeasesDetails2", "longName": "00000052 - Disclosure - Leases (Details 2)", "shortName": "Leases (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://bioviepharma.com/role/LeasesDetailsNarrative", "longName": "00000053 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative", "longName": "00000054 - Disclosure - Employee Benefit Plan (Details Narrative)", "shortName": "Employee Benefit Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bivi:EmployeeBenefitPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-09-30", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bivi:EmployeeBenefitPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative", "longName": "00000055 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2023-11-012023-11-14_us-gaap_SubsequentEventMember_custom_SalesAgreementMember_custom_AgentMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-11-012023-11-14_us-gaap_SubsequentEventMember_custom_SalesAgreementMember_custom_AgentMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20230930_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r296", "r297", "r298", "r413", "r654", "r655", "r656", "r695", "r714" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/OtherLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities [Default Label]", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r72", "r380", "r438", "r439", "r622", "r712" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Measured at fair value on a recurring basis", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r12", "r61", "r63", "r109" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "bivi_ThreeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ThreeDirectorsMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Directors [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r260", "r269", "r292", "r293", "r294", "r358", "r359", "r393", "r434", "r435", "r499", "r518", "r523", "r524", "r563", "r585", "r586", "r594", "r601", "r606", "r611", "r614", "r662", "r666", "r702", "r703", "r704", "r705", "r706" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r121" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Options Grants", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r277" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of derivative liabilities at fair value", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "bivi_AccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AccumulatedDeficit", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "AccumulatedDeficit" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r640" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r269", "r359", "r393", "r434", "r435", "r499", "r518", "r523", "r524", "r563", "r585", "r586", "r594", "r601", "r606", "r611", "r666", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "auth_ref": [ "r201", "r202", "r203", "r204", "r260", "r269", "r292", "r293", "r294", "r358", "r359", "r393", "r434", "r435", "r499", "r518", "r523", "r524", "r563", "r585", "r586", "r594", "r601", "r606", "r611", "r614", "r662", "r666", "r702", "r703", "r704", "r705", "r706" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "- Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r162", "r163", "r164", "r165", "r166", "r170", "r173", "r177", "r178", "r179", "r181", "r318", "r319", "r378", "r392", "r591" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r269", "r359", "r393", "r434", "r435", "r499", "r518", "r523", "r524", "r563", "r585", "r586", "r594", "r601", "r606", "r611", "r666", "r701", "r702", "r703", "r704", "r705", "r706" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r625" ] }, "bivi_NewEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "NewEmployeeMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Employee [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative liabilities", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r694" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r302" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r625" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r56", "r58", "r59", "r60", "r432", "r435", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r476", "r477", "r478", "r479", "r482", "r483", "r484", "r485", "r544", "r545", "r548", "r550", "r590", "r612", "r614" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r625" ] }, "bivi_TreasuryStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "TreasuryStocksMember", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stocks [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r228", "r261", "r266", "r322", "r356", "r597", "r598", "r602", "r603", "r604" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r153", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r305", "r308", "r309", "r325", "r442", "r592", "r622", "r664", "r699", "r700" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/OtherLiabilities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r228", "r261", "r266", "r322", "r355", "r602", "r603", "r604" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "lang": { "en-us": { "role": { "label": "Additions to level 3 liabilities", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r62" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r625" ] }, "bivi_DerivativeLiabilityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DerivativeLiabilityWarrantsMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Liability Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r426", "r428", "r429", "r430", "r433", "r496", "r505", "r519", "r527", "r540", "r552", "r553", "r569", "r573", "r574", "r575", "r576", "r614" ] }, "bivi_DerivativeLiabilityConversionOptionOnNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DerivativeLiabilityConversionOptionOnNotePayableMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability Conversion Option On Note Payable [Member]" } } }, "auth_ref": [] }, "bivi_USTreasuryBillSecurities1Member": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "USTreasuryBillSecurities1Member", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "label": "U S Treasury Bill Securities 1 [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "bivi_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "WorkingCapital", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DerivativeLiabilityConversionOptionOnConvertibleDebentureMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Liability Conversion Option On Convertible Debenture [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r228", "r261", "r262", "r263", "r264", "r265", "r266", "r322", "r357", "r597", "r598", "r602", "r603", "r604" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r24", "r117", "r137", "r138", "r139", "r157", "r158", "r159", "r161", "r167", "r169", "r182", "r194", "r195", "r258", "r296", "r297", "r298", "r300", "r301", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r326", "r328", "r329", "r330", "r331", "r332", "r344", "r394", "r395", "r396", "r413", "r488" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r642" ] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of financing costs", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r6", "r66", "r92", "r236" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r714" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r117", "r157", "r158", "r159", "r161", "r167", "r169", "r194", "r195", "r296", "r297", "r298", "r300", "r301", "r310", "r312", "r313", "r315", "r317", "r394", "r396", "r413", "r714" ] }, "bivi_AcuitasGroupHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AcuitasGroupHoldingsLLCMember", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acuitas Group Holdings L L C [Member]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r7", "r27", "r311", "r314", "r344", "r394", "r395", "r646", "r647", "r648", "r654", "r655", "r656" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "bivi_UnearnedDiscountMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "UnearnedDiscountMember", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Unearned Discount [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r84", "r111", "r387", "r610", "r653", "r659", "r696" ] }, "bivi_LoanAccretionPremiumMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "LoanAccretionPremiumMember", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Loan Accretion Premium [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Awarded Vested rights, percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r668" ] }, "us-gaap_DebtInstrumentUnamortizedPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedPremium", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized premium recognized", "documentation": "Amount, after accumulated amortization, of debt premium." } } }, "auth_ref": [ "r66", "r69", "r667" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r78", "r243" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r554", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r92", "r234", "r241", "r599", "r600" ] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r156", "r215", "r216", "r217", "r218", "r219", "r221", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r239", "r336", "r596", "r597", "r598", "r599", "r600", "r652" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OPERATING EXPENSES", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r47", "r50", "r66", "r67", "r69", "r74", "r103", "r104", "r156", "r215", "r216", "r217", "r218", "r219", "r221", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r239", "r336", "r596", "r597", "r598", "r599", "r600", "r652" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r25" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r154", "r155", "r218", "r245", "r350", "r588", "r590" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Embedded derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r57" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r9" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r20", "r67", "r233" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Options Exercisable", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r290" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "lang": { "en-us": { "role": { "label": "Transfer in and/or out of Level 3", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r154", "r155", "r218", "r245", "r350", "r589", "r590" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "lang": { "en-us": { "role": { "label": "Change in in fair value of level 3 liability", "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r9" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair value, liabilities measured on recurring basis", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r9", "r63" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r96" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares unvested at beginning", "periodEndLabel": "Number of shares unvested at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r289" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17", "r610" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Options Exercisable", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r290" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r180" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Benefit Plan", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r259", "r261", "r268", "r602", "r603", "r604", "r605" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock based compensation expense - stock options", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest payment", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r21" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, warrants outstanding", "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r281", "r282" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r636" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r228", "r261", "r262", "r263", "r264", "r265", "r266", "r322", "r355", "r356", "r357", "r597", "r598", "r602", "r603", "r604" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionTypeAxis", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r590" ] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionDomain", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r590" ] }, "bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentUponSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentUponSettlement", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reclassification of unrealized gains on available for sale investments upon settlement" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r91" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r38", "r41" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://bioviepharma.com/role/Leases" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r337" ] }, "us-gaap_FinanceReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceReceivablesMember", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Financing Receivable [Member]", "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of dilutive securities were excluded from the computation of diluted loss per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r33" ] }, "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfrelatedPartyShares": { "xbrltype": "sharesItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsOfrelatedPartyShares", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock related party, shares" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net loss per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r33", "r34" ] }, "us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less unearned discount", "label": "Deferred Discounts, Finance Charges and Interest Included in Receivables", "documentation": "Unearned discounts (other than cash or quantity discounts and the like), finance charges, and interest included in the face amount of receivables, that are shown as a deduction from the related receivables. For example, 1) finance charges booked as a receivable when a loan is made and recognized as income at a later date; and 2) interest charges deducted from the face loan amount, resulting in a discounted amount actually advanced to the borrower (wherein the receivable includes the amount actually advanced to the borrower and the as yet unearned interest income)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails", "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "totalLabel": "Intellectual Property, Net", "label": "Finite lived intangible assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r98", "r361" ] }, "bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSale" ], "lang": { "en-us": { "role": { "label": "Investments in U.S. Treasury Bills Available for Sale" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsLineItems", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r122", "r196", "r375", "r595", "r610", "r660", "r661" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intellectual Property", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r98", "r362" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r107" ] }, "bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableForSaleAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DisclosureInvestmentsInU.s.TreasuryBillsAvailableForSaleAbstract", "lang": { "en-us": { "role": { "label": "Investments In U.s. Treasury Bills Available For Sale" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r644", "r649" ] }, "bivi_StockholderEquities": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "StockholderEquities", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r626" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common stock sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaids and other assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrant Outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r281", "r282" ] }, "bivi_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value per share unvested at beginning", "periodEndLabel": "Weighted average grant date fair value per share unvested at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r281", "r282" ] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value of common stock sold", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r285" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 1.0 }, "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows", "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS", "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r118", "r132", "r135", "r146", "r153", "r160", "r168", "r169", "r185", "r187", "r189", "r191", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r303", "r306", "r307", "r319", "r325", "r379", "r388", "r412", "r464", "r486", "r487", "r593", "r607", "r608", "r621", "r648", "r664" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r116", "r125", "r126", "r127", "r153", "r173", "r174", "r177", "r179", "r183", "r184", "r193", "r205", "r207", "r208", "r209", "r212", "r213", "r243", "r244", "r247", "r250", "r257", "r325", "r404", "r405", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r444", "r465", "r488", "r577", "r578", "r579", "r580", "r581", "r643", "r651", "r657" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r432", "r435", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r476", "r477", "r478", "r479", "r482", "r483", "r484", "r485", "r544", "r545", "r548", "r550", "r612", "r614" ] }, "bivi_DisclosureEmployeeBenefitPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DisclosureEmployeeBenefitPlanAbstract", "lang": { "en-us": { "role": { "label": "Employee Benefit Plan" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r641" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r353" ] }, "bivi_AgentMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AgentMember", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agent [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r267", "r348", "r349", "r437", "r438", "r439", "r440", "r441", "r461", "r463", "r495" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option to purchase", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r8", "r78", "r79", "r105", "r407", "r488", "r580" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/BackgroundInformation" ], "lang": { "en-us": { "role": { "label": "Background Information", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r76", "r108", "r401", "r402" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://bioviepharma.com/role/LeasesDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term (Years) Operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r341", "r609" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LeasesDetails", "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Total operating lease liabilities", "verboseLabel": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r339" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r610" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails", "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "negatedLabel": "Less current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Options outstanding at beginning", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r273", "r274" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r631" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options outstanding at beginning", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r273", "r274" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r612", "r613", "r616", "r617", "r618", "r619" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of future amortization expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r42" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r88", "r95", "r112", "r118", "r132", "r135", "r139", "r153", "r160", "r162", "r163", "r164", "r165", "r168", "r169", "r175", "r185", "r187", "r189", "r191", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r319", "r325", "r389", "r464", "r486", "r487", "r593", "r620", "r664" ] }, "bivi_WarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "WarrantLiabilities", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_IncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossAttributableToParent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS", "label": "Income (Loss) Attributable to Parent, before Tax", "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r90", "r139" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "NET LOSS", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r144", "r162", "r163", "r164", "r165", "r170", "r171", "r176", "r179", "r185", "r187", "r189", "r191", "r593" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r292" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r70", "r71", "r468", "r469", "r472" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r121" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r345", "r346", "r347", "r349", "r351", "r409", "r410", "r411", "r470", "r471", "r472", "r492", "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r294" ] }, "us-gaap_InvestmentOwnedUnrecognizedUnrealizedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedUnrecognizedUnrealizedDepreciation", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value", "documentation": "This element represents the excess of the cost (face amount, notional amount) of an investment (security, contract) over its fair value which deficiency has not been recognized in earnings of the entity." } } }, "auth_ref": [ "r115" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r321", "r322", "r323" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails", "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r110", "r124", "r153", "r185", "r188", "r190", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r304", "r308", "r325", "r381", "r456", "r610", "r622", "r664", "r665", "r699" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r468", "r469", "r472" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r25" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r75", "r299", "r707" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r353" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r612", "r613", "r614", "r616", "r617", "r618", "r619", "r654", "r655", "r695", "r710", "r714" ] }, "us-gaap_OtherExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpensesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE (INCOME):" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r28", "r134", "r136", "r142", "r377", "r391" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r630" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfDerivatives", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative liabilities", "label": "Gain (Loss) on Sale of Derivatives", "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings." } } }, "auth_ref": [ "r6", "r113", "r476", "r477", "r478", "r479" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r623" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "bivi_TotalOtherExpenseIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r68", "r114", "r140", "r186", "r334", "r473", "r620", "r713" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r639" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r100", "r199", "r200", "r584", "r663" ] }, "us-gaap_PaymentsForCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForCommissions", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commission and expenses", "documentation": "The amount of cash paid for commissions during the current period." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r13", "r133", "r136", "r141", "r326", "r327", "r332", "r376", "r390", "r646", "r647" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r33" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r340", "r609" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r93" ] }, "bivi_ChangeInOperatingLeaseRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ChangeInOperatingLeaseRightofuseAssets", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurement of assets and liabilities", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1" ], "lang": { "en-us": { "role": { "label": "Total derivatives", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r130", "r131", "r324", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r434", "r435", "r457", "r459", "r460", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r590", "r711" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r29" ] }, "bivi_TotalOtherExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "TotalOtherExpenseIncome", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL OTHER (INCOME) EXPENSE, NET", "label": "TotalOtherExpenseIncome" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "bivi_TotalOtherExpenseIncome", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r614" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "- Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r172", "r179" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r93", "r150" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "- Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r170", "r179" ] }, "bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "IssuanceOfCommonStockFromVestingOfRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock from vesting of - restricted stock units" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r44", "r45", "r46", "r47", "r48", "r49", "r50", "r103", "r104", "r105", "r125", "r126", "r127", "r183", "r243", "r244", "r245", "r247", "r250", "r255", "r257", "r404", "r405", "r406", "r407", "r601", "r643", "r651" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r157", "r158", "r159", "r182", "r360", "r403", "r424", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r615" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r183", "r243", "r244", "r245", "r247", "r250", "r255", "r257", "r404", "r405", "r406", "r407", "r601", "r643", "r651" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical", "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Common Stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r79" ] }, "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOf94160RelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsOf94160RelatedParty", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of costs of\u00a0$94,160 - Related Party" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY:" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r157", "r158", "r159", "r182", "r360", "r403", "r424", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r615" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/EquityTransactions" ], "lang": { "en-us": { "role": { "label": "Equity Transactions", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r102", "r152", "r242", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r258", "r316", "r491", "r493", "r582" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2023 and June 30, 2023, respectively; 36,922,760 shares issued of which 36,899,880 shares are outstanding at September 30, 2023; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023;", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r79", "r384", "r610" ] }, "bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock from vesting of - restricted stock units, shares" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r79", "r444" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r79", "r444", "r462", "r714", "r715" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r333", "r353" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of note payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r30" ] }, "bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "NetProceedsFromIssuanceOfCommonStockRelatedParty", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of common stock - Related Party" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r333", "r353" ] }, "bivi_SupplementalDisclosureOfNoncashInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "SupplementalDisclosureOfNoncashInvestingActivitiesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets, net", "verboseLabel": "Operating lease, right-of-use asset, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r338" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r116", "r125", "r126", "r127", "r153", "r173", "r174", "r177", "r179", "r183", "r184", "r193", "r205", "r207", "r208", "r209", "r212", "r213", "r243", "r244", "r247", "r250", "r257", "r325", "r404", "r405", "r406", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r444", "r465", "r488", "r577", "r578", "r579", "r580", "r581", "r643", "r651", "r657" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r333", "r353" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r645", "r709" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of note payable, net of financing cost, unearned premium and discount of $661,467 at September 30, 2023 and $894,926 at June 30, 2023", "verboseLabel": "Current portion of Notes Payable, net of financing costs, unearned premiums and discount", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r137", "r138", "r326", "r328", "r329", "r330", "r331", "r332" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r117", "r137", "r138", "r139", "r157", "r158", "r159", "r161", "r167", "r169", "r182", "r194", "r195", "r258", "r296", "r297", "r298", "r300", "r301", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r326", "r328", "r329", "r330", "r331", "r332", "r344", "r394", "r395", "r396", "r413", "r488" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Summary of warrants activity", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://bioviepharma.com/role/LeasesDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average discount rate Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r342", "r609" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "Year ending June 30, 2024 (Remaining 9 months)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r99" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r6" ] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r708" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r23", "r51", "r52" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r31", "r121", "r587" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF COMMON\u00a0\u00a0SHARES OUTSTANDING" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r32" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of vesting of restricted common stock", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [] }, "bivi_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "SalesAgreementMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sales Agreement [Member]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r636" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note payable, net of current portion, financing cost, unearned premium and\u00a0\u00a0discount of $469,937 at September 30, 2023 and $227,270 at June 30, 2023", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r21" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r81", "r105", "r386", "r397", "r399", "r408", "r445", "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r343" ] }, "bivi_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "StockOptionsMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r637" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending June 30, 2024 (Remaining 9 months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r343" ] }, "bivi_N2019OmnibusIncentiveEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "N2019OmnibusIncentiveEquityPlanMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "N 2019 Omnibus Incentive Equity Plan [Member]" } } }, "auth_ref": [] }, "bivi_NumberOfStockPurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "NumberOfStockPurchased", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of stock purchased" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r624" ] }, "bivi_CurrentPortionOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "CurrentPortionOfNotesPayable", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of Notes Payable" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Options Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r53" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r343" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r637" ] }, "bivi_DebtFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DebtFinancingCosts", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Less debt financing costs" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r633" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "bivi_AccretionOfLoanPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AccretionOfLoanPremiums", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Plus accretion of loan premium" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r627" ] }, "bivi_FourDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "FourDirectorsMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Four Directors [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://bioviepharma.com/role/Liquidity" ], "lang": { "en-us": { "role": { "label": "Liquidity", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r77" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r628" ] }, "bivi_NotesPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "NotesPayableNoncurrent", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes Payable", "label": "NotesPayableNoncurrent" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r78", "r383", "r610" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r185", "r187", "r189", "r191", "r593" ] }, "bivi_LongtermDebtFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "LongtermDebtFinancingCosts", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less debt financing costs", "label": "LongtermDebtFinancingCosts" } } }, "auth_ref": [] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2" ], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r121" ] }, "bivi_UnearnedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "UnearnedDiscount", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unearned discount" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r632" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r79" ] }, "bivi_FairValueOfEmbeddedConversionOption": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "FairValueOfEmbeddedConversionOption", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of embedded conversion option" } } }, "auth_ref": [] }, "bivi_LongTermAccretionOfLoanPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "LongTermAccretionOfLoanPremiums", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Plus accretion of loan premium", "label": "LongTermAccretionOfLoanPremiums" } } }, "auth_ref": [] }, "bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Less unearned discount" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r137", "r138", "r326", "r328", "r329", "r330", "r331", "r332" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation \u2013 Interim Financial Information", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "bivi_AmortizationExpenseNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AmortizationExpenseNextRollingTwelveMonths", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending June 30, 2024 (Remaining 9 months)", "label": "AmortizationExpenseNextRollingTwelveMonths" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r99" ] }, "bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, net of the current portion financing costs, unearned premiums and discount" } } }, "auth_ref": [] }, "bivi_AmortizationExpenseNextRollingTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AmortizationExpenseNextRollingTwoYears", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "AmortizationExpenseNextRollingTwoYears" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r82", "r83", "r97", "r446", "r462", "r489", "r490", "r610", "r622", "r653", "r659", "r696", "r714" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r99" ] }, "bivi_AmortizationExpenseTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AmortizationExpenseTotal", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "AmortizationExpenseTotal" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/IntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r123", "r198" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails", "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Outstanding at beginning of period", "verboseLabel": "Aggregate intrinsic value, otstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows", "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Amortization", "verboseLabel": "Amortization of intangible assets", "terseLabel": "Amortization expenses", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r39", "r43" ] }, "bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of future estimated minimum lease payments under non-cancelable operating leases" } } }, "auth_ref": [] }, "bivi_DirectFinancingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "DirectFinancingCost", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Direct financing cost" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r89", "r236", "r335", "r650" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "verboseLabel": "Total Accumulated Other Comprehensive Income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r26", "r27", "r87", "r128", "r385", "r398", "r399" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r426", "r428", "r429", "r430", "r433", "r496", "r505", "r519", "r527", "r540", "r552", "r553", "r569", "r573", "r574", "r575", "r576", "r614" ] }, "bivi_AccretionsOfLoanPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AccretionsOfLoanPremium", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accretion of loan premium", "label": "AccretionsOfLoanPremium" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r197" ] }, "bivi_EmployeeBenefitPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "EmployeeBenefitPlanTextBlock", "presentation": [ "http://bioviepharma.com/role/EmployeeBenefitPlan" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Benefit Plan", "label": "EmployeeBenefitPlanTextBlock" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "bivi_IssuanceOfCommonStockForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "IssuanceOfCommonStockForCash", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash" } } }, "auth_ref": [] }, "bivi_IssuanceOfCommonStockForCashShares": { "xbrltype": "sharesItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "IssuanceOfCommonStockForCashShares", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cash, shares" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://bioviepharma.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of note payable", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r635" ] }, "bivi_CommissionsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "CommissionsPercentage", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commissions percentage" } } }, "auth_ref": [] }, "bivi_InvestmentsUSTreasuryBillsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "InvestmentsUSTreasuryBillsPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Investments in U.S. Treasury Bills", "label": "InvestmentsUSTreasuryBillsPolicyTextBlock" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r19", "r120", "r153", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r305", "r308", "r309", "r325", "r610", "r664", "r699", "r700" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1": { "xbrltype": "perShareItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rsu granted, grant date fair value" } } }, "auth_ref": [] }, "bivi_RsuGranted": { "xbrltype": "sharesItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "RsuGranted", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rsu granted" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://bioviepharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r352", "r354" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r634", "r636", "r637" ] }, "bivi_TotalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "TotalCompensationCost", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total compensation cost" } } }, "auth_ref": [] }, "bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock", "presentation": [ "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk in the Financial Service Industry" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "- Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r143", "r162", "r163", "r164", "r165", "r166", "r173", "r177", "r178", "r179", "r181", "r318", "r319", "r378", "r392", "r591" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "bivi_SharesIssuedOverVestingPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "SharesIssuedOverVestingPeriod", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued over the vesting period" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "bivi_GrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "GrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Gross Unrealized Gain" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Term, Options Exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r290" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "bivi_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Less amount representing interest", "label": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment" } } }, "auth_ref": [] }, "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Contractual Term, Granted (in Years)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://bioviepharma.com/role/NotesPayableDetails1" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r25" ] }, "bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ScheduleOfUSTreasuryBillsHeldTableTextBlock", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleTables" ], "lang": { "en-us": { "role": { "label": "Schedule of U.S. treasury bills held" } } }, "auth_ref": [] }, "bivi_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in measurement of lease liabilities" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r629" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Remaining Average Contractual Term, Ending Balance", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r106" ] }, "bivi_ScheduleofFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ScheduleofFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://bioviepharma.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of estimated future amortization expense and accretion of premium" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r291" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r321", "r322", "r323" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r80" ] }, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTable", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "bivi_InterestExpenseFromConvertibleDebenture": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "InterestExpenseFromConvertibleDebenture", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of unearned loan discount", "label": "InterestExpenseFromConvertibleDebenture" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://bioviepharma.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r101", "r151", "r214", "r220", "r221", "r222", "r223", "r224", "r225", "r230", "r237", "r238", "r240" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r35", "r36", "r64", "r65", "r192", "r583" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 12)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r22", "r73", "r382", "r443" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r35", "r36", "r64", "r65", "r192", "r400", "r583" ] }, "bivi_MaturityOfU.s.TreasuryBills": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "MaturityOfU.s.TreasuryBills", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Maturity of U.S. Treasury Bills", "label": "MaturityOfU.s.TreasuryBills" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock - based compensation - stock options", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r55", "r78", "r79", "r105" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://bioviepharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r40", "r42" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r636" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining life (Years), warrants outstanding", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r106" ] }, "bivi_InvestmentsInU.s.TreasuryBills": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "InvestmentsInU.s.TreasuryBills", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investments in U.S. Treasury Bills" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r625" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of costs of\u00a0$118,891", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r78", "r79", "r105", "r413", "r488", "r578", "r621" ] }, "bivi_AmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AmortizedCostBasis", "crdr": "debit", "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Amortized Cost Basis" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r119", "r129", "r153", "r193", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r304", "r308", "r325", "r610", "r664", "r665", "r699" ] }, "bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows", "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Reclassification of unrealized gains on available-for-sale investments upon settlement", "negatedLabel": "Reclassification of unrealized gains on available-for-sale investments upon settlement" } } }, "auth_ref": [] }, "bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock", "presentation": [ "http://bioviepharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of weighted average remaining lease term and discount rate" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation - restricted stock units", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r8", "r78", "r79", "r105" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r267", "r348", "r349", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r437", "r438", "r439", "r440", "r441", "r461", "r463", "r495", "r698" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://bioviepharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "bivi_StockBasedCompensationRestrictedStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "StockBasedCompensationRestrictedStock", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock based compensation - restricted stock units" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r636" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r147" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r625" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r78", "r79", "r105", "r404", "r488", "r578" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r658", "r697" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r147" ] }, "bivi_AccretionOfLoanPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "AccretionOfLoanPremium", "crdr": "debit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion of loan premium" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r93", "r94", "r95" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaids and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r302" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r78", "r243" ] }, "bivi_RealizedGainOnMaturityOfAvailableforSale": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "RealizedGainOnMaturityOfAvailableforSale", "crdr": "credit", "calculation": { "http://bioviepharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetailsNarrative", "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized gain on maturity of available-for sale", "label": "Realized gain on maturity of available-for sale" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r637" ] }, "bivi_UnearnedPremiumAndDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "UnearnedPremiumAndDiscount", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Unearned premium and discount" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r625" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r444" ] }, "bivi_UnearnedPremiumAnddiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://bioviepharma.com/20230930", "localname": "UnearnedPremiumAnddiscountCurrent", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Unearned premium and discount current" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r145", "r148", "r149" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://bioviepharma.com/role/EquityTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of summarizes the activity relating to the Company\u2019s stock options", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r54" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r78", "r444", "r462", "r714", "r715" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://bioviepharma.com/role/FairValueMeasurementsDetails", "http://bioviepharma.com/role/FairValueMeasurementsDetails1", "http://bioviepharma.com/role/FairValueMeasurementsDetails2", "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r228", "r261", "r262", "r263", "r264", "r265", "r266", "r355", "r356", "r357", "r597", "r598", "r602", "r603", "r604" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r638" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-22" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r643": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 73 0001520138-23-000473-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-23-000473-xbrl.zip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

>BTFOP Y:5K]OB5G*.+ZX1?GV M*YQGN*[1A9>F5!]UX"^IH%"I5U[V#TN62'+HH&:9.-9Y?P\9H0T4 A]Q#+ML MMW4:U72CXJ#-NAAQ+;W%=7 4;#[WS]1W]*GRSU] BL.N=*S"XC8PS^&D \IT M3Y/^3^T/<'SL(/I8\/Y6\OW=NM@ZEMTBM>@O';N+89M\;ZQWD MU^)%,L8^\?Z&.,*3C4_U'[.OCFF4+YN7Z@"'X;,Y : @= [POY+357&(*A\/ M.C5.>G\O@!1BD",-]Z2MR)(S:OZ"O8IYU&Q".+X/IT33]%9W\2EX'4IX3P/; MZ$EE,5K2OWT_E/;W?&"2"$K]T7"D]GIC-G^<#<2&EQLF3C$-@RX]Y@[*AOO6 MV0QLA[:EXGFD$9T2I"GNHA!ZSC1-'10IO\TH/!H4I"]U7)@ M[ GOK:#$R_8Q@9RDU9EE8ZKH#=T15]YKF6@US>8G,D2W*.&@:C\;? M\^'P)D:C"&N4/7MF[B\..U%"8^'\XLQG)/!]O2L6\G(^IX08"22C?+06@$\D MTA'DAFB,2:8^E :VU0),!ZJ$%?XSC4OE9+B$IIY9:&C]+*+3Y+UU=?PPO#B[ M+*G)\>K%^)0%3/+,SO),N.$PS-YDJ"2F::MM8'HS?*7JX0)N&H0 \N$KW4:C M"3A=%N_>STI\FY8&[JYC[SGTG%FX8&(5_(H/\KX[O@*;X\V[V;3]_XH[;OF@ M@,)0?Q[HIL,8B#H ;O ,KQB"CC#+#/QVSY4ZI@X"_!X%01Q;SC";,B7@BW*I MOX7[G>=7BCMK%I A+KBHU.1<+BQ_C[!!*"!24OTCJ//N[X4J(,<+*R!Y%UGR MF4"6K"@@>1>1\IM30!2Y5"S*U4H^;15$"M- ZB_10#*&3Y-OWX>]KX;]^?9[ M9U,:R)I1*48#*;U8 SE-HH%D[.[7IH%L@E>L5 ,A"V2."I)?1 7)&B:L4P79 M&+G/J"#%7"Y6!4G;;S<3AUJ)CY.N0;H<<'?Q%OHS;T$NMZU>SWHB!9 "",ZH M#X\:$U@;Q3;>U"-Z+FV]IPZ9H\H*<^EQR64Q<##QGM2C]7=ZD$LA9-3JZMJH M![1/VM&1ZN@:P@(8&(62"2TX5M0Y]"@TYH\E)6MSY\8K:OZY*7=3>,.O?$SO^EOR E?2@102&)'>GNA#U>@Y?VVZ#]]+\A6G#U",(-E*SI-YA,GO2_3%,]5-Q*DA;^\P5^& 7"/O]"U@W^; MMO0_V$8=, (32,3?I\]@(QF.]\$5"/XD19R[#*\AJ%T"'M=Z7S5,E$Q1(*2P M-0BRD=IS/[O5[?Z?"\1Z!TRB#@: !3S. 42&Z8!.*3ZAA+55@&B=K0\O1T-G M"!8XHH,ZE&+;V*ZB1U2BVKEPM=9G:1^-O9]PL[C^I-H:9XZ^0X'B3]9M2'[R M"6BDCRHF0YR;#BCZN,JUX3Q,F?$^93K$G<._D:P@')LZF"1(8ZOI);5R@"2I M>IH]^5(NY()<*^7E:GG^I,!-M2^+Q,U*.K@I.#-GOT)PD;Q*#V-=>:!RKJ\+ M@3G %\O2UJ%T'!S7B.AW-R=7 MDKA\K\AAD;PO/XE6/;$@9",D&2:,Z_RN;" M5^FJ*CZ-!!61?$,;_ICR[ZZ,6":?C=^U;J]5&_4ZLU0C="5/B_)K2[BY4 IZ MDR!Y.>\/&2^ H%B\\KZ:L\XJ]9_-V_>E0\+,ZG;V>I4F:@EQ(MAQYQF M'MHYE\.N;M]V55-XY80ZZ6J1I#SZ@+UB_A\(.WC*K*?$TOL!P;/2A3#%1@\T3FU+S=X;BIELW;3J3S];LW2I&?H"--GUN Y921Y MI/8P(R6)K3.;'KNUMDXNH:VS)404(FR.LV44K4H"I6 4I29_,F8KK40HQ26, M52IROEA)N2M"2O&5"$KETIX2?[;#@,JM4,G\ICO(3TWM]'F@M^"?MQ9^Y /* MNNPJWRLSK394/^D#I?OKIA5BFBT2B_(3\);:9ZN[ M,BQ *NV6V99(@BT!?!^4@]:"LBFK;!.2*14 ;LK(4DI%N9A+2?(LW'JNT)A, M1I_.!LY][_9C9^7=L=*LH%$-6WK$JT2/@*ZVNCRM7^K8V$,'_H$% !J@,=6W ML4\-1P+F155NFC1R1 4VX2J6>%A8+LO6.90NK*GRFB?=UED/'DW&ZCG#QG^T MT/V&W88LV_6A:Y*V6'UW877E6.N\!59+[(?2 9$BUAJZY"H*#??W6'T20.-@ M#C2H/A&S,Z0G-;P\>7[J8EKJ09!9T@]B#OTRW3MA=X,4^50U5Y5S^3!G$"LF MQ0N*;501O?5>[-_]V!L6>-% M($%0--%2:,%]8C$][8)&^V/2/3ER2=XB+[ M>RIJYUZEK,+"#F 8HU\[H/>J/NL;DEZ((^:4H^8)/ M?I'M$3(2\=K='XF%.]P=;&JFO<%53S61@03EW44^I]0N^Z;1'#GG)K(P.#0+ M-.$#8A7''AXZDDEPMA"8.Q37?4(2$TLS/0[)@R M46:4)5]3E1<[8.=&&T^?6[KM&+H6YC_X,_!8#K^36/1>_X7L#!GY?>SE0R6Z M>=4 1 ;1DBP)+HPM64)I9289(L*P6#5"OQ@5-V>.+(4Q+T>"&*L%$T.+M6A$ M@-=9'1-43PU;^!(WI5;%'IP,,\J1<@(: /,<\-[0A](M_2I$20@ZQX?P_# M S[]84%%0>=N"8E[)7 &9^'_ M6X;=&O4Q>;4%DO&)/L=UQ0,M(,@F]NC"*)F-D3<GZ0[ 74:]H4SN(UC0&IGT"E#D!I:CLVV)R\2]J8X#_)C&27351QWV MH9M2>X2#)AXIL6%_CP<*/38DT\HV1E_%P [AR_)AVM#E3Z&<:881G7ERGP:R M^>D1NTD*-@1T%S*^;?8EL7(L] VA$6].ZZLHM*P4B[(2H^9;(:Y"-C4D@.HR M&\HA0*[I/9!>-H; M[L59:$R*PZK%R9#(WY$S%+4#)#Z5ZI>XQ5B"GH(Q?ZYTZ=?& MB%,Y *P8 BY=]&.3F!3X7LI._7V?Y4B\&\AF#;;^V^FMGKU!2"S_3N,F]"LO,E9K?Q>OZI> M52<55U]V>8M0&4<^N&6L,5I2 *Q@LG6XTEVJE>5B:7[MYJ9Z/Z7536.NX_7" MXE@S5:9 ;!BYKSN\/!(YSCN&>%Q?]?7F4GD72'P5H[8?G=R MZ3"_P@:6:^G?1/H(XPH))/8+2E-\ZLH"3+^Z\F(NQM?X5 2G85PT-".2O+*%E M<2VB@-W&7#<6T-L M2LD)-@7_\J<^WHR:#E6K#D\?X7]"LF"F?C&3$!Q?SAW<*;OR1?(G ?BG_4'/ M&NMZ2"KPC2\WU ^SN2K+7+!%\%$E)S)M\%]>^F0XD-QO9\XNLGBG3[>4(@^R M4E;*T>7\7E8.&U/,Z1#@9@**=PU0'76^&^; &S")GR#=QF_C#SI=V><=>R(4I 8#4" ML%K-[/3\K"KO#D\'RD#>[/H10"3UQJ+#BV#-*K\ERB-FB:688*H?8&J,!Y57"O9/8R,E.?7\DL*9GY8;4:,JO&D-F3T6.I MYIC*#X< $Y"LM]X8/G# (NRQ3'5*GXTST])I>Q?=K9Q7Q(7T*?RR6_EN^'M>@&B;-M$3F,I+=PMS^ (SI_)>N*N%;-2C13)+1[,Y-^G0&<>O.N M6(WHH^C6O& _-/HW*]10VT/=/MS?HY*7F2)%OP@SG)>T=?(!P9GCTZ9#.1&1 MI) .O#M$-R]J LS@M;2C=777LDWFC]]56S@L*O.+$ETUS#6W@>0,$QWJO%+( M5X9%14 Z4IG/[QY0\VRF ](7\,!3UVAU@RHCO)(5)+F] ]-SURS0I*OR9S7I MJFR\2==18S)Y'E2:I>/!QT_EC#3IBFS156Q,[,Y-W>J_MZW+ARUHT<7\&?>J M37QNQ6[#E3M%Y]01/;%C2,C$'K$*):+;Z/Y>5,QC=65&:ZTH8LXI)C0\M2G] M6J(%W]N8-" 18),&\.B/CDL]'6I;?,P?7G LZ;(B'@XDV3"-0Z MKK6B<;GRO6(UI+HDX@X" PRQ>TMP$EVRPK]%[C?IG;ZH6G!^ \:5)O6)5-]S MGDE5#G2)OQD"6N$";$'\)K??3#O.C4E>/O[W7/#<O,VD&*"H)[393E]V'G#W-AC:EWC+ 6&&>W M /),!;764W.V^'AKQQUME_^DG/I\=&$':" M\&W>/[4F(6G,'6B7E;MZ\ZZ8>!3YUI-EF+R;H:)-32D'T4>YWZL4@/=#I_?E M^5OEP7\EZ5"_#_M=)"S0#67?RYI'M\ MCMFX>%'H.NNXYP]E2]5*K*V"Z)6!>5>V'Y^^WI568B5F48]-,,-\DY;A>CWW MB^-_!KK91!E^*R&!+_K]T<\O=J=>T-=D^&612)(9>RLFEH6-O:S3RLMLN03V M6S[S]EOT[-$7TN7/XU/UNO+A<62JZ[/?9J>.AF)[N5RJ5?+5?'5;#;G"8512 M[;:17)AX.LN*G;8Z,14UM'P5=ME.V&)+BZ8X6TR1R]6\G$_0QI:^:87[(,8K5I/>HN?Y9A>44N5'-\PKB8:=$V\"[V]ZB4 MC+7N" 012[)4*,E*I13ZG!3U6)D5GE7D M!2>&WK'@_@G!;1T8*L ZS4'7+.*;O6/JBVJVN%!AE)NJDT<1@T,2+DUHCVV:7C:6= M1;F0 Y4*9VX)5#;,EDVQ*]O=$9S& MDSH8V-8SV$E#'2 [4S'KE[]!R>O.^HIO#W89?'?LR"^A(YW(=+GZ$Y%J8S=#(")P2]A::EG.0X;P=<2WAEJJPJ:'*PI M2QT0)+;*)_5I?<,TG*%-I=6B'Y_SYW(3E.;H1#JPV@)\/_ZW&'/GEN@'T;UG@)'6,X8&3I4+7KGDWKCONIMJC[JL.5U='XKY MB+S,T-G2@L 3O:T#L+1;];F.4'7JIO;9@\O2Y8!GH>6 "[VU,;FTK.Z@8([; MS4YL,2!3^-WZOZVJ_A->/G3FA1D^"U0$'@/$2F-#ZZB=VY^=R(I W_ QC=^' M-%2?&74Y:RL*%/LNUHY\S7IKHX?APV!P>URNO@E;:ILJU[P3UKQDQ$GEY_?' MWJB:^S JK.6$K\5M4R[+%Z4"[6BQ46PU318+BN@0H#9:3.7ZFW>4,TP]=&MU MSM/BIJ"E58@Z;\$L[<9_;2[;"@R!#^K_U&GMLGWGZ 1A-XOT3;J"T9L&E[R< M+*C\R6$:I00*90:SA=>1"QM[K2OH !\WHSXG5[R&7+M;E;$%%[K M+&8"ZW" MA59K6DG>R<6ZSV;,(HBRM9MPV5Z)E.T"N.-CYDY91K@O M,-$IS@!^\^YXUK43X]9YX37,<.HEN>\T)-.5I\6R7$H@3U>,NIN"V6I$5K$H MUW+S1=9+".QX/H%=6&9K>1I+P;,T'2#PD18IRTA^4\[6K4Z1?@E^>I>7+EF# M=9[/AS7@W*[DVJQ?UHKX25XNY5(IU EG,F?SF4P&Q/]DJR^!JRE9W6:Z4YTN\K1M,F)U[6I$Q79&+ROR"W?6,R%,:D^91<3!Y M*#[7[HS,I8F_>5WLLUS7(F[8R^LN:\+M!V#,"R*F !Y\'0[C-"RR<.P0%R,QC%Q!3:; O MB B?^(9,K'0OC4GA[N&AW+)*E4_*(G%B2=FJ2'$D34^%@4\;DZ_-\VKYL70[ M>*\D"0,G)!$I$85,!9!7'$*E(/&'_O?24VOP\=Q0%@^A)HV6>DI6:4Y2N"L1 M!,J>C/0+>,OMD]Y[U+]01E+*6MBLQL5QL5H!5/P14<-2E-YZ71AK/'=JIO6B MZZ^-E]^+^<"7\G&_]!)2-M1J<#L+=9EZB<9??P$RXOW?/EEI.!D2.A2PSFH# M1F?JYN:"-Y"R [ HEPNI5+[/=R$G!<2:^: P,<,%6MK>^M7@3KI(4RW(U5I^ MA1[0]/6=K8FQ%#R5]U@=&("(3 -E6B]7=L5-GV-&#JA@YSPC]=SDWS2,"]&C M2S,:DT'%*O:+E]U)J[4N72*44R/Z2FH?%A]*MCZ K<->49$P^$&VV_\%G+X M+0KDKX*15U\4I&Y,OG?;#X8UU3#.%,M M6O4;(4[W"MYS9MEU]A9/0_WB+7_9#N .K)V@\/9X[B'F'2 *L[G2_<*MK[&4 M-R_7%BWEK:_J?7S ^D/6E,[K3:V/I^__1=S?A VIAV,T\Q[3R)EXF6+_M[FN&T MF->*IDY3#7\$F0?*XUB/@#1B_\E:NZ26$!#5ZY.X-7;YK)O:"0?:-+P MT%2 Y7;1F#R<=)Q'HW7U?ORP4!+ YH?%)BV]G0[TUQN3HU'M03NKU_JUR FP M#(O\X?[$M"(%2"518#^D?C5!&7$B%\\*EGZMA7ZMALYN:.IHE'W.V=I-*I'?14N\9K]^,)WH5.4OQ9<0)IZ75(AVL<_4=!?VM M7D]\RGQ[O#=:P\+%\--=S(2). R7IB$7V\H^QCL8UZ%^T8."@7Y82MA$?HDK MVS@R1/=36!09J)/,\'E4&I;.OQ+9VLS9YDER&I)80,,4-2DFY@=_JO6(=1HD;#/R2X>+FY/./SHWRZ]Z( M9@9!UT^O_5QLH<;$^6G]7JRWO7Y-'K75X&, M\_7>E7YQ_O&]\>:=[R+) Q>XRNUM:7]MC=7><"S515=V9RL;VP,+$3-IBW1K8T@ ?TENXX%CW/TU@^UV^EJZX*S),>N%!-JPY?-@T+4!N^/S=; MAZS8473=-QS):L+F17?U@3K>WU.EGO4D.8!./90+'0.$ K\79/SZ4'* ZU(\ MY.C\&^Q1>MLB]!M9(XP6MT<.2H@A-N;!?%]8Z2]6<#!1*)[X[QD_Q[_O3 ,8G8,C$0#H M5ZIF/:K2V_.AVAO_-1@$, )2UM%$+V%7+>M0Y$MS=P+H8 MMY1,ZU"JR>5222X72ZS+-6R")^9BG!4 !WM":+40R" K!T@S*I 4@/J9$G=I M7D0NAVW L<4^35KPD"(],4UQLM/^H&>-=?U(-_6V,40BCY'((JX5]U1C\N'Z MXK0^-N['ZNOHF*3BMY"&^*TT)O?*^=??Y8)]9\%UBFN3^+T13]]*L1LU.@W$ MT*@#?_$9&$J0.S3U#L#'&5@F2"# %9R@(>D"*$T.E $*.F?4_*6WB,7=Z,QV M*.:4MY_^$FW7J0K"5'O2M?ZHFR,=M_F(@SJ.+4V7WN)/<#9(/O)($U_ M*__\)0U\#/2I:[2Z(#60\XBM."!C=+)C=#B@P7(<)5O_/3)LWIF?"O61%(C) M(18:@Y4.9%G7E=UX@&X!-:G 5 M1AR;]O>>#+@S,/E:7:GT7X$7;<,&]&-_^[#+G1,3OQ%0=/SCA?JJ-KWUZ2DC M^WLS:7POE3&0F[Q5,;" MBV$:G[NX 9BFD(%8+,FE:(C**TY!3-]S<>-.PSI]1'8;I1(I_CD04<^ #7PS M:M>=TU;U\^J[R^RJ0E1,:9;>C_+=]_*'Q^%D7"+AP^],8I>V2\J0[W"DQ80W M$!*BQK%ZFA0[35W%/+:;(6 TD!HL!'_02/ISL&\P%YIL/T;Y3)@HBA FBJ(4 M_9.=@Z2".:]3,YVG?L%G.WO?^][E/>UFW:$UYQJ@XEG''J(G<82:!&I,8TRN M#3Y8[WB_GWRZJCBCX2_GAYIWN34[.!7=6'U@8W!Q Z"W=Q1T N +T(4*HJ8 MN [_ H"*(<[AP&*':H0"@W_G.^\B[FN7][,#O'E756IRK1"=@4[^$\<#&QCC M!#<4"VA^@SK3TG6-?A$K>7U !(GG&!J?376MMW00$MJ5;ONQ<& 6S$)#Z^\" M.JI'1O](5^M'UXJ+CM]$*? RV)@ D-G%QX."JY249]2\PVB,[(/J;G#G#\"O M\%\"H>&0"Q#U#S&>#%CG4,5A9O-F^_FS'T2E_)EE'[O+.KN A4L9Q..3FH6 XD+*+:K-E-[E2[.@^UD\,92QMQ.=.QSF;;(HH;2-:L_7I MFDJ^,;DX5SYU6IUQ^W;ECC5X>4R933[W1Y79Y',;*K/91#%--KU%4^J[VLCE MJF\$:9V#)BOE#Z4OJ@F'0))RW2L8#QYYS*ANJKTQ.F\ /F>&J9HM YU( "K- M&(H?7>O.J,>F75ZZTRZ9";!ESK3;+AS5UK$2G/BH:I@T'?I)M;6#GF4]H"#S MYGNB"VO8]2IP*9&.ZH48P\XKI\*M!1^-;#94\O2YU55-0)YZBX2G4BL499H" MVB>3GL6ZW#4J]9 UO$<+^.C^'G_V$&YL[-NA.(4H%/:.-^QB$,76)=,:2L&1 MI?"KH66C&2JU@2<#Y-#U&P.'0^F^JYO2D[Z_AV.3<*]/P,\4^^H-."573K/R73P M:S9(G":0VLQWC6Y:%CF4 ?ITG:"*FHC,>$-3-X9F@W=E9Y'7":CR:/4><;RJ M\\#\MB.3.Y=9R)F<[H07+15O'(/3@"ELA#LQ QE]R*07(./'LN)6%R'(Z8;% MA?'R;;A.T $X[[9&' -]M:S!BQ:CQXS1F>\S(GY!F$32+FF MWON';J%GT.%HZK>M=T8]%7X2C#/\0RL0>'@4 D[NP 4[[3%]W&+MHN#:P7[; MWZOWX.2C3A=OD^,8O9_ 8Q][IX7HX]'K>\L,:$= NQ':ND9<$D-% M.'D>-=,1#:@G!-C?L^;>0)#Y"@)R!J#J2)8)^*\Z@LMKF(E'_W9_?X@R0X?] MPJ\X,^9(1N0 EE4/N#5<+=R:^D3WJUFT9=*AAQC 00HB-HS'& W86Y *'@U. MP-';9Q+IB0;B@6H-*XLL CX'TTSXD61C0"FZ$>'MV$NS-,9E50GR'; M;4+\R(24[2=8V)_NPL,7JDHF*6 AAF M?2;/'2XF&6OC+T?$: +K(&$_HI>&,BH#HZ!PR[%<^(>WK18LW!XA,\1+ 1"P M>>',NT"H\0@OQ60;S4W:<_!6*$ W#5'.=IC,8!^"*@.GU!C#H@GF/HT"'W U M$Y])ZH_$WIP>NS%8!I@A'&1 E*%JA$BBO1^\AL*JNHO7)$SDH"1AV\0M[N\) MEDT+(Y:K(!%:['::(P?0QMDM)G-++ .+Q1&3-$_QY@#CGF6AF@.$A ).T\<] M_9N@Z^G@OHGS'+.(7ZB$D?#D+[@">E;@@:?92S<^H8&Y9*!PX8W E>(5#P8, M[??W0#+H3_CQ%-[MU 7]:[R+M9!6FJ2XT9,>&=8W0Z=LN@#!^U"0JZA"<=5= M[=;[$"C590\8[Y=:/<.D:!9PO([.-%<0$9QULVZ@IO7(]%W-'G4(U4 CTEED M'Y 6[+"N;<$J\!1I4"P_W24 H>(15IKZR$9MF$P7Q%_ZX$#3.[I)-/%(&>_D M:F$(WL/$./P,$]AW"GG]:1!JB\M$O-JF80THP[*ECX8,4C0&&6ZR#:\PB]?1H9!M=287@04=HA41$D; M8I>@D-.&O Y$%Z<%)5>A5PH+$%[JZ#T6VX8?=HVF@?HY' $4AY[:[S-='"!C MJQC,!>7 R W5\Y)FZ)$%YTAF_MVP,U#OG%&#(#H>@](B/:N:MAVU&&)G4X?DY?Z M%AP'>S"0 #20[:(E,"1CB9]0\B]_H '\P>PV3&#] %40 ; BZ>:(VGWU%P $ M+-^N2Q(!T+14IZ5JJ$&@&!#[Z^NH AA.7RC^>(Q;Y/3[>[ G8(6(>J 0WRF []=ZD MJP,AV)Y(/&&4*[VMG_S%LJQ5&RX5+!T_OV8_N3KYBRFR_%:8E2X9/"$(+]/M M5$RI1W ^&[$;U=$^>B205O"G8/>X_(D8#S/48;NJ,\N@F!Y#(1#3-T6C[ 91 MZN2M1FW3&:$53*8[6L'U$]JO,O^75R>'TF=8%M/)?:%J+TS=@YTA,N"M,>-5 M'W*&0%_169CU.P2=4G^0"CEQ#5.*B-0'3<-@7F59 O-1L_K&!/U6K"WA 9@& MI@;T0\92TSJ@!"Q0=.!]5UV\B@*1TEAZ>W%\FRN6R[53+%5P,ZN M)7751^S3VV/I:!8%V_19='#Y.+$3L$A4I.#]O5:/N^8H3NHXO.J53RQY4M%Y M(E0AP<2 J:I]Q%:K]\@5?41;&I+Q>P20Y\HK08&NP M\ 5H_F,@^?XA*5P]=X<29KF@9DR @\48FCI>_@&@(>$P:H;6 ??N@H?)=8) M'Q4OPA_0<_ =DW>=[0$ R4K&B#E\8 T2#) M><"409 [!9A1RFM0SD[J> 9-[P.''A([P8]5H#CR K31G@4E4?>OQU4D=E[: MN Y<_/EV78='9E_<,.&PU['/+8Z"AV0-"ZS0;)OJ6Z"*O"IOD4N>-?WQLXY M #S@-2%=E*%>0T9Q]>+G("2H\D8G!4'JCH">X!J.4#A[,&9WV]>'AX&T6=>= M3O?,F:9!_@/B3PX3.@8JC1Y1N-#&''"0I)2STG;=VL]8-3)">[_M<5FN4C$L M/Y1V20&_F%8'Y1 EB'%ZZ]G0R#I!RK-I7I$G(GT.E(VIPT; M*MJ5/8L(% @9X"KC=8%,0E\-ZI\@;YHJ>M#ZI$NS/=3[8PO8U* +2(?*L8UQ M/@=$IVUA_.]M_?/-7P&%UB1==DIYE:5FS[*T@Z:-B>B81JXSES.B"=T^T8VK MQI/L.O#KI1Z44*D$%6J" I$YZ4%-/V@R%$2T'.C,P>1YC-"9@NB'3G9A'?3& MKO:,S\O2Q=G__7^U4O&?HP-65'9Q=H!*&3<)PA1X3UAX&_=$6R&(@L\&,8$%MBMJJT)G! "L^TJU3[=E:&.5ZKI)I"[ M:CZ*.##BT+^'P0PL'^&.%N83:1FVW472/W1A@E3OMUM)YV'X=C#@ ^1Z!ACQ MU$B8"$J8CT(G:W(I@0(<7=@HD2G30T+/-VC3J"CA_AATT;TN3@5TS$/L\%,@ M 2Z?=;*N''1B_/_M?6ESXLC2[G='^#\0<^?Z9;H_;[2]G3AN0:LG*RN7))QW=#.TB/G$Y MX02/,:"NU VA%I,>'[BM"1Z"7YZF3$ K\\F8TAC@!;_&#,FI"@H \AO;;0, MV)!@UT8[*_A/'*6O ))2OQ8@*?4!2'H+@"34P:[IA4F.EU6T<'\:OWQX\.5O MI]\V\@C3"I>&SXPP[^>D.2!4F5I*,M;FS.'[WZ\]?$?P^Y"#M/E:?%N14YQ< M[BBF&-A?9*P,4]9PS2AX&8?[(OR- )=GO\F*W[#[]AO&D*8KA5G;+@803#M\ MLG@QDW5C1%%I^M9(XDYBV[ 3 ?S%N^3W="(,^S&?W#,X,@;\]O"%S,JU,&!$ MC@!E/<0ES1T#"<7>+GV,_9[/ @(7'(#(-$02%Z*);!;&GE]FTU1P+_*//'$L ML"B:Z8:-MM@]8O(DC](S@%8_D9&S?'[M(5&]HQ.D:?2RO9*523_+X1"'^2<; M-C8M82(LJ:2D^'WK^48^]9T#7@H/N#C;%/;\O9@H;LL21.9?(ARTUGVN&^11 MV!5[]51^TWP.#_Z.2OC*2+A^ "C0/NV@*@":5[^?M M=\&\-9^@OYP-*1@*CQ^!5@CK!4VJ$UX*XH,0&_%BRF+[$K:G.S9BG/4OE,6E M"FEADHWV#8AM2G5JS$%_K^-0P!$ ;HYR?8(1SG4LBD=LF6SYB,56%4O2-[0Y M74WL%7)RV^-*Y,1BD]GK4W.R2+I44L$0^M 'Y")D"" 2ZD/JB@??HB\+9TE8 M5O6UA6)H9OY>2/&U4<_"YQ<=J<.#3!*/U.=H-^(MPQ>3MF(24T,;$3DF&UT>%!77&+RE'#Y^-&??UA MAQOS$G]UKP>P?;FF$\F_<;D>'NRY76/B9;RI89&-&G9U(9U'3A+<4^'AN(.I6+]@1(QG5L;/#[,%/ (85W MIUSCZ/JJ+^>_3.';T-WGJM@R)E#^)9Z=RN5(]8H:)*G7]JQ-KBAU-B3!7,Q] M?<'/R*9>T\]X->QP&Y>J01$4@M?C$KP?V##-D&)$U$YW7U NCZ(C?77$,Y(8 M<9F0G7C9ZWMX7@HM]-0)'I411112),_R>9LJNF,]!#8"%")X)).&2/VE116^M=*8:4_4EC_?.IF^)\J+]CL M&A[S_W3N2C8Q[6WZZ[>=?'KFV)6?ZW*I$EQ-M1$"4Q#P+,I6=]52257AV+L: MR]C@_T!EWA, 3_WG_=]T*I$.?X_6TM2QH%Y#^([P%"(RWN9Q+(0^:IR3"<\$"5L+ < OLXFOYF U?V8/($G"H M3#K*=O4E[P!!-1%F(A[V$>/0'>\+DIA*E;A9^AZDH1\YR1[6P'+PH$&LVRXG MAD6OR';$OPF+2*7GD6)S9A0AMH^7YD80I!)DQ-K(@% >FAWT."_0 M$6/Z7.6C8T\<+))4J_2Q.G8^-URH7#0WY$P9XS%4NB*?QI)YFX1']2+E]U#T MRN8YH@(-<'.H_M&>\$106/7')TX8P\,#/AVA^=EPH78%1@;P0UZO%+*ADZIB M3M/0%UVV'."<",D<"'L\,?68'Y)/O;:=]<.N%4%F, _7,PHM!AYG8_^6ARM# M/!U4A0J8+2:;4+U-;J4D1Q#"C:3"0RE2X\!"BU_N !3.F%B\%&Y[C+!]T3AO8SQ.X$O? XL[0U+MG]8'_O7]LZ9'0=U[Q"Y+NL8Y(5%[3"_ M0)?%\(*=YKN:=/_HM$]5C_H3V@. T3:=T3ZK &-C&7'P,!C'CAZ 3J'L#^C7 MR1^6+-S;,JR+)=;")5[()?8$58T97BMEVP[0MD8. S;<.9O[IXL0ES,V@:V0 MJI9HR)&^O%Q_?W>[_YO\TLROY9=F/OS2M^"7PE=55>8ZMA/P$J&?E8PM4I&$ M-"B\9%4PWM =B;$S]CW=Q[0GX.B1Q2E4.I'%X"@;7HHUXEQ3Q$AEF&B6(4., M9-4!I M+78-A ZO6HT)GU2GIC%FPV##0D77!F^4]!]]%'(Q.?B12]2@$)M:N%#?A-XG M53K"M($[D>WY.F2WU]S9T%/(A-C=E4\ 8#3JS0)M.\;D%1:7B6,0,]5D I4&6/)7$ M$._H(3.9 UB3/1$!II Q,(0R:_7X0/\I9;3A\+"V M'JK#1UXB5I8A*(N(<<+->D(6)HLKQRQ.!WEV> M0[1ZB#U ^@_F_P4+=N1$4RLD[%MPTPD- N0N,6>&94X=9T3!.(4D4)QC WD< ML1I^-W)$=%0X7@@4%#Z/6(0Z8K81Y@4/4 X^%?Q M+^A&%_:1IKJM(<47\ R"$B&Z*$[?1,-#'3Y"O?DR#4>1#BHK1=/4Y_G]W<,< M0X[4KRKHPX,]&CJV3T&_#XF!Z!J/#+%C)!O]<:..*#85,O&NL'3?CWG7CX3, M]' Q0 1-L2"ZQ.K"BH1!W-#T_T/;,>^X=3=6;;OQ<[8=I^E$1B 4M3 G*-B M]@!EP_9&[+?D[(9$S<1F!;XWVI=O.\RW9U+I MJ.>?2L2:B#OM4(H?J(;>]IR>T__D!LYL9VD9V*C&!\P'BR)<9Y_ M!A*Z8@^A^8*\7$R](.68C=P6XOF<%Y(WD4#'@L=7 5_H^1 .@$0WL%#OFUDB M=NE0V=&S7SD\ *P">E=L2$\F1F#!L8B-#?B5IQ,3I+32ZTRPE=O?PL/ M(XY'-EU!;XG"&OCCL::+. PGRU4C!,\UX\!'H7EG^^Q1<,2)DM^C@TLQN/ + M(X/) 24[S+E8!>Z" XA%M=R(8L?:2\4>C^VA(T>?^Q@.O2S_YCR5[^> =7$? MNHJF@4A1A2\+;E##'@'-UO<%@_[3\QX@QIVR;0BR$;@4HD!FGV",P'2A#))3 M_Q-Z!=J DUC+:D&0,'8!-&2/&_B=[!C H2LAA <@[9H+C(H4]S'IBG)Y8X91 M(-0\QMU$K@[\;FT$-3ATJ^QY*K\69#(.0F=?:.<2IW8+:WS0,.P@3_ B]5=$ M+(517'ZCAD@U:K?!/L>%D=QC7N(=R,[Q<]\:%C2YD("14< M=Z+9'!OH28K7:K?MA43F4:F,>5B]C (1^8!)-7.>@8/5XJ428 >Q:R(>OM?2 MAF!5."[2A(?56U'Q_MJI$"=M:FA/ICA7\I2$IXMZE6#8-G ]:4EM/4\V;Y$^ M-UPY85B5\(T4O3-=I?D1L\\,Z$<]-2S4][S!%)370#8>V\T +@=318(V/68 M.38?B63W],2$1605$CUA\R0B>7680^=8@NA4I$31/HTK1XN3(X?\XS*@3KD& M_DW8\+AL@R)Z]4@=I>@:?H>ZO-U2X(GA1Y0 GS2OY\%-XO'E;?7%AN$:D>B[ MJEGX31R;0,Q:;M4"*68!)RAD5*]7.XJ04I4//5C.#T< 9($&*3D#4E6Z9+D] M/ #60*':. <2..80[E9U5>!/'6XJ"Z"5%-#QMCS!$N[J+C2JQ1<5F"ZS-^6+ MV,(H;^*#C>%$P<- J"A%C]FN,@]B02WP9&[N$S4;4S_9&5[LF4-*FT7G&$\X M7CY+:F-EKY5N:Q'I&&NFM;V#BG#2V*$]$?\>$1@R_T2!F89EX8*O,XZM\K8[ M.2EJ0<$F;Z\^>#;!@B+HF/\!5 2'KTLZ0B$O2VS_PL1#6_,@]LX%!6H-DZV) M6(N)!NB4>,30B_%QFISN$([P^$MKQDQF"T5B; !3NQ6GW D&#(7TC5TMH&R? M-L0&,,#V ZT?*GT"J)VD_H9)!P9P];/A&^6N0- MR0Z>P+QLPHU/#!L1B+B9S(:%X"B.CWF2%C,8J$#9X86-2&Z,5.U(ILV,"PW^ M%A>Q5":V/E3YSAT;.E!PVDVD (> *_#!([ 6EO1%[/>H:)F)3_F3PX,EYJFP M]8['#?2 MV\1#&C*H4NX:2H?"84"X?X);(319N]>0C.HR\(Q0MW+ODH7O+3+ M )V%FH$HA V8..R.9-9&W0#5F.&=3]+YDD7:6ACVRSW+DF"V"3(1(T.)PP.(J,@+FP8C.;LQA?MM@L-6@Q]G/'_4\-&RJ,,!4JJ;'+_NFA,' MND$X[#C[H#;H,F8*!LOBPD0A]-2@8X&4=C@;T]M[)*B+B;3 ]VI%86*0\AR; M[ISCA.VP%R4&V.2:O:\Z<[5A)$]D^Y$V%G1KC"D0A\I^Z^;FN5=F$J-YX6O> M3'#H0D1"MES"W5"4W#[+M1SV\4.@R!IN#795@2PIEJ;Z6[#NPZ(>-KR)J\TC M).9P>CB90'BA"WYO4>JGVBSX;W.^;]"*',1EJ0A<7)"E=20M$7JSG,.%LL80 MD!06-&%#GCQ\PS");=]@Q.*A;3^?I0)J0)2>I0HI@5H^(EL2#A:>) MKR*FO\F4VK$<@.YZ*1K"X?.QV!S-(&KRP.:-E'V\\\WA 4(P,#R[M"4SCI= M^!2AGN#[W(A7UP 0%SC9(7)#LGG8$R2J5#LX\=L6$X; D3ZCN@!1MP4]84T= MFLV 48U16P=RYUP>0T?E/1SES[&AIL\FV"*!W4F6X_XO&'&^05%=\S^]L*!) M.3&HVW9:>J'+-34G4[;(,EI(9\B+5M\QX]1P@9R*MU_DQY8]-/0XAL;:X7Z4 M. '$8?&CHQ5?6)-_>$LZNPX050B2H88=/$R/.MS1Q:.24 MS'!A!H'C-9*$[3")G36,K@1B CEE'$';UOL\& K\D9."K@X%&4(Z?#[B8ZTQ[$[4-R^HBSRRV0SS%0<3Z:GPA'A60= M]4?FRRC7ZK-BR7#LJAIDQ"U'G2XLO\^QQB6U L/.'+%+YM93AQ4TS#XKS4,] MI:MGK0Q]:7CK +36\-&*&;50Y(CN/^G"L_=_9KI#UCWP=CNXU"KI'%GQO.0J M^A'65W\&6=%YFGRE*"G8P&@4DZ/N3XY;X]Q8CB5-/M^UN= MZ$)+5BFQ5>Q7+ [9&]A%$'8*FAVAUF,B"0A:Q-2HQKV#QCU(:F ''H8 L,LO M]\?'^\3S)=D4 M39?[1;S.!9[$/S3T*?:&-_G!PNMX@67=?N3%.#GJ4!$)4X]^\,7Z8O7^%7A. M[M>"Y^0^X#EO$?7Q!6GFIAL"FR,:%R'X:!GL.+0R+JU68EAL%,8G*($U=G^Q M6_F>"$D^A7D ]MS8I;:"T$,U\"!M3L%\=F,],65#5@N3:C96GVM.V6();\AX MS#*AE /O=](G^^YERHQO78OA52["JA!?VYX,+0W&.K%HA"AK)?GJV-F*?%*N M#6\WT8F10VZ)%7M/M'N-O*QLW92 !W2MPV"=+;4C+HO/.YC%94P"2U^X>T)= MTJ!!J"\P,5\$G',/6&IKW#AN$$;2DZ%K"T91X-(>B6_N/H/"=7M2^-SHDE6* M:K*:$FH865\[ V/%DQ$]R8%!AL(C[ M><9SKU=BSUS'F3Y1C""* /$^''07X3V P^XC(@?G^!S+52)VYBS!=T-J3:A@ MY1S_96;867P1Q0HAWYZ2IQAJ]HP -%QU06#)F;'I&0N/VL^Q8\Z4K^0?5HJ+ M(2_VQ95GVT3IUG# MZE-!#JDG6%J0E5!-00M6#("%I=3[V"3"V2$5RQAZVAJN,G[,!.Q*@9Q7##H/ M&0+?@=%(](;9.G/V[OU+%9=5X9HHUHI1I)Y7&NJP1_3-KU"Y:&0'H)Q@YMQ' M_DSV"?28EGPTD$%V 99&*HG?-R$(4^X0!O.VM/X>G0\>^Q=Q6SSC029"I$S] M1RE\LIN_T=#/_UJ&?O[#T'^+AOX^%&"?4( J%][[,0#(6KICQB%H(H@(,;L9 M^YE2R>.(V::B(%"#N G222GUF(*QD7CW,%Y'60>, D^06;J/W"=["P$C $5 M(2 FB#A;6P+0)XRHJ'KRE8+2K[7J#6BPBT5=#BP;<' M2ZU^/Z1LY/#B.?8GA24-N>A"P#R [:&Y+@6X8$, ^$!0:8$BVGF2DK,[/ CK MT;Z!"/(/^#Y'#6Q]%B*A1E1ZCY,I!Q.V7+%,*LZYG[]&)9F(O*,\B3P9Z>C MOF,3I@M6-7!QF5%>"7#"_".*"O)@+_XW7&=U9; -%>;DD.1J@KBH >TT.^Y >M1\",50U3&%\>G2)VBCW"XY5>@( N%&)C95);6I75E;>R Q@D"M9\0B&PI9:\!#8EJ6*T_BS695H'?X=<2K0<>''C(X89K.B[R84!T0-Y"MI<8EP,#9REC8H M;E%DL35A(.24@-:V(E!XCZ[G<2HV#Z7YR&.*D[>N\S MCC@$AS")+[= %04BV]01?P:QM,D$"M&Q_(F>6H@7"LEXNIA[[MQIVQ('E):8 MTR$;9DD"^XYVT!@U7B(>(Q?"-&;C!14O2'!W^8"2,1EV!5]M]T*87_S::H MJ0[\_T*Q]&=$HR-MGP>8OU 1B9,EC#H>%BO0:8ICZ!X0DIBN5VPQ]C8C<%O& MR%S%#P\:MDX]V_G517P<$6CKRK MV _HE*;"'B&T2])^B!K%(E!%7A*?B&SO\67)?R>23@YDE0N6:EXQ.YN8?S Y M+6J ><-%60(=I05'U81&9B0FJS)*1)F1WIEC^'P\/H0JBHH'0Y#I@'#R FL\ M4NP?EHF8F[ T%#!^TC*@N;"GYHJ%>+J4WW(AU4B'#$?*)P%=)\9/V0_RV43R M7^)GI/YI?]5+37W<%HSTF0G%GIN/E XM(A^F/;8H?L:38.PGFBED+8*N#!&( MH&0MB_.5"48MI'NGI1>91Q6N2KA4CCUUC;GS%/Y +E_% 7.8_:,F9A>'IAH! M^EN!1Z4D$XUWU%:HX7D)2CA=P+Z0_R9^CC@;LG($4)?<*RB/="?(* >W@=#S MJ)WX%-'N@=*4!TJ1XJ;368W'6B[3GP;L<:QCF!OXDX1=H4&/V#(;NVQ0E'Q) MRI-)42J?CZ=3:N^(2-^(J6$AT$JJ<)0HZATI!2FS(TBQ+\E1#%D2]>T$'1L4 MFRAPFFF8)[YQHY7&4%(-C6$;X2ML M*H;-,6CBB^1!XA#4[%1?!.@5Y$U9(ZY>0$RA?!PF&@^Q'PD75 Y1_0(8F,HE(3G M%1U.;!#W2UD?9=X+B:QK=U6HZ&HN<$+ MFJ<:YP7,Y..E=#I>R#][OX37Q>$!^W:Q5(H7B\EG;I$$$JDC2Q]@<$2('<6' M;'_-5KWB0I[=;VS(J722QK-_$+Q7!X5*PV#?]E"IXDGX'I&&(2+/P@6;"Z,V M,?999?).A0]\N(/V!V"YLW]X0.T,P<".+ETDQ(NY8F:Q#TUVI3*_0*$!T7G' &B :26SJPISY2EG;PK8TC-(TP>:=%MW9+CO.D)F8CVGFPYK ";'.4Q%!3^S@*3_0#J I +ILL;@LML/V5M1*NTZ#JJ M"0$1_.:!E#">_/WS _D=3OL65(GWJ(I":6_P ML?+?>>4+T97/,9?6IT;,DL?]9UCS;_*_BK^6_U7\\+_^<1G=.7?%Z+G+)V(G MJZG)[,0WK^+^T/YDLQ&/'?Z'CSL&%!ZK'S=P:C.H&Y;%5@U@G__^+?D;_GL! MS@7_]S>_=&F._"E\-?FOSS%^[J&07%MX3$;%__L-9>[_^:YX <(9=,T2QYID M_S7_++%?*U# M^U6I3D"@Y*%;'\K0I4:X3Q3&5R23I"(VA'Q[FCO4 M;,/[U%Y9QEH\ M16'J5<_>@##UM15P-:V9:>,#/RRDU?2I,=<^I.NGEJYJN?DVI:NJ6;I@:FZ: M]@R:I7[(VD\M:\URY6W*6E,;&M:'E+T/*>MT3]ZFE'6 L]WV/U3:.Q*VVLGI MVQ2V&O31-5\D:C*7^%Z3OE_W/E%L^%.3B4S.M/= '?[G1?OTVW].D3\8BE^A M>B6Q([LO>,0WR,6S1^2%L]Z=YLOF^8P\G@:N;7I3=0%B?6AYH$>B-:;'*5C' M\ON>8_%VRM C@FK?L%D"M4E^69R&.+^I7QD^'O<"\*SLY\!PQO'<_$=%$;;Y M6DXC\FC>3U "OBF9XD*]C$$=-SF+&I0M\5X4D7K.Y=3@94@C*($!< Y"A,<^ MS[8@=S4LH#..\R;J%J>-@^<*DC)3Q9S'+#:!@!=180$.O7Y; +_?6!L*XLX>*13@#9 HP [6B*_HJK128]"V2J5KB-Q MGS'5K#%OZ4;Y9_I"'"F?7", Y8I/E%4UWY$BX<= !RNF.#; M,+A>#GS;K^6'I.43N5#/\Q&D80 [FJO'GHZD(_LMEQ=BK%X\B%QAWR#ZIF\! MP/TU1I!.[1M!C5D-?QV$N'=DW_&/?PT9^>*5V5F-8^\X5@V 2^.&>3YO>_F;)O&LEU"=:B9TA"<>Y[^"YOL[;Y?D046JG_P04U5,SQW- MMHW8@+D:Z]B%.7^;DWN1L/Z%J7Q!9+\AGT^4.-A<$!R_5Q#:M^1(99*_E".5 M27ZK(_5Z'LKQT!FM02J.I_[<^D]TWWJ&+V:S&JT^QQHU_#__318K_S5$\,ZC MP>'OC/.U/[CTU^G9Y.KXKEDL%V\VZ]E)-JUELOU!S;MN>-W*[<7Z:#-M-.\? M+K2&-JINACGG.-,L=+/G^G)^-^NV;F]Z^:NCAPM[F#?LS&UA_&2-,K>-2G \ M2@\?+&=A59\JS69O?MTHU^=7]:-D]_AH-.I4CU.7=WJ]E9J5[H\S5V[Z5'?* M:WN=S]O#^5&K>AP$=_7BPA^P\7%TX] MCUIWR66_8PY;V5-_M2[>=(QJZJ)ULC!O9R?+I#5*7WO%W'K8KUF+HV3NX:2] M&5J7FT%O=C&[3@_N>^UEK]2NY*;WMK8ZSM:+]5%]<6[.G^KWN->?EJ[E=J[27E>/AM*=/AH.;X&SE6OGE M9>YJT"IU[M+^2<&]=EN+AQMG73JK-O55]Z'4NG),M]V:I)DP=$[ORZG1^N*L MT%O?W1J-W*S2772:7?UA4^G=%;W;WJ/7N#<;R8J6;"0[_5K2\KW+I7WWF%UG M1W=7RT%OK=?6Y>2TU>_76]I&6[2JC\W*J?98:#Y=YZN]C3EJ,?W7Z*7RSO1H M?/XXO.K>5XYO+P87@7&G71QWVLO4I6E=]IA[M2UM^,)K5K MLY O]*SBQ:9PQW95+RR:#\=Y;6.6;^^>_*LS9W+7JZ:SUL1;G!7'#XUQ\'#3 MGGQ;7WB5W/%1O7,]'2_2 MBVM[5=/,=:-QM-I^G>ME!V>K.V?<'P_.6[?V0^ED;!N7CT_G#]E%H=<+M*.[D3.M7$]7-[G' MSNQ.2]LSHY3?'&7N9X'UZ)]9V?9C\7J5"_1::7Q<&^C'C\%\Y<< M%2ZNG9G>+:6/F_:TGLU/EXMQZRI3OQBNSQZN!A>9YJ3RN/!&TZ[1K3:O.O?F MIGUR5>N?I$>+7K)GG';:9R?Y0:K1K"7GJ_9):S+OU+W\E5^=9"=:[K0SO;FI M;:SR?&0]N8/!Z6QY4M"FK&U86K5YSTK.31ZW"Q?FF4'/RJUQV MN''/Z[WJ^FJ2&\QOK_+=?C.;2=873P5_/K_O3:\G;JG<;%T^M/V'JS/S?KIL M&Y7,^:E;3AUU5XU4^WAR>3Y879UJJ4JK7UI*-_M%Y<_PX/;X^N[R[6^3OQN;CLI.JMVYGYX/& M:G$T?7BJEV[T^5EMJ)=U=]8>7AL-STA6JM=NIQ,K(?@XM2RKZ?SHZ>[N;N/&-.F68X M?BJ.\KV+Q]YI3;^N/+0J_;NK8<\8-+,WA2>W7;L.SIXNW/2C=_O@&L%E<-YA M]T3NK'W67@;WRYO-&^D+JP5@]/E[E-?52JE2:%57)^$K0V1_I#[FHSJW;OA_T^.P/6 M^G35K1O^S#>OCFNV5:R/S[*7XZODRLAZC0=]Y4RZC5*_VR]:FZG;/#^M)YW\ MP.G/5MY%W1P\ M M3>MVY^;/>;-R4R;G5QT M.^9%J35K%U*WR;(S/;4'[9*A;9:9CGEWT_+U._.XTSB^/$\-GCI#_VRZ"L:= MHUJJ?A($Y7_3]?S_ 5!+ P04 " #,@VA7Q[@@KA(( !2+P &P &)I M=FDM,C R,S Y,S!?,3!Q97@S,7HQ+FAT;>U:6V\:.11^K]3_X(W4*I$@0-)4 MNX$B<Q_US;CZ\NNT.E>][DFWU>AU+\[9Y,G]U6X>OHQ:Z::^;JO*R!!T4;*[ZJLS[W;H59)Y!<]%2A]S*8C&0MT*.T+ M38T!'QL!FZ7_D2.H]:Y2-U/KM5GK@C0\_[1S.%)#!.U;CI>)> M]!54]O.&7H*.@]=#!QOQB6!:3*28"A^PD(9]3;B&$PAF:!\K'3,5L1.E0\PI M_LG4@#6E^BP%ZT;>?G55##WS]:\X?*MP<+"Y.&AR@[>/]QS.V&VDIH'PAZ+@ MX)""P%=8)%(QW%T4TE(89%F Y-X)3) M17LC9A+ZN)\_%5JD0F@#H32!X+Z$4YS*>(0-FK'PK((D=PS5E(]M C0P2G^6 M-\,KXWVUX1O/A,,M9()@ QD!:P3;>VP50 ,,1[?.]0PU6 @\;AK]BR NHQK8:$*Z,E^( A23( ?_4":$O:E\0)E$LRC2*)5X# [ULH3/IH-VP5$?0',.QQV[KP1CX:"->"DKY( (RJ' MO%@YVA5.B\J1[Y[F-6G4 K2%X!DNI)+:E2B(0 N>B*-=?P8)2(KA\JX^Y"1#SM:!-QB/,UJ M[G%92$,2=4J$#^AB5"!]'EM%^T;ZDFM)&Y N][*!,"))B:%\R'H%8Y,G&R:4 M$5 H1EBB26-.V$D"3M$-V[)*W.=5F.&RM'QRB?_Z@@8B &&^\+<^X&PCX?J; M3+B5O?H"[U:/!RO3#Y2=2)]8Q8V*. 4^;L!(JD6(:ES[&>Q!1,G[,I#QC)*Q M9!W_'TP-%?+V/AZEVYHG.@QR&=L\NAY2OM6 5O5#$6$G# !]$C MQD1N&H**S?$,3D".$>)^,NT5F.9M%M,Z$QXDUO\3#,5@@,)#3@ @LZ2 F">' M*\0S][B\IK#$PD3$(N,JE[Y*XJMG!9_U%<)9 OI4 M2?A/;OSWW/ WBQMM![M%^-+Y5UHOV)ZE''E&[*%43GE>H@FDN;QIB=10F1CM M]&,-9!F\L>S0ENT^,64 MB$J/!J=*NZ! QE;>!0E<\7VG%HC;N99)@442T_A MVTAK#9)&P1D,>"N"]"#OT?C"#]OH?T')C>#8T1,G$6LSQF8>5M@?._R,T(5[ MWT^A*$^J^S! M'A&ZKE0;?94<&_M9Q _(]G6'6 T E02L(8$ M*^A\BDZ^/"F X313FQ\D3 6_I=3+518V^;(UD?TM)SMJ?A8STIK?G18NB1;< MQT0CYL'B21:EE12F@ HH> HN_S,PA4G"D&O8P&XFC=)+#^7_%X%D&QFQ82<, M#:1P PU'7 ^A0T?0+C]C3"E0L$E0#*:J& B* N*^##]J5.G$4>$XT#-!'JG M(^5B#'] -!!C+3GB_C+(ENQMF/H+WL=9TYVE-DQZS-@Y=A?VL<%?"^R@?'#X M0[=Z5M#@X:6>U>_N/$&;OHIC%:Z':MLHP^U_36)><>FUB4DAY1[1''#OEE7V MCX!,>ZR^4R^94NX.UK,+A&RA%,@'E7_SUO_]1:SM$O?(6.N7>'CP8_,_;L,> MGU#R16-QK4E#,Q>C(N:'1M[5I=4]M(%GU/5?Y# M+U5)096,;0BI&>Q0Y2\&[[+ &C,S>6Q+;;L+J=OIEDR\OW[/;4FVP":8B;,Q M4_!@+*G[WMM7Y]R/=M?/^O\^/WG[IG[6:;3QG]%?O=_MGW=.ZN7T/YZ6L\?U MYF7[,[ON?S[O?-H9:A4?LVIE$K.^C(1E%^*.]73$E9?>\-BU,'*X@XF8>I7/ MB[@9277,*CM0]U>GUNZ?=5J/?O;Q@ M5S>]ZYO&19_U+]EUI^7N'58.V.4IZY]UWKZY;O2:C8O.-;O\\[SSF35:?7IT M4*ELR$W/M[]QT6:]F_-.ZL7J8:E1_9"9RSI_MLX:%[]UR,ZW;W"S^NOAAXV] MSYWYF]LX. KKJ]_2OJ-_^ 3-__>7)J=^R?$K+]7F8@QQ47RGNA[Z(ZG[1T2LP<"^I.@[ ?R(.<2H,%Q0 M(T.E?: :[ LD"?9H1!)B /B@ 5JGSCI[?&[';!CJ.YN3Q8B1M+'A4,3I9FHW MK/0*F+>Y,4O6OL)^$]CZL+VP[]_#R'MCOR2Z9C-@9^4D!4P]'$I<[MH]!Z N MXT8XJ )Z\5#W:%:D5U:,@O4HO);4X*N4* MR6<4R0L42B%-MJREB+U7 ?A4@YK=X5SA_;M[;MT/B8:15'BM78&ORX8"7M;% M_S.)MA5TX7NKZ?*3*-(6%KX 4EQY\32,/:I\?)[8]:=0"3(0@&2F*2UJ=&(@ M "%Z*JT+_!@EE)-##=XB9133CA$A=QC/JIH%+KTL)=%#B?0!6ZP.932A+8"!L5(2S1IP@D[2<@INV%9SHA% M7849:956+"[Q;2!H(!(0YHO@Q2>AF77[]F M"YHD9@+R65<\^KXV@3/ =34CH5 3AN @GH@)D9N&H&-+>88@("=(<:],^PE, M\[>+:9TI#Q,7_PF&8CA$XR&G )!=T4#,B\,U\EEZN;JG<,3"1.0BFW8N YW$ MCUNP3L;E\]&"VK+ATPT]&^0-GXL5(O4$[*F1\%=N_/^Y$6P7-]HI[);A2_M? M6;_@GJSDR#-R#Y5RVO<30R MU$TKI$;:QKA//^9 EL4;R[=SV>XC4X9@&[+" M@]&9X3XXD+.%*Y7,#=M+S1IS.Z\R*:$X>HK 95KGD"P+SN# 6Q%F&WD/QGO? M[:._!26W@F-'C^Q$;,P9V[E9X7X&"7)">XO83ZFH2*I%&B!:/*/T7.JVYM9Q M=%RQ-G9>[;D;$!E%,HZ%^$:B'6C4D_0\D+#/"=D%\Y#7+.5-_*>^+X\7XDLB M8;Z+#8GRW:[@WL;W(%XSV8O;P&B$Z"3@#0E6T/X4[7SY4@##6:4VWTBX$_R6 M2J^TLW#%E^N)W&\Y^5;SLYB1]?SI;N&*;,$#3+1BGBP>95'626$*J("&QTOK M/PM7V"2*N($/W&*R++UR4_YOD4A>(B.V;(>A@1)N:!"(/>!3N/0!A+O?"#,J M>&D!)-54AU-!59#BH^RG3I-E'!%-0CT3>'HWUFF.X?>(!F)LI$;<7P79LCLM M<[)-1XY0-,-]Q^P""XD&6,LO'CNH'!Q^UP&?-0RX?[YG_6,\CS D/2*V&5:] M1!GI^CJ?CK,90? _J #8 L-WPA4CRG*0)^< ME&UYZ<#6LWN&7%T&^(/J7T''7S^U];+$/7#6YB4>'GS?_(\O88TT/SN*31-7 MI(IIUAO=DK*NJ>[%ZE^^(8LAA,U61C ML76>S44ETW5G95=G8WS_1ZD$*2(,CMD5BH8:[/J2H-RFBJ3&+B>N,SMFYQQ] M9ZF4OY)V]_?[A]+GT>0C53$/(DQS.<(4LFLQFS[,M@_.;B)GTM3>20$3RP>' M[^78Y4HU7WZ]C%7D"RJXH4Q^2-=*OJ*#^\YI[L#__P!02P,$% @ S(-H M5^U+2)W$! =10 !L !B:79I+3(P,C,P.3,P7S$P<65X,S)Z,2YH=&W= M6%EOXD@0?D?B/]0BS2B1N-E$$_ @&3 ;2RPPV,E.'AN[@=XQW9YVDX3]]5MM M8\(12'8FAV:C"' ?55]5?W6XC4OWSUXSFS$N+;.#WZ#_#-=V>U;3*"7?.%M: M31NM0><&'/>F9WW.3017=:B40P4NF],(^O0.1F).>#X9R(-#)9OD<"-N':;[ MYD1.&:]#.86BV>,YYH?^3@*&T<5F)*1( ^7-+BEBGD$11,>%8X;XZ$2*I\E M_\>\E2I =[6MD6MW[;;IVH,^#+K@7EK0OK2M+EA?K?:5:U];.(PKK%$V,[P: M.5=FWP5W )5/<%5TBM N@F.UX^V5VED93 ?,SF#H6AW86/[21[%O20KBHGR> MVN&8HY;9MYS"X&O/N@&S[>),-E,MEZM/XGGFR;WB*?V]B!2;+'--FX,G.*>> M8H+#'5,S4#,*7Q9$HO'!$D8T%%)E,V("+2:N&06;>T4XT:L^!O[WA6BTQ3PD M?/E1QD^G@(*Z0LX17^$+3(2,)8:(1_A D>8^@@L5G8^IA%HY#]5RM98'$L&$ M!3BY!N%0;R&98F@?X7XV8]U[,\*G%%#AG$611HS_>JE/%(49E11A;D)+T*?( M\F#GH;T0? K7T!'X>\;H!*Q[5*38+87!9,(\1(52M)"58=D,CFEWY2% M*/P4V1JO5ZSE#LVWW__B<*^?BYZ'9Z:3/ MVQ@JB*&-#!M+=A#%'?/53.,M?VC F'C?IE(LN%_P1"!D'>YF3%&<$-*G4@\& M)(PH!N/JET[]ACM*%=_J@_%(D/):B3"W*CJ&VTE7I3I18\ X+74*&D%NOAU#D*[N'@';"Y2 M, D0F"P"C'4/^1[H<%N'H*3?%TS2.1(ETMQ\8#J<$(QT"94S./%/UXQ^"-EU MM*YH7;FH_=[0@;SI#_P8)2>Z[YI'$*<BX4BN,S'T?C$4P(1IJM%*&FDN9+7TR0(,.E@&<&LA$R*0B1/E(]W M31@GW-/C*-!GL6BDAEZU"!*J":P8L#"7#IB3$KF0/"79E=O/5&H_M'L#XK5" +J.!7X+K MD(-M..6>QM^ 01AW177HD4A!H9#RJF-?;U^(K9/AN;9Y)T&V]A/D1G.PV0SL M-@L[+U58\O7647.#V/O7*%LMPGYGGKK1**$5J4$;;BAI/R2VQFU,25\;)O>( M^KKQ7U!+ P04 " #,@VA7^ ]T$- $ #@$P &P &)I=FDM,C R,S Y M,S!?,3!Q97@S,GHR+FAT;>U8;6_B1A#^CL1_F")=E),,&-)$"7!(!LS%+04. MG&OS<;'7L#U[U[=>+J&_OK,& PGD[4(O:E440>R=G7EF]ID7NW'I_M9KYG.- M2]OJX"_H3\-UW)[=;)27O[A:7BTW6H/.-8S=ZY[]H1 (KFI0,6,%+HMH GUZ M R,1$6XL;Q@PII(%!=R(6X?9OHC(*>,U, MH8GAO\;E*Z[!64P=%;U61A&R* MEY)-9PHUMYKV[8Q-F(*3:JG:*+<>-V9)1D(#+FGXC2KF$31#>%)\P!;C/M5; MS=(IXX7F$9\D^>&B$RF?I_[Y@908P6FU[Y#I=IVVYSJ /@RZXES:T M+QV["UVG;_7;CM7#VRAAC_*YX=5H?&7U77 '4#F'J]*X!.T2C.UVNKURVQ)\\B5=[DH&X,,\R/\;6J&7U[7%Q\$?/O@:K[>)*/E 70=!?^!V1+.!7%AG0GC$:0)=QPCT\&!@$ M ?,0&^K2JE;N&?DRV1.N (E,JYJJJZBJ*F:^D-\@7[Z=\0S(4VE ME8$QD1/"T%RWRN2]6FVG__%#P2RDUT.KT\FN[V*H((8V$FTBV8,H;IBO9AJO^:X.$^)]F4HQ MYW[1$Z&0-;B9,45Q04B?2GTS)'%",2=7_^D&T'!'F>%O^F \$F;T5B(NK%I/ MP^UD4IE-M!@R3HLSJ@N[!G'V#M.\.\!JLN5),2 1"Q>UIU(LE4W87W09_KW* MCROO&V5M0+? SH/0+B[> )N+%%QE>3 /,>4])'RHLVZ=B9)^G3-)(R1*HKFY M83H<$TQX"953./;?KQF]R=QUTJYH7;DX^;FN\WD['O@U6I[H;FCV(,XXNB^2 MCXMO#+V,.C^<+]7'^?(6'&$<:WE$TH/'GJ$(BOEX-SWQC$"$Z:812YIHKAAZ MF80A%AWL)KJVXD*,Y$F,=%>PKKFHT&>I:J2&EIJ'2ZH);!RIS>1>/2[M(U Y MK5?-P_3*EX]DSS50:'8P(#7HBV_+-GB^[(*O*KO/ '"WZCY17'=9=S]7)D(I M$:W55LTG;!<0I$0IQ&HE$XQ MG1(1,K_0+"?EG;'QR;ZUW_1W<.80O/N/Z,B.[R!JWM#TP=3$Q/<9GZ[)>QZK M;'I)->QI4F5M[06=:J-M-P6&![;UP)-8HS7:-N0TCX>2H42,(AMA/3A8GH>/ M$0I#DNW%.Z[I_4)G.D)ZEY):>V6E*T.O]W1[W?\>T\NINZPNMIL46/WE<6= M/K\[_F;.-\KH1>;05AC*.@Y+7]-9I*S?T"U?V>DW>W\#4$L#!!0 ( ,R# M:%?H^:N4S X &F\ 5 8FEV:2TR,#(S,#DS,%]C86PN>&UL[5U;;^,V M%GY?8/\#-PLLI@^.CT[N3R\O=U":!30*8D;QEQW*=G[^]]__AOB?S_\8C= %P7%TC,Y8.+JD M4_83N@YF^!C]@BE.@HPE/Z'?@G@N/F$7),8).F6SEQAGF/^B>/ Q.MH]V)N@ MT0C0[V^81BQYO+M<]?N<92_I\7C\^OJZ2]DB>&7)MW0W9#-8A_=9D,W356][ M;WOEGT+\+VHNGQ6TJ^[(CGEH]]/=QER=/X8&]O?_S?7Z_N MPV<\"T:$"KN%>&U_^O1IG/]VV51J^39)XN4S#L=+.*N>^6^)H7T% M24J.TQS>%0N#+*?=^ABD;2%^&BV;C<1'H_V#T>'^[EL:[2R-GULP83&^PU,D M_N7LK9XZ(6Q!\,MSD,P"0=I8-!B?,NZ4'&TN^IS@Z9>="5D0_H2#P[U/AWNB M_W_6&F7O+]PY4R)\:P>-MWCVUR 6MKI_QCA+;1B4C7O"3&]>Q+#G?I6>T$@,]00_8YJ2!;YBJ=6<[7OJ1XO3('V^ MB-EK*\"24$_8G@/ZA--+>I^Q\-LSBR,^C9[_,2?9>RNT]FZZ]./PVU/"YC02 M4R__E>#5[L(&H>ZP71&N= 2PGM2P0W[)$R53/CII=A*&7.6,1^!;%I.08+L/ M0H2[PWI)%SC-Y#@H-TGKQ_)7&3&%^PY#X0SS*#WZRW M+K7AD?&)\$>U[P[1'8[Y*(WXG)V]/R0!38,PGP5MR&QRW2&\X:$D MN2+!A,0D SBHKGUWB*Y9AGF4>Q>N8D.C:ML=DHN )'DJ^6ONQL5L:X-D%.H. M6S&[M_$IO42'\R_7V>Y#]5;=/9TG%C-2S#]YFI%/GGP-!'!K@&B'W/$NV#O& M7_FZ:DJR6Y[=6:3%/\QYT8X7T!<7==^H%C:24SM+[8:'_L@9JSM MD->[<)43P!39IL_^\@,H=I-4/W$/ADPOT7,,A,$#B/89#V$@;7)=QT88*E7; M'E9)9SCC(R^]#A*Q.E]8TRVKX$"S9_GXK:;/1A_#(@=;?*/.7,4"("U;=>I8 M-S!QW?3>7^P# MIF[=$QKX!H)1JM<=]M;.#^^BOQWXUML%0'D3XC"(PWF<%^BO^,\U"?R681KA M:-F/ -WF^$]&,B%0GLK:1R-QA&LN B#_;]FR5S3J,SXU5 <=U>0< M)&'-9^1#<66+<3J?%6=61ISOV5)^FK"9R=2E6=DFJE0IX2AVT"LF3\]9CGXC M"N790GSRNWFC2L&(D+()P7@X<,,#1('.K;_U +I-\$M HO.W%S$9<0?*]S;J M!U?D<6.6@M%TZ'2X0/3VB2<;(^ULW_=4I3&ZFAB/K%P>**5/>49Y)]#<3!_3 M8FM5;WR+F!_3EH83D,H^<=3<\+[&V?E;&,_%-Q)^82QZY5.MGBJ8M!\SF(:Q M-@;PB3@[.6T)^.B& )^-7*E*6#-X55M'T:TH0B_WW.UK#TU[U]%/;_UF)#0J M[)-#-6M=5FZT J[#()@L5.+WDO,[W:2+'*N R"<*Y !?**L6ERT\J1L M[#HX@LDQJ-K_#L1_Q.XDS11?*FCL.J@:PDQ\Y-#$.N3^.?SY;(*C"$=G."&+ M?+]X5:J\F!DIOH6FF+<*%M[E+_I!I!!2Y_8T'_W6>9" MU=;9MOX4LIV/"=J3WXDO@K(*(0.N:7KB1;,A4Y) MGX@XB2(B5 [BVX!$E_0T>"%9$%>@&_:= +*NIUXP67!#>$5?&,YG\_SD>+Y/ M4[OVXY*&;)9?_G&-LYOI0_!FW$-LUY'K93>9!0GKZE M%97.\)2$Q)"Y0F1=K^_!7,(-X1-]RV,/D'"G:NMZF0ZF1Z^H@HZ1#ROP$QJU M26GMDJX31:AN^@5\NQ'D<)7;1C_;G4TZ-3^/FUI>\9\'.SRIOH>L=I+R<(.3 ME.A#K>/O>CX/NL$E9345/VI57/>,V!2M^T8!C5"M=R2Z=W^:=+4%4QZU,FP! M*IHZRC%G+,G(G[EE;Z:Z^YP4*:5%SO54J>6BF4""]/9(Q G8,[S M,7L18Z14TY0J&L5<3_U0OD#:^T37/8YC<5HIOP$VYK!/HAFA),V*[Q-8>8/* MNUZ+0PEL9P^?F%QIN%Y7 B;X:F-O)D59 UTU06*SPUQ?4\U^8%D0YZOY\N$% M6DU)6]O:T;H?H-8)XG4^^M+;X298E9#+/\AOW6+%381KK9CG7/@?32ZKB M2K1Z-!=O5VG:K+RT3;9XA\,X2-/\BK=B$?]($QS$Y$\9WC=1* M#$? $H/H!N7]N*\E/_:PS( M$&O/RE\J]W-;#.IO9MR:ML&K1)ID-X](/!3AO+K*Y[ ,,2<$-92-/>]:V1 ^45:?%,[P)#LC:?Y= MY]L$S\A\!ITPE:*NC^UU/&<:S#/$#4VU+? +KBO/ 1>8X\NOO9WP#'">Z"I, M8&G71_FVFSI;&FF 0N!)&":X<)\K%E#]J!*M=8UAI/S@*2EF$_0_ >P#)WF^FU9V>ZJOHI)TSJ#B,IA\]I:FMF088/,4;+2L:K"\]8M-YJL_I MA314&,;:)T]9:V]Y2"M<23^K9.*,/8^U MQ;^7M+RZ[ZS\VE_+JPLW[0_(O\?;+-M9TG.G:%RHU(9_211(M<=;,V#[^#1_ MRZ U7]]O0ZZV"R#)/N[IM%?V+T&VF'/6&D#N#&G5"9!PCW>!-K"93Y1K]"_J MX=M5;Y1]=+EP6*]>H'=9&R4\+=D8J*@N$0#&\"I;T&A[06A P^T<3]F'L[)A MB'&4BCVJRS2=BV_"W4Q!UQH 1#WU6 .'@E/ MZXUP!FW&&&#_B.M@]:/J:PTUL:%]-YX6( 'D;::O?T-1J-]XN<:Z@EJ^?*/^ M0:7E+4X(BYKYV^K6;OZ??-?MCEO@?#K%H6&K:F@<6QNQO3O39F*:)V>TK8G'*JIBR9U8]SU#3\0;S-C*1AS,1+/?D/:UE4$^X5 M\!7A)HJT-/S8!%EIW^]%&Z87V:NQ?FIBK?2!UIV@=2^]:M#NC>Y*E?;WFBI5 M.A4N_[A[OXN6_:*\8[3J&7$?0O5ZP53KHU_JY7?)JE%+(6\IB4I15,CV&ZH;+Y%5 M0CV00ME:#"WEW&44QLSB0(I=ELP"?5C^K_?[R$Q*/8AY5:.2%-^L*A6]]:U0 MNZS)I*$4$3?*G8;3NYY$F323 JF42@V%NAKT38BED%H+_4.A5>8 )MA2:-5D M D,I(*<$)O12Y%4D!D,A+X*^":V\TLQ%!@.X7-=J7X%>0RL%WI4\^E#V@%9= M. T")1JE&H=R4+9%@;(['U0R4W38/F@/3ER[8&=D4HKG@&@7U*)=FD>[@?C= M2',+X5T%? =N4(_]1J(AP7]%HI."V@6A),-7W'"1XHVV^@*83=" ZI?$ M^%5NNZ3K$AR,J49A FH0GVJ\!LR5>_>KW^';B%9M7Z[+@UT3;3&:Y<#&\*4H MS0R[KYYBI=6*?HI%^XZ"@R462BL7@PJ#Q3G=#CQ,)6DYH]^1=Z!;II.T MZ)%V[1VH4EW4&U,1:1'46-4/E$LJ\*H']D=IN:,&W/^@5D V>\I':36C@3Z8 MER@W4TSN\E%:HFAW4P9R'),*&@^2UA@V'?KW)9,6!VHMI#6$58L#EUI8A@:T M7N=@D,@;=L81 BGE#38ZM-@U0P.VW3C8L-#"UXP)*10;X?<^'K3P+8-!K@B: MU!AL(!2;N2;G/Y*"\W(#>"!_KT%4^_B1%(4;&/MWZQI*M2L?28&VB;)W[ZVA M-'OLD112FVB'FZWELCM,!2F>*LOP+BH#C=(\3!TIH$JE>KTJY=I>_#7A-/)/ M_@=02P,$% @ S(-H5Q,HU-B<' X>\! !4 !B:79I+3(P,C,P.3,P M7V1E9BYX;6SM7=M3W#B7?]^J_1^\;-76? \$&D(2,I/]"@B9CRJ&IKAD=I\H M8ZMI;]P6XPN7^>M7LMW=ONA(LMNR9.)YR"2@(__.13K2T='1;_]\6?C6$PHC M#P=?MB;O=KVS8(9_M2[L!?IL_8X"%-HQ#G^UOMM^0G^"OWD^ M"JT3O'CT48S(+[(/?[8.WNWMWEO;VQ+]?D>!B\/;J[-5O_,X?HP^[^P\/S^_ M"_"3_8S#']$[!R_D.KR.[3B)5KWMONSF_V7DO_E>\.,S_>/>CI!%Y!5$GU\B M[\L6_6[^V>?]=SA\V-G;W9WL_,\?Y]?.'"WL;2^@'NZD MOUTVK;5\N0_]Y3?V=Y9P5CV3W[KQBJ#8^& G^V6QJW_R[B5RMY9Z2H4=8A]=H9E%_T\4O?KJO8>? M//0XM\.%3?6[0QOLG&!BOP1M2CH/T>S+UKWWY)$O[.WO'N[OTO[_L]0H?GTD M=AQYU RWK)T-OGUL^U16UW.$XDB$@=E8$99+.T1!/$>QY]A^(V!,RNY0TM&& M%N0+T70V?:0S!+&KZ"APZ:P0HCD*(N\)G>-(*,[F/:GAXL2.YM]\_-P(<(U( M$;:Y'3R@Z"RXCK'S8XY]E\RXIW\E7OS:"*VXFR[MV/GQ$.(D<.DL37Y%]2HV M80Y1=]C./<*T*R&]6L,.]>L]!-Z,C,X@/G(J:F(T+#:=H?DF^V%Z:KSC]2,L]E6!(E+U!VV;'9O M8E,P18?S+^%9;$/E5MU]G2PL%EXV_Z3+C'3R)-LE";.6(.U0=Z0+_(K0,=F" MS;SXDJSNA,J#23KT7,E]A/Y*B!!.GV1,'6K?DR_MQ*>J\ZWR2 MOJ*8C+SHP@[I[OQ)N-P2$O8T>^:?WVCZK/31+W)IB;?J3)N*2Z8S2I.)4M:)K.Q(BQ""V2W5H1&:&GL MUHK0R <0N%1*(^R-C5^^"W41^,;A DEZ'F([=):@68V+ (!5X#CHZ;0EC2]VB2:V8D?MS;* M)7D9,_FQ%WC4W9^3?Y9PHY<8!2YRE\AIATVR_V(OI@1Y_N;$VJ;)G@E=_Y*_ MYBU5@F%G^)5 [1$DJ]2J%!7Y1A AU\J)K8S:^N4VL!/7BY'[CQY!L[/_2ASL MM^# ^J74L6*.6F0&ECA\#W*X[MG",VO=MV4'KE7JW:+=]Z=$?FYAB;L#2>YH M-U;:CR8V))(.2XQ]D&4LZ]CR JO8]7_9CSCZU^2GG[W+&[/:[NA%?5-,F>(@SMM5T:[-ZBA]G:'K)B["0-^5[I9KK@WG?PV55[*)*2_?6WZ MHUF8.%M/_)'O0B'=U9K>=:ZV\G884 E_;& Q9N-FMR/7345F^Y>VYYX%)_:C M%]N^2"%<,@6#JG/MB!D 5=565_4 'OW)W3)5)+64"!0\;L>:@$T1-A' D.WBCC7QFJ*W5LR 'D:;/J]H0#Q M[JD=!E[P ^NG(#=_NZ]^9KB((?4\EZ;6N 0 FNK4VU[]U&/.AKL19F0C7/] MUW,[1-$TB=-Z L1J.%JH-C5?"4S$H,O1.A3.HBA![M>0WQLVNKHV0[=W\-".+R9 MIL'N!JUL/E>@BS-1WQ?H.?U-2_VNR >MSS(7D/X.#--?YE3:*[!"/U0-LMB M5/BAV\TR_2(]U9S."N&5;X3![V2"( "GL\I,<4MDR5(4[:U=9^9J;4.>(!5^ M-$&%FHS@)GD%(_=:O4RQ ["+D1A<;$?(%B^N^(GB4?OI]\V"U> M,P'4NEFG9BNV ]X@U1YJ5&U8 ,D=LAOV^H:4"S#'.\'6LR@BH+.8WSEW0+1]Q?VOD./;493>]Z6RF,YN@Q#9OOE3!*&@"A3C1;SL5&1"$/Y0F!O)JJI52KS[25$LO MH@DN28C(/]:T5HE89?)8O>9:">.G*L9">Z4Y;5(EUTI0#ZM0"WU8ZTZL=2\J M&6A9=JW(T62WRE&A4YJ(=_ON^IVU[-=*.[96/5O$@*RL;[5\ N7:2IQ,ZIPL MR:PEG4J4PM)M);1[5;0YN9726^4.5,(&Z[J5X.Y7X:9D5HE.)4IFO;<2PO=5 MA"F)M:)1B8Y?^JT$\Z *D])F)8ZM,K5*P)R2<"6T'ZIH\R3<_LRS4C*NA*[F MW):-U=YK$!>,*Z&LN;="#WEZ>JD/I7KG5),K@:XYNB6EE9-:&:U2_PQ5F2LB MW:LYL#69M:33MHK@KB;V:AY+L)JP?EG^376V?X/R9DO2%3U@PKP2VYFY7]-8O>0_6J@N= MDW^UY$*1B_VZ*Q;-_GEWFFYR'1$XKN MRBO1C_%WY39D]OB5W0'_IIW2C^J[IZ?&@G!_H@-MUBSKI&]:B>ZEB2GUW!WL M0W\R%E.7H4F7$-7IW>2KB>;9AJ%W'-/3_NDC%8/H\DFMJ:8[CM*CD)$K6(5O MW#3])]U/!;%(%Z5FNF[8M51$'3LX:VJ\F%5/6KNZOA7?S^*0Z;JFU5)-8EX@ MM>F[N+7AM'^TH,$ 98OMK/N[0Y/,H+--7W>R@!GEBQ^@!A][?MLS6 M2H963Y"%(WJ>CGCLFQ0=4:LTDR,D'2K6T-#&[75Q ;->DXKTRJ?3%/1H,+QP M0VZZGDF!ZP1DA1_&-.&=7BLYMB.FNZ(MZPUU!3B:K2PXV"6V-%V(.+UP7KY9 M ,B8T7(X0H; &[PDF#X'R*60'4QV?7]G?\_@?T6/Y,>>H'9&XZZ&HFZ#6_@XD)?2*BC%Q5+89.N\CC[CQSQGV4L M,2F3T[F*^^B /6'CKJ5VPKBMB1[D O.JI7ER..C+=!H_YECBJ);["=]78K*F MZ6R)R;)$8%%,J3NT"*GS^+7T&]FH8Z/NC E(RBH8#$FVD*+QT4HYGOA1S"9] M&!#=;*/&ZAEL4Z$9M/LI0A3E&K':Z@EXMA YK#-ST\(V4X[)@4T%"E03X(3B M9$[BQ7;T>XB3QW]AGY8&C<[/3[AUM[DTFB*6G'& &R W;EHK5,G)JN%D]>?@ MX0,0Z-JTMUR=\+B0"&_VO3V7?FJ]M)^H7<^J%13H?X?$>X^]!+YV7:MR]["? M337WE?8BWO>UBUELO'0SK2N:1Y-RHA364>">8S)8KI"#O"<*4&*_)M^#[GU; M"6D*D\#]Y@5VX) 9>0U9_L94LPZ-V;LU53I\]:F-1(W?Q&/2FV MU]WB;8#L,$ N74A1YKC;1'9C;?M#SIC ,J"-F_,R6T)KSH2Y1A"%KA?*9)0B M QU43<=)1704DV$=(BJ5RQ MO&3!'0(P@;[]N-PX$" 'G8F:-*XT"^/TA3YK M@B[()'R%?4+[2#\B"!GF58&8X@9,5L;$PX2J"*RI*,P[CQD:7O=NA1P%=V M+(@6U5MJBP#Q!(X%H(W;O10ABK;^K+9ZHC6@8&'YFQM_V4P%)L=>6JO)T,M% MER$1#44IVN%7&FH*MG#,'XO@&C=1E6?=,V*((8KBE+7"(W"R+A^BO_N@1U6; MN'PN+UWO-3748CO_GD@U#:V(6>MIOKH!,9Z>$/]>E M-]>")Q3223\KE@1L/24H#==%$RXD]I\JHOF2;:\.EWFZ#>SE;=D\G"WKLNN4AFNI"1>0UK2]-;Q< M5.1!./(^J$.R>SDI3-R]/BD,U#)4).8 TU?%SP*N#U&@ZHX<4L /*DM29K0T7 MN0@Y).I#?6$G/[VN5YL"G2_36DEOO^-*+MO1L;)U4G@-UI\$5K<]" M]^VDP06F91"R?Z:E1&J:YNV-._F,[KA >R8$ISX=?L*8LR(E)@8&+CI2C?'G M4B>CH08&"I!L2G Q8\)G&4LCP17EN"B32MN]H-3$"= M;*[,G;4+>/?:J&Y/[Z4S5;HKL@4NGXW2WGX;[>WKO;^F2GM%ML"AITU[]86_ MASA+8V;SN[T#S2I3&"GF< QI4V.Y(-[!$U"^IE:L5W3RI*V0S7CV-)X]C6=/ MX]G3>/8TGCV-9T_#49[)<9/Q[&D\>])R]I3])/;26_?WA%WB+C8_A()[U144 M478:)6 5U/5X+#74%=%X+#4>2XW'4N.QU-"/I3:*CK_-X+B)QU*=A,8G+--[ MTZ'QE&.)T+C^B?E/+Y[?!O@^0F%:UBNS2R(2LF0EW&0KUI)$4F%>)L34[8AG M"RJ^]J9-29W C N2=E7P+'#H4XID%Y3]OQ^S9'YZM-'-I6><'^R0[_2= MEAG9QU\@SM5>11\#[K'@V[I M,S0[FA,NZ/]._TK(YLBG$XK@B)M#\V9#N6)!&;1BOT)1''I.C%PV;/9/14&> MS7K5=!PN5EOU79'-16=2?-<\4S Y^MNKN1@: *981?I?M]'VADT'P[0^PQM< M>W4\C!T/8\?#V/$P=CR,_@N_&.X)"U9_8=P;/@"67%W>G+ M?OQU,:OMFUT#PX+IKA9XQ]H[L6/T@,.\=*EH",K0ZEG9M2TM! MSU4 4."]0?H4!)_J[M-0%"++#*2.3_JC>)MG/:3=])*3DG9SMS\FHS04%F1^ MAI9;$#RB>M X&T7W@YG!C8NLW=&RY!7.%2(@ZN05.$$_KF_(*^.FQG(B?+_X?45(]?UTWR M9VV/GNW0+0HO6:0+R^CTA2QXO$A*\TJ^^>8M29W4C(N(I,M5)S4SOUM5(I/OZ;R%"R[?"K^RXKZF3]>DW;Z?*A0*E'@V5_?#39S<4'9FOIR\^@EQ7CU[2@B>VD^+F/L'^H MYF1D]%:Q ]T/L$]G,V(I,;6%U&1JVJ^/'PZ)GMFD"DB0Z0 T-R9K0:B2RH#D MLF]\-L'Z=. LB @0*AKJR/C1 #EI/J@H M],FGTA/3EA(\I"N8>9,"U]TKR^2P=,<*[?6T_SK&SH_L$)1_O%]OJ"EX+#46 ML BX67LZ:3BJ M(#D%EML!JC=OPEW)Z.W$N7.^OZ.(CN/ 71U!8?JCW.W0X(+JM:8L@D'9:%_R MD AAOS5[U+-@W0S7:+O24H(L^F!PJX6V,H%64RI2.#K'."A+-T=BD-5_&*K5 M%P117E$IM&+XFS^+50HD %G91P,/O%=V4C[Q_MCDQ-N:_*/ 69_H@1<]/C5" MK^LUCR/'21:)3S9#;KI-HK88HCD]2Z$'((1[=(XCF8/\YCWIF>TD<0J._9OU M8DPV0%MU5^:N-C(T/G?@.B;\4.EE Y7RA ,D?")#0*8M>Z"5CG 3UHR+3E=@ MBDZH@>9Z\@CD9(UE&# O@Z +Q9B<,]"9\@R]J99?EQ?=32LUTY10P!\3F(_7 MN!FM=9!&& 2_P&DI/N0JB_DVA:!KX];1FJA?.;V=- 5Y]LO;7*T66X8R6FX+ M>?U$?L,DF*/E=RS+,8%B3*#HP>8-SZLP)C(MJ)-[V"C&J[M&[HEO M1]%TEJ902P1T@>::IB%GCMS$1SF>X]<4G2!(RR4R)B;+54MU\(K%,)PX:Y%Q MR1AKG41;?%5&%4 X%6+CK>8@*BAA+$1N7O1T,UT,(F[:6E^& M!DS)TFJ!@Q3ND?"!W5I;7;55X=%0K7#+0FS<'$9ODDUGA94MW\D S0?D8+@, M&[2G+"",LJ(1]OHGQ;6S:.@T[DB/6^+K!6_&DGG^2I=Z3?9T"DV@WQO&MH_( M1C]$*1C^'6-&4TV>K>V@PF)NC)ML9"&&,A#$-=UL]: M"$/38P@=5,(P\VV# E#1@J_6]&XR &WPP8/;8GUO9J?'.90?_IJ@TFQ BP F M@T.Z.1E!!\]KS@+WTK>#"WLA=$!JOJ9GE<'6;,-3_0VD:])R9/A69/+R1Y>E M&1K1OD)D#>C1VX_I)'Q+-!1=7=^*/#J73->SX$HG"-R0?] Y:5NP+1GCKP[* MK0:T.&"Q9] ==-GYV Q_S!0F6][F.M)V(C?9>3562Z^[\XN]WH41<7=L$O1ZG(L?)?0##[H%[K=-D9A7!@BY%_KX4'^<7=#\]VF ML[/ )>#=Q(;>(21M@:9#\ PP>D@+W19K:*J$/[UX?H7\=-D2S;W'&WQ*#"F& MWXYC,2CJI&>'(M0!1U=R\E#N<@Q4HY%.2IVJ>W5CWW 2?O5"Y! "?I29T;)W M%[7!N,%B3D!OU?9D#9#Y#?DMDA,ZJ^G=AT%*'60%=$\=B_T"/9\N'GW\BO@/ M4=?:]1_ [T;B "-P,%]?5D*7N$Q,ZNYMJ-F\7CA*D?./74; M3!9L=*YH'!T.%!1^/0274T8,B?A3[P(&K7P)6%/2,U->F W-C(UY$W$:.]WFVTB$J[](A1NL1%U3=$E65L3U MV ^LZ_:T,;.M^;+FP ;7)MJ.J;-$E"5?2S,YP5',R]/@4)FM'VD&P/6,69EY MG TIL_T@M,.##AX*=#M-747)[[2.X[KD2V5N6CKX3 _'ME_DC$[MT*$>JZWY&N3 M[OK$@C? (^H\D3M]0B%]P<0+'LBBQ\/0O,FE,5_H$O"[CN;QKJ/5!G E-QA2 M@@SM )0ASP:DE$.M-]BNT&,2.G/*P=[_MPP3$0=YZ!5=1SP4/12&%P,-E_J2[S^MG)H M!L SVQS-DQ1\+&M6@$+F!E0NH)3?Z"S(/("B=SJ[ V&VQ>J2!WQ6I:\4[SDB MS"W+[ZX@%JON'NQ6J^YF-*M"NXH?@BLA9#]==S 10%3^6ET))/N%NH,]$FMW;D.'A?*Q:=]V3E75FTK_X9JN03 M2>KCH,K-NALKZ\>M*CIB@[C6SM3$%KT7J$"0C#JO8 M]1O(SN;)?\.T;'U%B<:T[#$M>TS+'D!:]I"3LHVLBKTN=RKV1LS&0_!$'"X- MRN@IH!1-;XRFFHI9_\T?KMAQ&QYZ M?6"7CY:7Y2!%&ULY7W[<^0VDN;O%W'_ \XSL6M'E-K=:H_';<_L1NG5KEVU2JM'>^<<%PZ* MA9*X9I$U?.@Q?_T!X)MXDL4"4CU[-[9KV^F!^?;Q8?(72S(M67AA'^*]?1?%7__YO__M_ M(?)_?_D_!P?H+,#AZD=T$OL'BV@=_X0NO W^$7W$$4Z\+$Y^0I^],*>_Q&=! MB!-T'&^V(5"\^$?TIS>';^_0P8%!N9]QM(J3VZM%7>Y#EFW3'[_]]NGI MZ4T4/WI/EJ=U:6^?WY;_5ZC_)0RBWW^D_[CS4HS(]XK2 M'Y_3X*]?T?>6KWUZ_R9.[K\]?/OVW;?__>G\VG_ &^\@B.AW\_%7E18M1:3W M[L.'#]^RIY4H)_E\EX35.]Y_6\&I2R9/ X5\"TD:_)@R>.>Q[V6LVK6O05() M^E\'E=@!_>G@W>'!^W=OGM/55]7'9U\PB4-\A=>(F?EC]K(E5$H#RH2ORM\> M$KP6@PF3Y%NJ_VV$[[T,K^B+/M 7O?N>ON@/Y<_GWAT.OT)4DO!#:M>'3EFE MTK>VP5[B)(A7I]$XU'UM1_!)VTFR'0QHZULWX2;.O' 4^+:F==@7>-P7;_3L M?VG2S^-Q7[JEN1?8&0]Y\.<5?]>0_GA._NI Q,\9&<#PJ@))BU#TP.P-;& H MRZY+C_U.N2'MS>.$MYV.C*S,M9?>L8+S].#>\[;D!8?OO\5AEE:_'-!?V$C8Y(X1_#:/E I@.&6"LL^O1@=1)3)%0J7:9&R["QX# M1J&W']Z_932BO_QVDV OS9,71NU42!V%G VZ:&%2BDB%G--"AZQ/A4JTZ&Q2 M0+V-[^>;/*3NYS)[P D=,Q/\@*,T>,2+R(\W6-WSF.M;[86&FM7ID4R5G=-P M+&*NIUH>+] \RY+@+L^\NQ"C+"9]5D)\)SA4O<*9%T1X=>HE41#=B[LUG;!- M$JH!MQDGE@1#+R6\/IC(VR2&$UR9&1P ,*42H^H0H9>!0X0JGQ&/UB=/+.'T;!5EZ=7VK M\0N5.G;=0P/X72]1H0"&2B8H>9^QTBE7XY@6^IKHI=_ (=PB>B1 Z6+T#7F+ MPNT3"=JDEAQHFT^\%!@22:'UF=,((BH)Q96YO:Y6?(Z",&Q<+67?I%.RR2 S M ]IL4FN 8981S#[+;J]1O8)'U3K.,Y3>Z0JS!:!++\E>;LA(G7H^==W2HY?V M$T6O-:0 NP/E4,.ZHZ:I-AB.#H;,CZ=,##&YV90]HV3#8>Z3R8*7?DSB?/MS M'-*0NO3\_%B^\Z!1L+8%802\WHM02CNGCS%$;EV@T$%,"55:Z)S\OV,X_=MG M+PGHVO05H;:B%^/%;/95,I#M'JDOXYPX&F!]NE1BB,I!\;@NDV##@"M=+$[* M)C8^[[<1YEZ46G86OVMF=WM5J3E;="=C>_MC(XN#PR7)S""][ZW3?)9)W3R!!@GTMUCX1:OX\9H;TBZQP33Z>9E@C=!OI%W+RII:UV, M'G+=S\KO" MO]*KV0V&-C.B&QNMUG'.MX% ^JA6VZ_S98RD]ZIO7N5AA,2RJ$+F<>+PZ.;%*.<8S-4*,T04T/O /9_ M+;,.!Y/L$ K)#H>1[/ 5D.QP),D.89/L_6"2O8="LO?#2/;^%9#L_4B2O=_W MTH7 _22SE#+;2Q'$NHSHDN^E]T*74@;-%HQ*/1"3?(.E8+5%48M\,[:HE3:.4N-(7+K MB422S:K9'RT=*%-LBDN=L:,E8)L[BAP=]5-0W%!GY: 4V//8*@L"%J^:F*G8 MVU0W ]_LKJOEG3-C $ANOQTI K,!+9[428R.0R]-EVMVR,4DK10O[R2EE RV M,)U47]@YP4P1D@2"-K/(B4"RJ>1:DN!X8L4 MFB215,&7.9QNA\:B+==SNI5VSXBOZ'(DLC8)HX3;YHQ0$ QM5.AXYH1$.TZ* M^5=+AWG#[?]F>5U0]N#1>5A;::_;[=?$#4_G]PEF(.3>D5C.FDND@EG[02(A MYZ31(>L3AHFB6A9.7],L(RRB-$MRBHX&ABBZ'+6*S9['!'R[ U+).Z?4 )"* MM:!&9\\]3)..0A'!(Y*RU[M((39]"R?BG 9J7%R_PES<4A).KS)_\I*5[CA& M5\;J^0H1O,Z!B;: =@ M>" Q1WI(O_%[H[8[RAP2_FGZ&_,=O-T$6 MDLG;(EH16U>Y)PKJ5,C9H)D6)F655,@YB73(N,RY5)8NPC72^^V*SHB9)T&" M?:*@\$B%8M:Z&07(NE,1R#BO?0TP+IZ(2*):=.]9L\E3;%#U8CE[6;,5,)NL MV0(A&+6O0,:U?2JZA_K??3\GOTOQWW-Z*\6C/AN85-KJ7HX:\4I8W"P%/Z%*T.ULY(KN_DAF(*UGMF8=')QJIE$_ M<%[1(C3\4J>7!6D6^&0F\8G%CN )E[E'5?2G( HVDJ/V@N>V*EP(JZKTSD,0 M%2]"U*_\4L9MN_[D/:NKN_O<6G6+8-75W7X(H[H%B+CJ+F3@S!Q:Z1PULP:A MI-5P##G43C &+^:<'GIL_ 5-M>3^)PB:[N&89@["R98F[Y1L>,C%;'46*I!5 MGR&2<&ZCCJ6P:"5S#YW7L@P1 MWW*)#&FMI93MBCZ)_;Q*8"^PH/O85C6+0%6UW'X&HI(%@+B I5*$C=F6*WA. M7KRB+S\+O7L!_-YS6U4LA%75<>(Z[$H&42%7U7R"4S\)6(24RHZ. MF/5*%X#DZKXE XL"/# Y$UJRCCKV*WP?I&4.M/IHB:(;D\C;[OJ5L/MC@5 8 M!&E,$$I'B[82JK4<\6@>1;D77N%MG*CHTQ6SS1H1R#Y9VC*@."( )J5&(8L* M84>,^*^2A!>U M/MV0@.6F'CTY4#R1@)-/26IYMTRY?L!A2*^2]2)]AR(2MLT6.> ^7WA)4(R1 MPI-RAFF@4@4.;5CDPPEQDPR-;8T:4EZ88L'%0Q56HQ@$3I8]/1A,H[(GY7(@2"*!ARW:UN(=XCB: 0ZC;(@>SD+0GR1"P(RQ"*VN"$#5W&B_QP$ M%R2@^APHQ!"50X6@DYJO=@FBC,;]2,WIB]EE@!ADEP5=&4!,$ *3L*&196%8 M3AAQC.FE1^$B6N'G_\0O4KLX.;N+8Y; MSAJ62.7MDD4#N\L9B3 @ZJ@12AA$E%!7RR61%I$?)]NX%>[ XI.3E^-X)?=0 M-%IV265D0I=:2A5 !#/!*:%91W56Q*2@.$%E 8B6X(1Q\]6*?*BT_-=Y$.%W M4ON%LG;9I8#;Y91 $!"3Y.@D_"DE9]4?B.J@902%-(<#3#UT3YI#4](<@B;- MX1C2W#S%0$CS?H"I[]V3YKTI:=Z#)LW[4:2AJ5IQ]./5 7CT 4;M]--PP73VW7)N_)$%&WDRO\5JK 51)6F9!)<)IB3$I"+8(4 1?+N\.N[;ZJ[IFVO M.U[$-XFW(D/B]$4K9(H(!8\4 @ H(*0BBTD6(!!EB6W7MJ,L_??8?:'ISR8$$L9CMKE\$LM_] MMV5 4$ !C)N4E**HDG5Q(*$9LN[U3L"],R?@7N,$W$-T NY-G8![9TY ]=HB M10CIEY9W87#O29(3*J5MDT(!N<\/@2@HJLCQ2?N,6@4U.K8S6K(49XMH'2<; M]OXS\H? 2HF.71RDM$%%()6[]U1 J8 MNWN$DP1!)"T\^3TDM0:J5"RS9DDXG+3G<0S$(L,;Z6D'O8HM!IF"KWBDDP?! M)D.0?4XQM>[DFBDBJNDRFU$[N;WL(6?:,!0![CG%+ @1'I+!D;G'[K@ W MN?/RNS#PS\+8DZ^R=&0L9\SCX?62Y34"@!C HY*ER&."B$DZJ?\C+_H]R;>9 M_W*9Q#[&-,HJK7LKW?J;H;9=S@PRJ@8P91L.3!,Q MU1DJE%%+V]'\+&VR .+5T2:&&";55T),/P1PN*BS:ZO3V^N@;"@]!2- MR,#)VN>$!"Y/C9X@,(:(T7&Y6FZOKDXO;E!!F!^=,^;82Q_FT8K^Z_3O>?#H MA70TGF?'7I*\$"_PLQ?F_7,5 W5M,FJ0.6V&&2F"8=P0M!P#B1(B+C[RZ1^X M4=^5BW?!8^'3O_WP_BTC&?WEMT7TB-.L=!)OWZ1O;A+LI7GRDW=.K\X0;^(& M.'2DM Z458ID<>:%YZ;>D^R\(2T$^66(+!!.++>87E41W9^3GA!?!?C8Y(P1_#:'E I@NAT3E-SF<*6#0JJ$$JIU$*\/K)S(62[Z+F:I- @XQILU#$STP M=!P EO>Z*E50'-3PS V75'P!QPE-O5>/G=>TTGMVX2?+/6('OJ^A8R/S:)8W M\W,$9-GP//#N@C#( IP2/YWM"#[$X0HG*5U=R%XT*XGFZC;),M2H-IU,=<%T M*0,!<[F$%_.CQ?GB9G%ZC>87)^CZ9GG\GS\OST].KZ[_Y0\_'+[[\T_H]+]N M%S=_@\15LW5NE8(C/AJL>,NE(7)NV-IWBVWN%\#+&./TTGOQB*NEF>)+A*T. M@DK G4%1* F&/TIXW 9;*8RVA31;(O)\/\GQ"N%BC0G D@!=L^+;A6RJ*I.V MN@R@AMQ9 !"+@B&4&I\X(KQ:4PH;-? MPS 3F-RP5U*,!7+&$8TEB7L+3I#8=Q%GV&PT%$K:Y)D":IM< C$PC))C,Z!1 M1)2K 9$M#M$?UT6<$N&6'Z?9#.41]A*:JF:;X$V0;]C(N0I2-IY2A3]^__V[ MV7??_QEY&;HF7QS3LS#H_=L9HMQ@XG_\X<-WLP^'WU.1_R %UD_WM&?\BYL!QBO1_,BSBGG1H7=P-%(0BJ>SHE[%RM\.H$)\&C1W-= MG'E!P@(>EFO^8=U'2]K?^.)L=G2[&MWN#<>6Y9R[$QG A<.7&FA5J]2$G_8P MV#3+'<:S<=?+&V;+&K#6;(UG#]T=:4@=I,1'O2!5.&8"T=8#,(?@S3"81C1* M8#HQ4Z2ZK>H6\VH/T.]ZBLX9>1Y']S"827BX/IWO08^4N0:XTB]KVM@[YFG>"[PV^<\VSPWCN4W?9A^^NO8$=] M\!ZZ?,_<_2;G94)/TR:XB Q0G>D12EJ.A9=![87 ]\7 4$>.31#P7DBBE(K^ MA/[X]LW;M^^(/Y:@1ZKW$WKW=O;V+?L?2HLS^EZ>/<1)\ ^\^@G5/P8T#_FJ M")S?TQG^L>-FF9Y >9*,$[,]0HI ]H?%M@P8LDF B0; ."IH-BMHUN79#V\5 M1%.X[AUW?8:(WA:S%,3ART_H_?>S#X>'LS]_W^^&E%ZP6T;&W#8@[W:ID63"%@:+5*!5C0SH1*UHM,.W.&"H7R5(K(GK8B1ZH M\PM=]^SS_7R3AS0%!XN.H!G1$OQ [Z-_Q#1!QP:?QRF-85^N;[QG>5S/L%(L M1T^-,;$75C6D"#B,'85;$(A5E5(>T?/;Y1 ZTX*<4_D*9UX0X=6IET0TDU8+ M]@E>T_O4)5_)1-$F8=BM9ZO")!F[22 VW3 MB)>R0YL/!6TB?$]K5[68*$7(7UU;GE=G+K!SHO#+"\;K$*X7=LP6=&"M.4OQ MB?=UTY9XM9:#F9ISXNA.>N@7W25JD,[F:/8SA#JP"&>(5KOSL>?C.)+XN]MR M>^^RV-TC%E0;>N(@%%,E:]%YQ@;4P7I:#><.TR"8?6+=*J- _6ERRQJSZ:1\ ML9F%C;1#_O0A*XA3B4)E3 _?(*HX'_^ZB^N77K),6)K&%7/^+G'",MD:K.@,DN^!R#2=LW 47,U.R:Q9N@;&R"*1\KQ>.C?Z&+R2.P;*#) SKZ\! ME'$2F%JF<;LA(!G'+B(>PK9*P373NL!U+"ND03.L ]&47<7&%4AFR7/]&VNY MYI@DV[^A"FBVZ?/]RR@'-$Y@H$MGI.DHFF"(,V>@!H:'YEC580AP?#CN&@VM M Z?4<,0W$]=-(0Z17X9.6Y=7\#PVSB*ENR:5=LHKN:,F$87+)Z6+)N02$/]L MP$5,9BI.&:5QRT!?P30 I!'!('EC13!(??N))@1=*FTWF:@2+B(SK][\O3BVL06=HV]"3B/SP:.+E<]Y/J2@S7*5F-.S0RH!-FJ-0 PRXC MF%SH5DO).;>N<(K)QZ,7JIS@1QS&6]J/EHU%8K5&QVZ H '\;FR@0@$,KTQ0 M]FE5Z10[EHT6G 2!US@,:>9O')$^.22VS5>;( IH?TS/3*A)9ZIL-3QLD$&= MD#$C33!\' 27.QM8*,_0?:%>9*_L% "'HYR_8.I7./;2C+PS6%%B,GCBL##> M,8/#E>;\@,[4MJ03OO!0A8QIQ(!RA@/(9?5>7E^CLZOEIXHYRPL C*%G1DSG M@V)9Z^EQC>:!(D$PHY<*'3?_N_GY]*KJ8M#7BXOCY:?3;]S/ 3]Z0439OHRN MO1 OUTV*-UF?H]2P>CV)'GKGQA*Y.+3S%WJHW.KG _DO>DX,K;V@W/^C!W8% MZ?<@I%,C,UI,OIUF/LA)6;Y(202Q=V=26P1,OR3&);@)B4E5/C(84A1#,.M< M-09V)%V00P!51)"6&+2N1@Y1RI=I#J-*PMK94:'VP%H ZZ%7BUH+:-> K:/9 M)7(P7& #A)*9$W-I*E>F\FUFZ.+TQGE?GMX@.C-R7O'-_&V>94EPEVH,X+=>91JP MB&2$548N-+^YN5H MS1]QXMWCBYQF@UNNN8@[S1 VO!B;/!MK9)N 0\L P\R1P+DK:TX7'W^^.3U! M\\^G5_./I^CB]M,1&2V79^6 V"6$U M\.&Z$1F@;KP"]CPF^C!'LA/89)@P72950WS76P[(BP[HFU#0O KE6WJ4KWX9V%'#('$WO&S=8U-T@\O+K8_J')^1 MNTA9*LK%/44W/\61Y;Y1&AXJ-2P?6-9![YU7EHG#(IL>J.#(,C1>U2=>E^MC M+WTX"^,G73RQ6L5N5F4]^&Y^9;F\\Q%[ $CN8$Q];)F,OE0),2U(AYA)RZ# M+I/X,5@1Y_OE-L6K152'X<_I;3=%HE\U^\849'GE8*2AO<6#@:6 X>]HZ%QO M.;_^&9V=+W_I'K^X^(CFQS>+SRRQLS*>'D)4UR&8>A& XA9M< 9C5)JO_B]C=:^5FOX]8%K''HWCKZZJ7X6R M&"75R]BUT;3YT5_IWSX=R7/R%GK,(ZZO+/?J%[GJ_29/PV"WES38LC'$J\K( M0'VQH%9$'M/!CX69GI4K1"9*AH;8%OD"'U MRIV1EO.N9C!4WLTGS] =569+%)4V.J 71I8%% FQ4!X%N[-M]]EE&4_7M58V M\9$(6YU1*@%WYI)"2>$M_=L^K;O=\@N^RZC:&\GX& MHVY=J.QM#>(*>2REIC4YJJ#5[Q&+.^R,]-B4I&!?*6WSVMMW?;,HNHT\> MX6N0O2S7[=U9FAE O,EKJFMQFWZ8.:TM>#-%4/W/0-#\#GIKKYQNE6_*$BCW M.MOFB&Z;[XF!13Z)UG+&.2;NX!4-7(S7>2I.$3E(TQK[AIE2<\],#49G-@BK M/'5(LZ844GV4T (.XO4!*6*B!8N=7?TF%4J3)*7Y[0++UG4-]&RZ^L9FM%U] MK1*4?G HX%>?S<:G]R 3W[+X=ZLA'GO;(/-"?;)OXP(LGT4?:%CO7+JAMO-> M=#1D,7/3W@H]ZSI9>LH6;=WG_N*M)6[PU@OH%?'L;J-R"C6/5BR22ID7>FQA M;OD\Q& UMTU*@M8_[V2%X$8LJEKPO B< ^(S\&:2"1V=R:>7W@OUIHT_#Z?G MEKT2,]1$[2E!VVHS!2R8HS,IM"W$BFS 9.*>D[D4F#3 B@&&^>S5#>>R&^<' MZ -Q%,1F&?H)7>77X"8($7.G1WH3+>#.+.W+&P,;K.9?1UZ"8Y;J3-/P5*8. MF:D:S.*33I 8:AY1N'-((M1841$]S;5AQ-YA Z#9M[A]D[ZYH8-'GKP'.#0QJS[=; MC_X:WWPL["+-<7<88U*_1R<;N7 M1:I!=^^)%,M"\3D-<7*;/X4PY5-$I*M%^#U-3@BAM6WA"H?4QDLOX1;31Y9A M;1HSUKQZ;C.T .<]W"ZHQ_=VZ "5Y2%6H//>S]SKV-EM@>I/[N9'OHJ9D1RW M=&;T=;FT^4UGCM0/Z=48ED#]04+B(Z2)@"CAMV4"\67/XV44]!I#!I #DP#%TUH8>>P?+[= M%NDOO;#*_+6(UG&R82=A=5G93+6M'J/NUXRK<[:77K"2G[OAI%Q8+H\&-&^U#R29>?2[.6?V=GD)BG- MZ**<#V)QBWY<<9GH?=@ MVC])SO$ZB^N-8@.L+^0DW>Z-;+.K*^&\'U/"DB?1_96)N<^96R,Z#R*\('_* M%DA$@DZ(P0$5DJ.6@D>0/C0%2:@H8K)*INSULS=W\="9L/BT#2_E9.ZO71A2 MX.S7PE&]J'/GA72C;U8<&7??8@TO;'-\)9O1I6MNKU4S)8WAY6D"QJ1,U3UE M*.WIUC=>G>0)05CL&7RF?!Z6/G%$078'B;&&::TEQ:T*M@N@Z]D.P'KRKIK<+Z M"_S$GHSA>$L7"J5NX6".)RRD#8*[$( /J]C2A].IC:9>D<5XYRRNV/O\W7;-W)'E1V&NF>L>"R0F_Y[Y<&]//;DD\ID[0@:5& %J" M11&X?=W\*+W?8(>P$'$TS611)_WB+=Z2,/E'F2;$J!>& Z+3G-Z@G:.*4'4E MP]BH(HBA >_A'0M0H.S7X2G; QX0%0!ODQW@N0PY2-WW!^)>+)-[+RHO%#N. MHS0.@U41E1^M+@E &N-:="KE45TOK -]=)E])BK;ICLSZ>=HLWF2@IV/-_NP MADNRVBI[ACJEL[-*[?+I0%2_ 36O0+]6+W$?JKC3MVJBRV_P,>7T1KEAG&!8I[_^WT2YZ0-MDYO.6]?U_D='7PS8M5)G-]E M\[LXSS[&])H2RKLDTK6<(078/2$XU+#N(4%3;3 \'@RYS]#S@/C JP! ]IKR M!@:ZWTQ:HZ_/@JA2L'KOKA9XY\)=J3084FDA2B[/H,YZI0')G3CRTB!=KMO] M.NGFKX/[B$W/HXPW6-'JH[6[EZFM47/JT@@L5:"U,+B)$ MB^LE!T=UB8@4B:[W=\-LU[!KI5FRSGR7@BS>O;Z#H:V;V$>4 H/,NT!7,3B( M1.GM6PQ>3\3@G?V7CW&\>B+@R!"U(*-5=$]OHB\NTVM:NL99'EB&30]EE'EM MEV10 Z2 M&1O2V??2:H&AH3%4\D..C<^:= MX+O,N..3"=ODEQIPFU)B23 L4L+K$X<* ^V[NG;H^BNIM#L.*?LEB2A0%NGZ M'W9-$;J^;SG&:8KSM0:T$X?&Z$%2BYZ)C\H@D_FT>HX9@&"./*'+*\/ M+,/J965CS.O<0#6D .>]W"ZHN7M8FC)8)$>G%*!+6T9VZ[K.H86 X[.R:QU6 MPNMBM*[/55)Z[Y[>Z68;QB\8'^$(KX/LDD S<_N4B@Y\0 -#! ZA0LLYRP9# MY68.I08J51#5V1.C!.B4P<1J>6O\,8%=TT8E#,7],P5JA2N3'+_$?\])WWCZ M:) 30"YN^VBE"G3_(*5(UGGG8PB0.]M3BZ-"'I(CUK?%Y.RN1-XEG[0GA]0J.SCY:&B0X(RC1A,,]P;!Y5,4$&6: M%*23).1?_O##X;MW/R%VCVBP:64,@93'X-1+Z"T\Z25.6%8A,ZYJM:SN/IF9 MT-F.4JN H:493EGN0'J/-BK26"*F[IQM%_BIU<22.")_^L4NZY"NC+Z&NE97ZH:8TUF@ M,U&$,@<> UIXX3==CJ-W+B/HV3Q)J<['_!V,L;B%:AZAW,_H8Y# M;$44#G%U!^@[B1HU-4L80:I3=L[NL8B%D:4L]S':-"50-GM%F@'J4(2 SNU< M^P]XE8=XN9X3]WL5A'D6/.)K[.<) WCZ[(?Y"J_HE0GT@M2\RO78G[%JEU+W M\"*K:[![^U"=Q=O)WP*F:>W--&ZYN'P1;775:U!:OP<]X00C7+ZMN+2#CBU^ M\\Y:DSROUU?2*196)!Y8\VUZGN//.%S=T$,V2C]KD+HU;VJ$4;7/-$#7.<%' M E;1EOG^6>7[W[%D2P^D($##!7'%@@R?D[;%I>11$G:GDMQT^(--%??HQL4X M9_3NV%7D#II<-QZ,7#<5NEAEYUF>T>C$39QD93+LTV=Z)S8>1/=I7N&B'4SY M<40-9(KRP;6<"8U2-:DU*PEYK:*(A\/* M.XEFMZQGC@V"!2<3,(R,&+>WM> M'APY%2!59(OB#*/M-&>_-?XP:3ZC>MVQA5CWC0<;R'G(QB4XI]].L%6$I/?N M;EAV*$4_R%9>/-]/<#7#VR9X$^0;4!UD$CQZ=+[:2NTRS^I%J<&=Y[#B7'6L M8XR6=;I#RG+>(B8R0+D 4A?87G9$7H;6]5*E\Q90F]T2T1XL>R+H6#S\GW]*RWOOXRV,-+VM'1H6:(575^2?2>"3 MO]AGNHV"++V*P_ L3IZ\1+WO-EFI;IK33I] W)9&%0FP(>UBAZH5T5)I8R%_ M)G71=->91NVSI@*HB12'"8K>H[E]>GSC&%R>FV8QTFQQ@QA8&,"F,,X"_O@> M'3Y>*/&)3N*Q- ?E& *(\B=XC1/B(-YXSR)?=/#:VZ#27"V]C3!9MO(VH"B M5!^#7[WN5I2',N]YHFUN;>Q0L:)^6JV&?PJB8)-O6$:G2^^E"$R/5C@A$ZAC MC] DI$;U\D.I8UNF>8.#"*0I/XT@2&F*XITWBOW99+!UW>SA;(H7H9"60/<9 MBQ,1.7T7BN+HP*_?1N86Y>L*Z?TWL5]P>$%4F7N#DPWI M-FC"%GJ8[8J8,R1V;]>R'32K:3Z'H$'M5C"TIC2)-:I&]%2^ 'G%&\@,HWQ% MV8PR\A*V [HJ7X-(N]G7[OTO&,Z)=OG9/4&] _(RC6<S5"Y[^S6H>0\Z[1Q,.^X>2JM>ALC; MBDP_Z%?V0O>I]7;\;.=!A!<9WO0'^NF+M]D]^E8WW]"U@/W41U7V*VIOW<\Q86,K"OY26EK'FGXSNXDAK#\TPWDK MJXZ9T\VG&(EF%$W:!E+WU#BG$9KV#$W%."#4NSC&L!!&5 M1$=3A !+:OQC$J?I;91@+Z0O_.@%D0BZ4,Q:G2M UI4ND(%1ZW)@_6IGDJ@1 M1536^>C2=$'+IPBO*#P_OH\HP ;J"=Z2GXOC)Y*^<$0Y-L>@T6:VAZ7!A3BG MZ*[(Y1?9JHB[SPE7LTB\S!YP0N<-"7[ 44JF%HO(CS?XG#2S"YPMUS?>LW!J M-:R(WPZA+*?O:H!PYH3:R^ZL.-0I#Q4%[FE\NL@W=SA9KMFFSR7Y5@_T0(&H MGY5)6ANEU%#K@4HLYKPCT&/CZ<=9"BY58NK:+!>/G\YJ5W<4]*H*?--F49+"=D5S>BK3T(C.&4N-CG,^#@3*9Y?.4.I/KY'&Y,VR#>_1I0&GT=+ MQI-[ENZ7B@8"Y5;QF1H*J1Z?'7N&(K6'N<_E_1:SZ*YZUR;A:KY2X[?W=NP8=_*+ND]P(V??;8K7>7@>K(%%*\WS$47KTTGEB%(-(4.*']M9''M.568%9=T MI2A@.LY[!1:_T>=OBE"KC,I5-"VT*'N"--" MEWN][H1>PU)>;1O=TR!D82"X2,H:-^00:T;P(C!X(,4EW%)>$6FTKL213^6= M#R15=KHJ25!:V(./R7!WCVFN.KHY2=.*+J+B$->"ILS& 4M:+QMW=B[5YC U MT2=HCVH[%@DMM&(:HA02)9.;E/;8,[3']7( %[5V@1B\V8\* MY%!GA6T867-WS.+JGR0C-7%Z5M#4VZ"'7C)"+@F*%%J8USUC!DAL&<$J_ M=]JBK?)OPH_1(>L$Y<+P8Z8UQJD37)DRP!G6JE@GJZESK)$'UVWJL4[G,T_ MH<[X3P\@=KO[VY+2E0FM/,2J#[!+J=:9N/LGX,@ZODA8G>7.=B@]R'K^0>^& M\GN3%V??I?ZPS5CB6&*R6&E.F@2S+FQ5S]QEB93+NUZ6BIE@P 0^=[T#O2J&P&YSGNG2.QNI6T\<--*J7 MQL!(%PRG!P(6I <>1MQS6_F4^@=:KN*0Z-XK3CP-UK:=?VF 2?V\3 :JH)SL MP;#='DX:2<68HAQ%PTH3# 6[IAC3KU![5=3K0-['$2%S,K%<,88VE+(N"=.! MJZ(($X1.BC9(F.E/Z<+N(DJS)*?YT M$GY 9^&(ZJ.F #BI3KN&Z7QZJ;0[.BD]=HDH4%KI_/$>B6"E*>^:4JW TZO. M3O*$C*V7. GB?IZQHD_== URN M3S=W>+6B&84CXC:F= =H*\A)9:YFS2.2=?'NHV\*B%]N?%JY)J)U-QYQ'(CY+XP MK^.<7@.!\EU,+5AM:Z,FT[=SWE7N>;FL18V4V"^4M)LO7@JUFQ&>$X.RF*B' M*)T]E1E&G/.EVPJ*F5_@7WHO[:FA40N2ZKKKL33FR+LMB2+0ODN-5DK!;2'N MG(+=A#W* '(S%:OA!0;@Y;F48,:3#\"JS*+$'U/9]Q&SM!.]*=SZD8G:/V(F M!LL?,>O*02&) 49!>,E^ F8G7$8LDN]%JU;B@4_82_,$KY8TJ#Q/Z HI$;B( MZ04OQ7^RZZ54.W(3EN]F>7*BSR)>RMRQ<#"C\M06R6\&FJ&Z$!:=U2X&S$[C M%)_C7+,_.?$[7EOCXC[/U WL'-P.ZCZL4C6TXC6LE;5>A*HWT>M?%&V1O0[: MOFT2/'KTFF!]%B.)K-T9G0)N=P8G$ 1#6Q4Z\:5AJUI#Z3;#_?1V#^)OV23X M.O.23#6G44/MU\21%]*#ALC+T!V^#R(:9^J\ =<]8-D'T4G\+T'VJ",NWP.NFKG(RR>_A8PL%VPO> Z;SV M:!PW1URM C:A1%F,0OQ(+'L_978W4*V/=5F+B,R*/;IJ7/S;0AU(WOM:VZ7R M,^ZKD0I?^D6V6)6E7/Z:!_)?& 41_?_K3B1&OS$#N*ANNH_$DLBN<:*Z"6Q? M;WNES5;TR?;46-NO^A*;J, ^;DY1BM!V26:IW\8)BG-VDON\:)>O$Z#V^\9X8]>&I$R?F/^Y"6K]C)WOF$!R^GI,T[\(-73:$\OM$[+O7XXCN9[ M>1NL9K-/$_O-L)*!U!+O]/;?F=F_Q7Z&5_2HYSO5!]_3"ZVWQ+U^.*XE[N5M ML%KB/DWD/"#R#$;[FZK_N0K2W\\2C-MG%VWT>^+WOMIQ4?49]S8\BEX*JVU: ML)2[DHJ((BJ+ZO#<*PCG:R?V&HJ^ZG,I/N4?75O3: M+[/U*FWMM]]&"$:[7:[7*:Q"60O01,H]F795QC*\3I%FHE#RM&<,(/ M\0L.[A^('S1_Q(EWC_>Z"#WT[:^T:9I\TCTU6-6KO\1F;&!OOW%7*L@K=!"N M5K*W5&N&7D?K'[/"J/U^=;;=XSC*$L_/VFE.F4W&6:KG1^?Y^PFTX7Y!,$41KX16*OYK-/7;&30'H5O$AG@6<8LPNI@=W+K/.*5]<[2J-SWCSRSK#G//V(5' M^UP:,'_]:YJ6#/VH4\Y+3-\-JTNP9[!LV:$E_T_0J!TL0.P*ZLOJ &PO5^R& MZ)^HL]AE<:.:F'3#])K%#7!]S XSO,%?4C;QFSS6;P\ 7\6\96\5,^6BR'3H M8/5)D#Z)MG]JEE+X)90OL:]JV=*='>ZK[U&]\#7U)?H/-V7?('_;%]/6M28. M69V VE*G]\]L12J8O_X+F(U8B6LP?3?$O$:6;>ZB,2;J1"7%]45W, M]-]%&[)Q3S71BOHBK2PTQ-"B?X+T\.ROZXN6:B^G>"@,749%)"YZ#,!C?E^$E MC*P6.Z["0'"P%AT ?9%=/063[@DB^U_3=-I%HF!-$B_KM@^:4.LSA4&DY#_# MM.U+HO(^OLND$S<@"?/FOI]O\I#ZV.P+T<^(//XU1Y!'=8 M$5;OMQIA7.>^JP'Z8)R8$: %=QU512!6!NH4@HI2T->TG&_ '/TU-/Q<#$ * M:3'GN'D)\]1:,YI_AI;=#81P5S=]'%]82Q=_9LLMO@OBGZGE"RT??$SZJ>@B M.N>DO^ ^8O@Q4N7>'!R,7T;?LD/UV.EW1@#\)^B3QG\5;7^5U)'%8; F;T'0!^$&=1#N8Q&$&P,:AOT'O,I#O%Q? M9['_^]'+<>BIETB5&E:'*#WT3I.1B\/IOK48N3L62@VZ0<5TT-T+8EI@UC(9 MFM(BW8*E1-8FK91PVX02"H*AD@H==UD^"QX!1XNV']V\9+>@O MORW2-*?95I9KTF-OXHB]^"Q.CKWT01@N9ZQE@RH#3:"D,51Q3I]A./M$JA0I MEWRFBE)&J76<()]HS\I== >T&FHH$"H-(A%\^HPESIX(0P$&:4I=O4M,[(\R M,B$1V201M$81)=":&T(I&*100>/&HT:61AR4PLX=F7+F4(VJ%6>/XS23^3-J M%9MNC0GXMG>CDG?.J $@I3V-3X5 A6Z9+W,!G8++<7+3%EI=!VP^3OO[6@'A M9_KWSFU=TMU?I3F+B<(K41?5?FJM8^Z( M;1M/AW+1IY((6FLE2J UD852,+BF@B:\N;<[3E/O:9]]?$K]-+Q:$M>#QNL' MT7UQW$3:;.0*=GM.'?!N)R>3AL$1$XC"2W]3%# E%!,M1/HB]%BH@LF 2OW/ M*[PEG^J!=J8G>5(;ICZN:Z!H=1/$V)#.K$*KY9R @Z$*IQ@H9N,?RF)4E>"> M>V-W*]D_RC9X1??0Y6M6>W[7JSA>;O*Y)ME35[T(3CO:HW7Q.N#G-2?1W5G*,([KR?M?N%NQ[SSP+MC-TD;?8R6M-7+=M60Y5RK M1<%T,FI\XC7)N$LM%)9:P>XA1CNSZ1P39F.)5=7.]4F.+_!S=O.$PT?\B7@V M#[*5I_'%V>3CKD:W"3NV+&B]YHYV])E//=PRY0;ZCSS"Z/W;&2+L^PY]W>1H M_X VK SWGK"I]=2LFZ=XQV]8EP*1]#T3QW"]+.*U4KP+O\]LPIT_O1J^[O@E M8#)T%VJ"<20& A9[%AO2CV[R3>E7;$NM?86A>MN O)0A3<_R+$_PI^+]%=Q% ME&'RG;)%Y(?YBJ7?*YX(8RUW*2.ON1C>!K^/+@I("=B([^FRFC0%YFSB/ M,I3@+5$ELM1#",J"0$R51TU<@$^/>:#]NKDL:J/,K1:OT9K5^(B^QWY%'>=) MTFN)9AJVJLT\Z;(A7F'+\@LAM(T3MM%,*A'RG+1KJNP@-WNHNF9M>#'NUD3, MC91S6%\&&.=G)/ AA_09J\G@L:F.ZJ/>"A]PGI\$J4_'PRO2,91[V6,^IK 8 M,#Q7&&G,J:NX7'<\F4!\FGJ'PBS.$7SG>"CE]/--HQ?I/D_!^C;[#@'F]7N3XV5H4V=AP+O\[E\ MC%%9 J)%.*?H=7Z7XK_GI F=/I)_*-/J"$6MQM4HP'8"8 1RSCM) W!<@'@M MBI@LF(0Y/1O.-3ESY.(.V<.!5C#H'%SR' U /9/.(>79]NJ$4MV+P8J#/8OH M)O&BU//;1]#[WV-0$59I-\*X#A4'Z,.AYW#0\FMM.NE6TC@$<#BK,8\X 6FP M8O.K.+K"/@X>\8K,Z =1UJ@01Z0=8*"$M@8E0"2N.>P^=3]7NR7PF%MMTM%D M1TT.&\G'D F[R HC!BS*!].5!,,L)3QY?B'D1:LJYXBK#386/)LJ]M,Z I9W M/57?7(R+.PS&I&:HE'/ZD>5?%]QGU7Q/1Y^QM;"D("PO!>CS*L!Q.[R-J&O^ M2I8V!8]A?FJ3;^SHT]XD;*7SA;DETGLN>"E 'UH!CHMN*T6+7*\S]%F7S66? M?C"%\$ <-YRD10H;H:_+2?WV'9@OKP#'+5&RQS,TSXIU3;K81!,37'HP^I5Y MM#*K$)T.H(9A#%71+3$?L1!W'8)U6GJJRJW42@A0-* JL,$9;]: MJ$YU?2.9KU)%NO;14G540ZU 9,(6EG!.5#,",4 UHD+'98XM9SM92=9(.)B'B1R +Z_$3SAP0Q>WAG_JRZU[=#=Q(4[)VX**@T M3(0 M*-] VG?-BMW<&;K#ZSC!Z,9[=E1QO5C![@Y**VO)D9<&OJ@>!Q4 J%K'X=9F M8FBVDLK4ZN&>@ J=!1/5FPLD.^-CBL)4"WO:(!@AL.*05]7!7Y#0^7+,JLE2[9@ M7(RR3C=K>>/G/CO;E%YZ+[+H7JT2Z-J5836LR$H=E?J.*HYT'>R\1Q(_!BN\ M.GJY36E47[U"._=)%R/="S;7!E25(T!S(8W$&V+'6JI"Z%6H7]-R2-6VSZ@V M9;EPCSYY9%@/LI?E^O9-^J;:CCT*PI _M*20!5!WQA#[-:70@=7B%E%Y;\&H M%B?0!E!K.X >V.+JHMRUN,K8*UQET5BN+^(,JT9 F2R@NM-"Y"[TJ17HA)&I MP!SCSH+(B_RQ+4Z@#:C61H >V.+JHMRW.(J2_H\&3CQZ(:7>%>D-DH!F"*KS_=+W&OG V:A!>(_DGY_)O[[\,:M9V M[(MI+F^#U6U$\1LV<&I5CDU\.]BLO67DSO]01W9U! #U[F)<(D?!9#_>5=BI M($5G>H.?LZ,P]G\758=: U#]& (599/#[!Z#:IFBT$2_4EW$E)5GB?>U7E%E M5FBE9A!6E%880!V98Y3EEQ I.70RR'#9]]_B,/!?E$W)2!% ;8W#*\QT0P=^ M@5_)BD"_EO]VW-"*Y1(V2;^][BR**>ITF": 2AT)F%_ -RS!14W.?3_?Y"'- M.TKSVO@!G["8%X%2-PIDW%%$3M115W@61$&&S^D1\D5$_,I[NH5>[+VU,,XW M-$GK/SS9H?KAI0"HLPG ]ZNU*.J E86:PE!UDK=5'FH7Z#+F2W,^LB\#J.*D MT,1Q6^V#2;^25N?E88;.:9&V!ZTFDJ+82J^2;J;%*B0^)G.]>W;NBL]97B1\ MH%,1877M6"2@VIW*$CX(I2@7U07/RM5?C,JRF=/3/K10I_9KO<#%\-C>L;@@ MLOQ!1S=T^3-)_@NJ_<+:'I3?OM9+@JE%@P0E'751P2R7O9'68#5:'4VPC$W*3 N B(M1FSC/:#:[)0>RVUV$,[M 8+=2"U MQPX%FM07$P1<0UU\!G7"%!P?_BVAT+%4Y,<+Q #4@ DZZ>'?4GB&J+BK9%8M M,BS73(5<^76U Y-V/!C1.J!(#D"M&,$3 MK B*Y%TM"WI!PO(;M3+D_Q)D#[=1?)?BA,V %]$VIT$(M+@@#*ITE&1^5IZ$ M3=FRES0OU-3O %#S>S>-6W D+RH24A[OMHH$?Y1G;< MF"Y1TI>ZS6U%(QT(&KRB1_C(D,&@SI.$ABA1ZXY>&I$R>^7\R4M6Y47VG\E@ M@U?SB)U0H=$J-S']J14X49S#E<:*6'@WM! 4FR8+(UL.6/&H#0&U,-!@S;9< MB0,Q('3KGT&9H0),D7>JA$,C-NC/L^YIZP+4:Z-XD4QK$:59DA=1S'1I^^;! MB\I/I.7UUWRIZLF]Q#VDHF?@\@YV6OYNV_\Y]Q M:38 1>J)+M.F*T2RQ=!=RP)$JYU-,(S[F]4;O2\S.O;?842O_YHANO:&EI&K MWLG4?@KSYBG>A05E$:^P\OO()ZES4J"+A0PHM[2[9\%D)O 1BJ/+=!?R8>.. M.O=U/AZS(&"#EH#:]]/-V#_KN*I.D=1=J H5U'+[IW/R%_FY^HG\@SHUY)?_ M#U!+ P04 " #,@VA7,2KZB%DU !(I@, %0 &)I=FDM,C R,S Y,S!? M<')E+GAM;.U]Z7/C.++G]XW8_T%;&[$Q[T,==O55/=/[PF>-X[DLKX_NG?W2 M09.0Q%<4Z>;AX_WU"X"4Q -'@B*4D*R)F*XJ&PEF_C)Q)3(3__CWEWDT>B)I M%B;Q;^\./GQZ-R*QGP1A//WMW?WM^Z/;DXN+=Z,L]^+ BY*8_/8N3M[]^__^ M[_]M1/_WC__Q_OWH/"11\.OH-/'?7\23Y.^C*V].?AU])3%)O3Q)_S[ZW8L* M]I/D/(Q(.CI)YH\1R0G]1?GA7T<_?CC\]#!Z_Q[0[^\D#I+T_N9BV>\LSQ^S M7S]^?'Y^_A G3]YSDG[//OC)'-;A;>[E1;;L[=/+I^I_)?D_HC#^_BO[SX.7 MD1'%*\Y^?(;GS\NV%GV3'\;*MK7.,G"7S/.WF7B>SE7 MN_8S(VD+]J_WBV;OV8_>'QR^_WSPX24+WBW YPBF241NR&3$_J3:6W[U(4R> M0O(X\]*YQY3VD37X>))0HZ3<Z7@0-K;$R[67DCB?D3STO#)^9,.>VE5V% =LJ*=D1N(L?"*72::%T[PG.U*<>-GL/$J>C1CN M$%GB;>;%4Y)=Q+=YXG^?)5% I]&SOXHP?S7B5M_-D';L?Y^F21$';.JEOV)Z MU9NP@F@XWBY#*G0 0*_3<$#]AM,XG-#1&>='OD]%SND*?)U$H1\2O0U"B(?C M]2)^(EG.K>@BOO^0?;A+B9<5Z>MQ&$79T9,71MY#1,Z3]-9CWU(SWZ^W(:6A M*^,TI)\XRC+ A"]K/QQ'-R2BHS2@I=Z<>;Y?!;4<::C&X[#,5U*TLO0 M>PBC, <8J*S] MY\TNL/8$,$'6Z=/>_@#*NXK*SKH'XTQ.87D-A+$'(+6Y'L*8U-$-O3;"N!*U MM7!*.B4Y'7G9E9>RT_F3=KNE)=S0[%E]?JWIL]7'9CD'(]ZK,ZRU *B6M3I% ME@VLN&%ZM[?V@76E)+/.WT%/!@\VQJ&!1<#H[7L?3#DW[<>>=\*4#W<+*]@HS7J MQ.8)"6BZ6L(-\*@U6CWE!KC4FJN><@-<@@T5WL/0IV2@90H;6^)%:X'BUI:X MT5J:N+4E;N .!"6550^[L?'#N[#G@3=V%P#I51P_IB2CM/R&_I+^H$%"7G(2 M!R18=,2X-HG_R<.<$51A60>C]RR&JV K(/UKV;)B9L%.E/@-#B(6ZY2T HH6 M<6,\HBDC_H=I\O0Q(.%'A@[["X>)0T3_\2?_T-%#EJ=T7EOT1,_C).+]_TG; MM)I\W !7"R3N:(]BIIHMVCS5%7>4^J,D#4A*L5[TY:5^0UW=$+"JQ<=''F/T MWI^%T5+3DS29R]"ID$@DC-:!HI_8#)I']/L!X^$\\J9B.%M-@'@>8 JE 8+ MT5.2^6GX6 _AD0#;: G$]Q 57X%L&X9Y,79NR#1D_#)6EL%>ZGE!0@($_C/F M3*&4%DD#1W%<>-$->4Q2#?#-ED"\?\#$6R0;$LS_I_#2G*31*P3I3F,@V#]B M@BV1$ EO?J +&3X0P+NM@8C_A+KQD,B(!/GMC$01BWOV8I"5B]H#8?\9$W:Y MG X SX]$IW1I@6-?(P'"_XLK\'>D1=+ -4G#)*!+>@K OM,8B/H73-0E$J+B M?18'4+273<'G'WRP6^(A07T>9KX7E1R=TY]E:K@%S:&0HYPYM6*BPOXOXJ5@ MT&N-H9"C'$,U(FX8\),B31O,*&<5>6LHY"@'4)V0&\;\+,[#_)5EUUX5\X>5 MX[2)=;<5%&.40Z=,*!1L%YZ&.&=)PRI\VRVA&*.<-57"H>!\0N5)O>@B#LC+ M?Y!7%="=IE"D4%PN TD/NI0$BCW*L1(D+HH*+F(_21^3FKOXA,5&IZ\G2:":<7J=)D]A67U( MAWJ' @H]XA%5+2RJP9>+/,3:%RVA>",>5\7"8>)\G62Y%_V_\%&WDQ2WAV*. M>'!5";II!V.I=^:TD(42M9I \44YJPK%V32D3,,I\>3FVVP!!13E "H29L-X M7B;L[F.6Q$I_;+<5%%>4DZ1,J$U/O"R8.),._=JOP1%L*--J6XP-P_A'&N:4 M U;"IH@K'XWD5DS2% HORO%/*=Z&H;[EF?3B6SF5;6'(HYRUM,+BHO\1985)#7%7T % MU0+*L0\J]*;G&>(7=-I[/3A\N&,9,Y)9IM,*BC7*D4\FU(:QO4KN4H]5Q;Y] MG3\DD3P]1-@0BC#* 4\AVH9!;O AAK?5! HLRLE.* [2G'#VXO-RO_+H!7%+ M*, H)SV5<&AS[Q0T]TX-YUZ4$Y],*"1LR]AP.J+&#U$X;12#%L,L) #GV6 B MKA!UT_E[/.6G5G_[G/Y%#+ND*11PG!1)E7B;AKH(PIP$)4OG8>S%/CU2K4JV M2U#74D$5@)-#"10:Q;W_!XFB_XB3Y_B6>%D2DZ#;GVE _CJ!"744"!1[Q$5 N+ M%)^6$\9S^$1.O=RK.%3A+Z. XH]XH:@6%BU^/CVA"\\T4=^9MQI"T48,A16* MA@+R[=R+HN,B"V.2*>>65D,HR(@QKT+14$ ^FY-T2B>UKVGRG,^JW$X5V!(" M*.B(D:U*47' ?UGED9?Y;TKD!:W!U0D089<*B55V8UGH^I:_59A*4%>UA^*. MFE@I%W3#R/,RN?7]$V?F@I[;5$$/>BJH%E".JU"A<=;66B:_8R_^GA:/N?]ZG28^(>SZ)%N. M-L"!"-@!5"6(YU,C*'#L-F9"4A2GUHA 8!H&:_O&Q(]O2W^]@K?>K_MGY5U(F7 M/7 ]%=G[J><]EN9'HCQ;_&1EA]4/_EQR.9XL_?G727E44)1/KDK70[YBP5RQ0#)T6K @G20]!%I&/UU:WFSG_RI M?D9*H Y&I2-"JP=KH@2(((X,G>N4/'IAPP4B/SH2FH(!%Q@$*O+]EY8!(!3INFN.27!92FNE#7.5Y[D7L1;8JEJ_$A8 M>8MXRI^+N FG,[K?N<_*=]/DJM.0H96M-5$E2'3TL=1^RNZ*Y&Z?0LUQ.,&JW,\;H#W]%:X*^"B@:O1F]? M#4@5Z*KOH;H(7[SDJ=^D2]KCU?:%8YV )'%$,>WW<[6:D1+@U0#NJQJ-[/BZ M:1P5%HR^ZE6DH<.K)-Q;4R DT!56?ZQ8JR5A8[P"Q'U5HY#9DL?T#_;689S7 M.)5X244-\>H.&P,L$\$18S^;/Y @(,$I2<,G_O;D\MGC\:3[R^6@E8^(_CWB M%3CN.VS610]=_29[AG6V"]8<$(-ONG?@R"Q99Z^2V.^YZ:B3XM5>'D;E8'3P M!V<23^](.J\OSHKA*6R-5ZAYH &JP !?02"*]2]##Z!2""/NKZ^( '\/I:*#4]C,ZVP-=[O9@8.*^: M$"5A8[RBU'"4.]$6,IG1]5&+I];%BW5:XI6K[JL)F;3H:C@* GZUXT777AA< MQ"?>8TC7Q!J_"M\Z@!:ORG5?5<$1P5>>[Q?S(F+Q[MP%S9*E4C)C)6:?"(N& MGY/+)&.A!N/)G?>BO"4QZPBON'9OM?;#"EW'-R3WPI@$9UX:LVR@FARG9,(J ML@9>-<Y M1SK>Z&^-CO?I>:"KV?N8T-6=!/0$.P^+.37#(,QX_(O\CH@1 NBV,"\/*)G5 MR_+N]T^K[X-5L2+ 3L(;3@EM$-"WG$V?#YU[QBF7-N";L6N2\NQUJ.M+3H^= MGK?&^F8&D6,:+8L/'!7Y+$G#_UHM=SI-=NFP<_L&TZ ,$BPQII0.*DM=743A6R]RIMLB=YL5SY9\SK!?,T#$6,G!:ZA1 -P7%(D?*E3 M$F&G!PZC.&<7N0Z/NA5.2H"=23BDHAQ;VPS+=LFDZK.JN9B:V+.8%X:/:O4H MPGA2Q0TF<1D94[O 8E=78I_5#U*?U:KG43(9K?H>41Q&C=Y'K'O\&E/E+=V2 M;;W?2DJ '!1;E;\ %)52D"#[L33*D$6\RD1'GR&/YJS(XG]Q^,:3=K:^XNI< M0X?MZM(CGQC)XXBZ;BB*]/.LZM(I>2)1\LBLL))1=2.N),-V:IDJ"X0"NJYN M212Q*AC8![&(9.,I:1HE0:EQW9HF6K/#!=T-7;$,UBV\'U7:ZY7 M.W#=O91I%>T$T&"],;8?JZ<.N_)NLQ99\)K!!E+<'-N99:A)E0)"+DCJV%=?%*MB7A(-+6Z!6O@&N1 M4HBMWU9I$1]^8M!D\]K+0ARNF:HY> M0&L]K32$=DXEIV%4Y*J+:"D!>O&L]=32$AQ=,7\05IR:!$=/)/6FI'PS;SSI MW+SJYS?SGM#+=)FILB]46Z-CS3QIV UZN2X[VI7-JV8;&/J1AR0CJ%L8B<35 M#&40BF+<$7I9L$%,0P?45AO'%_@G+XS*#7PM.J?*.]/,&L8=H1<0,S.. MGD"A+PJR1'N6IAV3X)C$]"_Y=>3%V9WW KS,Z-$?>@6R'M<=O6&SE/]U0_S( MR[)P$OI5;,A]G!(O8K&H[ X@&\=+RYPD:>9%I/8FT_TCM5.2YQ&77^(B'/83 MZ'7.UE1C8@L8QR<'6,628C#[L*D,?$O#S6VP]SJP M3:6MF1:Q<7>M^1 #J3%#NW>A!D8 MP.'(H%_Q-)>VQ@[XW.,C5D*%KM#D'G9*'?%%]J*I'!)W)A:38(>%H MD[D"2$N^U%:T[3F%@IYYZ1J0LR6%\D-!*(0%*\JG[H'4V&'DFYJ7#>%T,)3V MR/=34EKC9>+%\N',6LL:8\>;;TK=:K"L77^LW.WC^)M'#2K,7\>3NM^=)4!( MKS:@Y-CQZIO2HBF@#H[:DQD]!)":Y/PYIQMVD9],BDQ^O&+44&+T\/A-&809 MFNB;L56>TRH#:O4S"H]\,P8@10^OW^!N#(SDEN>1^:PT.MV.E'_6D*I>F #5 M,P'W@1[,OT$+,L<6??KHLDSW,8]>R)XPX(9=;6:/XO*Y"IVKKF]_Z'D!J&9B M@OF.S3ZMY^1-+*M#BI[&@&I$$B2W.C13,:,VWRSMM5BUNT#/MW!CK1(CZ^!2 MQ6?'%=N0)TB-.D%/VL"U!QVZZ!8!OW4=(E3$@30/JT$B.Q#1)Q&V#$(=)H9( MV1=ZLL=P!@+ S)*+<^6#N_^0?5@\Y'4<1I',AZ6D0,^Q6 /@!"CC#IP,X"@- M,60=R,58WRQZ2+VK,WQ5>'F0&5[9%WHVQW S/ S]!T>Y=DG),C872HK9 M-Z."0UX%!I"BIV6LH9E.6"D,)W2-WI!'[[6*Q[]*^UOL)[L@(AHL_Q-(+U_L]OB\;&LJ>!%"^0NXDF2SCW@L]K0 M#J VLHFGMJ V8H@.^NYZ$41^[86!,GJOTQ"U;O^7]YCDOU]5'[!J6HE M70",RI:HR)&V80OF[M3N['8[W0S0&0>V5P"]9MI;K)9$]5009%W0\4LNZ%\5 M)R=16\=TTK H&?@U]NMWU\@** V(I3$G,9NKCEY"B"[$9-NH%K$DM7HU2$7* MFVR=)G.Z0,L5(VGNF$)4QM:N52X6J)9Q,ZD%W&5PZ/3BX8,NU11'QV!D+!TI%N$NG$+R:3@\V>1A$VQ MJP,9 2X7PY5!X?O%O.#7TK(RH=H! N\"NZ1/K\%BBA"Z3F]([K%2P(L'/'0* ME+7'+M'31UMJV=%5(_<3B';/W;;.[ @Z)['.AEGJ$-GV*S^#YR7Z/R!A?[^@ MU>#@CT,XHT!FFRQ BP2G14HE*P,A?O>B@AB7-^O1ES,[&- @[@64&Q.MA/56 M:;VC9R\-OJ;*XK4]NW-FO[..IK5P.:WL*_+,?]-3N35R9[9#ZRBS X>KRBN7 MG_[:Z]!C%R)<5WT20&S5$A3%+[/ YM_+*\3QI#4MW,>AM"A5W\ZP*PWJ5;:. M= [JK[2Q0;6XZ!*[C*!-739ALZ11;78!?^OC),G8Q?27'PY^^@1(UUBW4^RR M@C"M#@.="WI-:WPI!^O:O:(7"+2@6CEZZ+N@1A$0^6:GU0R]GA]X4R.4S\&Z M]FL%/=D/..L9;V:O'!]LE%I %7W$KN?*-8C1MUD;@)(FS) J#TISBX+J&V7A2Y9]ZT2IX%/#:[3#=([WNN0[S*XW?4?,ZCI3U M)H;_$O*+=(.:5?N%44MJ$2SR&#/+94C7O$ :U/U+>S99M=^^0;+C$\AM\<"6 MOYPR=9H4#_G10U+D7Q-6TCFA1\D4>QGK%ML;F$!@Z,EIK.647<:=8XM)M<-YZUZ4^? \^M8=OK5.6 M8W7_X?;#:-'OB'<\6O8\HN>!$>][0#_3BALS^31IJ^MW.^R#9'4>;I49=ZL49%8YV+1F( MA^V!6)&/./VHT0%2O+M8'/T@U%-B1?"+^3(:?T:=((]#J H[T?[&.#DR!'DJ MB>@1AL;0^]P>>IQL5*?#\3"UN#=9^""T2,YE*6<0?S&$&-L;!%9;V[\+1\:1 M\26LNML86S^TQQ8G&2UH4"QP\68T="S)VF.]75GG!C!FI 3(XT2MALX[DTJI M'1D/YUZ8\@#P;_S 6#IXQ0/CQ_; 8+0C3CQJ4*,8V5*0%8N C9Z:"F>XB'@" M#!H-&?+0@:BG-8! .#@RC,K@%_V9Z:?V&*I*-N$?EJ#%F5RIPM0./&*KM-$B M8] %\M@!5F#TL7_U$6N+/Y8Y2\$G), M8C()\^O($X>?'G2B21:4HXITQ&FM+'\")L%KH9)VR(MCP8=T]\-J$C?6.0#V M];M>" H[L-ZQ.#+R5T&[/'N2>B4..R$<*[)118<64%CG'E*?7T:!%Q)9YP<8 M 2DA05Z$=.H0Q# J97=D:5%&;BE#%P\[<12:T,71WQ9_0ZHJO5-1C"W&7LO_ MPN,5M?1;&ID(Q 4]RV]11^Z:I#Q_"JP_+2%V*3=CS0&A0%?9%7FNR98F,?VK M7UY9&(Y!\YZPJ[L9*[4O6.A:KMZ#:C]I!U4MD!R[5)NQ/HU@<3#_OOZ"2#.Z M5:_:5GRLCAZ[.!MS(QB4$#1IW11C(+ABFW0!78]...IW1B>;3B[\DMH>W(\/?+/=)-1]THJ%[9?&M-TN\Y72^E:FV M=J#_)%' 0=5MTHQZ<./.9KC4O1[P.3.$FQE.JD':":ONI.TA+]-O*7]O97+T M+!#FY)(N+1UVM2.WLU(9=+8#^7UK@(A^I%KPGJAX/R]RAL(\2?.J5,C9"ZOH M3TPM8YBO8#O&A[29(7%W9#&H9]:H%H).&D$COP9Y$=CN1)O5C,3X,I^_153; ME'(#D=]2M>;:P.X]:]8W@P;]8,^+,!7U%,ZI*4Z8+*6:ZSKI'I*4*>19;W=R MI^HS0!H^>9':W,?)0T;2)R;)1?Q8Y/372>Q3*JXADTN%0;^&/9VODZEG 79W;*K!SR QJSP35GD58RP",N\1>M@U5WQ,R1];C*FE8 ML09W:[ES$LN7QEN9DUX_19;AA7?>BV@GU^<(;M2A&S?%H"SV-4&S[-4<5PZ[ MLRP/YZRRWK&"_8N"/IG!HL@X'%.]U0<0PC0-;M'FWA M[*_^81!U92U=/')R2G(OC+(K+TVY)U&\L'9RWI?TH[]5/8R672"=;G?XX13) M:/\C2;^S!SN\QS#W(LF8;3?"KF)IXTT3D9R.G%=:N3Q'^0D=)J^44>XZDYN; MC@[[T&GS;1H89K:6T%6)+GZZ"N5;(E%+[!.AM?&EP,62)HY\OY@7O$8TW6Z' M?B@[6XD:8N?^6=.#')5=J":BRC:I-AK"'; MN2;E=W2S0V= 69DC$---2ACJS\#C&-":=T@TCV<#@ M UE,'9F5AP.Q+'9YZ?Z-S!](JMCW=)MB'_RA-BNJ?"T2&MU#\P?S6\:Y3A6M M9MCGRYYJ$ J+K@)A*,+MO4XE&C+T:B#]5 0" UUE:T[L1W-V\K&V?UITCUU/ M8.#3S;";HZ8.'+F8@GB U)=5G\UK9KIRA;4;3J%:E-&UEXY3[M<,N.]^87J* M>P\(,?:P-J[K!D?$D6%H5CA!Z9GM% ("%/[P&H4_,E[X8RU_[9NH_#&@.[?& M-]@UVZ5!/H/:J 4"D!K?JRKD#N KU=&YX5/06RE$64[Y*%=\W=&OJ%V+HK9; MJAB1*.A.N293)W2EGB9I=9.K.Y%":-W0E=SBE#H2BX3M46N69%H=A73JTM%A M^]K@IMA2&@P06W$;9<$ EFF4Y3S-3Q:W(6B(_0(%:.5LQ&-(I;4$[]GA(+LEZG3 MD+4#W!5VL)F9+OO+Z8BR:Z%7_$UUYEU+R8S$6?A$CQ?T\$PNJ:E>D7P\N?-> ME#X;LXZP;QMZ*;HG7#L0QM;+>Z+Q:@Y5/W4@7^>;<*A(A+PJV"YJ/"D=>D7J MSUA>M81U66,WTMZ&*Y"J!L727NBFMB<8Q]^\G.US7\>3)>.3DG&);N#DCJ2K M#:ID)I\,^!ULV MB1HVO0]'>9)[D1-'(^$"?B!>P3MEB.4K^.A@OX:CSOW=,K%7U#[NGDGT1+XE M<3[KM\*#^MWM]=\ 6J=W!UTQ_D6\].XY&' M.[XY@*#ILC5L8N-GS2^.LO%SOBY,@D?4.X^^C: M2YOEJV&3=:>0==7=B/?7JF?MRJPM$UD_4>LIL6-X91P>OS9^ PW3-NK.C6!% MJ':E<;]&,N/';TO8O=1'<.LIW=#H6M;=29C4R8P?X V34AWX;=+'F]&R4'KT M&/(Z2[I2#J*V;JC/W&@5.ANH^H*T5EP1YAZ[*2T>_YE$K*QY=GEY(@T +RNI M*6FP-Z]R&VJ6@P,(CN[_J25 \FS'["++"F'(5$4A)4 ^6D)79GD"J$C^'0AY MY!&>M0KHL+-&IV _[V94Z\>=(T9'0@-O$(069V2V.8/+@#X6X0IIC4:9S#LP M#.OO^RICXSH5O5L/_.+&Q:&^\"O98IP4*3/*:^879#[!.M22'8::9"L>[=6+ M,DG!@N M$R^^3LD\+(0^JJI\M;@U]E4N?+!J!$8?L?7IN9JZY:-0V!BHBQ^<&%D*<0?> MT V2.U3C]BJ)?:E^>$Z-I#%V93OX6%&+ZZ!^+I-X2N?A.7CCH2( ZNDG?#WI MQ7945W>5."/DA\X[ M+V*_%5HV"*KG:LCW7,H:EQF'E\TNS'J6YK6:[.$/MYAUZ,8-J-%!I+>L^ $G M#8;94[:,YQ6?EX!G5L ]N*'9-2V]6^H$*#U^* I47G;+OY1=6Y5PO5YWWB:, M$7$@A*7.E#Z(1=3:#;4.8?"=P!:1N'9"6Q:[N,7631G3(FN,?16BLJ;ZSE8M M++IKM3H'U\ZZNA*3<@KLZPN(2K1"6#[H>_'RC%L=8I36KR+ OE^ C@"]T';+ M=K:SC&^2B-).-7GD&,O>C8 MU'(3H.W0\%TB?R9>WAQ[G1I8BPT0=C/B2QUT^4/G?1R)"PT[X'*[76F,FXN8 M\E#P^MUJ-YFPL1NG)\,H%X$<^.ZM)EL ;Y:4P!V=2&Q+J1"G_%"_>VG(.+_Q M?=$;5U0P4R(U+@[\HSL-=I..<,Z5P(G8;8^VJY MZ;1@EXB([L9I#MQ%+ ,7ITC9LVXD#1-%=A*4WH$(;\6RIUPJ=*"@Z_#<"U/^ M@MY1\)]%]9[ I'K>5E5I3DV&/;3,5 ;"P)*[:/GM\>2,#NX@8"^@Q/13*_PP$.OW/R%_K7W6M\=0L>?E-R%V.B^@U"#"?I(;):PTR8S M+-SM2BH7@J3A^H(@X.+5S>+Z-VL$=LMN;F2M78AG!NY!-!+OP#7-\I#PC3_8 M0_@;/JH,_1\Z[Z:S+D:\CU&]$^Q<_:5D*V8!9??45-@NA;*RSYPO*?_/%/S47/@)]PPP$+T;[4:[$V!OA72T,(TYD:[=C- MI6O76(./-PN&=NG2E=E)$OL4UI3KZ2;,OA^_'I/8G\V]]+OZ"DU/^39,0H\# M^L5UDD"=[[?=[>.8A315 4VF.@)UANT\'$AQ!L"ANS.62\/QZ_*O M_PQ)2EF:O5Z2)Q*IET HO1MSY,;V1AHT:O=LR&JOGWF[+.O61L-N'#,"D,G+ M- R3&#L<9LG91?Q8Y!F7[D";7:,BPEY<>UFN3(ER5-R9F&L\'O;1W*$KJ5&V M-'>X!9K[W$=SGUW)LK*EN<^.::Z[EU/6[I4T1XY/L^([ZUS9*8!RI/J)ZFY M4@;EL^GE %I!E/WUP/YZ8'\]L+\>V%\/[*\'G/%Z[*\'7/%@[.SU M0/F3/.0YTP]41#IOK']/H.H5VZ5A[<) #R7Z87E_<["_.=C?'+RIFX.->#&W M[N9@[\5T=+X=RHMI%AW]R!,8;G,OS7&?HA>8^Q]A/KN/DX>,I+S,3VG%%$2Z MCZ'RE]N8!H8<_NN"#@PO4UF1G:\Y,V58M$*;>D*?BX84CH^KB]A/:5=T5US^ MN1F+E'P:^_BQ;>:IU. NV2I_Q):N&=D5@5S'#/U!9^Z+M\,N1=I"M\8A=G%_ M'N+GS*-MY)CP@VSESN+V W^N76>O)&U<9_]@?)U]N+_.=N!J7U#Z%P9^CD)Q&R* M?ZKSY:[7JQMFH3?VSA,DZPB-[;-G;.G46F^#[5X;PG % ]4Q?_S^HG1_4;J_ M*'U3%Z7[%*M]BA7JA< ^Q6J?8N5D<,)%_$3*FLKMQP!%=2R[;1U;WRQM#F9)FE5!U W]B"T;JA6;J!*'8E%PMZ;W-_>I=P:7X_#*+IE]E>9 MJ%I=.CKL0AUP4VPI#0:(K8+BDH_+=XN\1+>."KLBI;DR0&(YLF ->,_,N]E( M.$#UI3<0PV=+/3M>'%7SF-V/QC?'V,_:[6^0]S?(^QOD_0VR>V>YW;M!WB=$ M[Q.B392\3XC>)T3O$Z)=2HBVYL;>)T3O[_GW]_S[>_XWACO'VQE% MXSH-?85+I-[F#;A-NY"XH27*/'OG=_:OPIGNZ*3?-X]=5D^IUN*-G+PWJ M>!5SOE_(SEY(ZH<92.N6ONG,Z+9M1E9UYH99/NA%?(")^$A8N.L=2><'&K.T M]$UG0I1LFZ55G;EAED.-/'90.T\)J3]/OZ%)4_QI[&/LULV=*@WNEJTNAN/O M242[8TH_J'6 _ M*UJRI+\8;[?#F3C&DPDUYYP9++=KS;6VI+D;KA(Q\JTQ)I$ _X*YS5AGLM!K MX]*UBU^E=6D4<^G2A>S*@;YZ&)IM"-3N9C75]JE(+0_ZA>J*O9,DYG, BY;4 M>8755&XH"6)^4EV)Q+)S@7J;)_[W\CI)?6,J:HCMS(%83_U.32[L]IX&*G'& M19[E7AS02>&J4'O?+7P*V3>L78>'VK3KP-XE,_J#A-,9/8PGQI8%LQV$*ZPWB&(:^QS/Q.,C9NXV!YP9.P'U5K##MHVMY>PCG ]B]O>@M@JILW8(PX MF]1U^<).%';/<-_$EM88!MF^R4:0A 4>@6;^DU-F[@AV.V+R-=F;>R>+)JSZ M)M D?]X5D]3C[_JMLN11ZI]-KI71'J3>KHME2\O\!EW3< Z0/=:@>^]-ZV/K M'W?J#9C6 W"5\'(N)&BMX%]9;MVIEY-E.(\%XQZ4.VR_N5W+MZ#(W1@5:V]K MRZEB/.%-%0$4=KZ&[4N'6ZTEH,VM\$MIA3%W7+;?:MF5>;F$["(N']%RQ>W;A 2VG-M 6']7:$AM^,QMH ]NWYK[?FBWTCCTV M)_5125Z:^\7(1X7URMQV^:B.?+^8%Q';TG*[9,:=DAFU;QYI2W5%+I-,EQ-A MUHL; <6@46\F&'X&!9#?CIN\MTHO7Q-5W^GUY[3%; ML1)WV'S-,Q=T%V#NL(E]<^:\V:^A?#>&Q#YMQ:FTE2$-WIULEFU][D7JL]6\ M]?+%R'>+_<[+=OEP;_T9"8J(C"<\(?_X]23RM"Y;)9$;C@38O8Q*#GR'+.>F MX@W@=94T=T,? #MK/V,@%LI1B(3N$:VSI'T,1-#6$9WH M[$PQ8%QQ@M+]TCR).6='.D^HJ"VVHT!N29U'5V2"HA],6!V>\:2V6U7/59+F MCHP)XWE*(@[ZHPPUCK*RV*6W^DE]9ZL;-L8=N:%)I56V+U5-1;14G\N+"#VQ MI81_5UVA2]@4>S;K:7.-LET*#-!GNMTM,V@^[X&*#>(]U;XO-@@6:WN+#5KS MZ^U2L<$5:[J57M 4NJ(XH0FY&([H@OML&?_J!:/5S(UIQWR%:(E1RQ)P]$XQ MD]TKK22)@^O(BZ^\N78IL?,U-VQ!:,>FEWB]Y,?V-]P0NN2&+#V$CX+[.,RS MF]M[WB**>IYNMW!B:YM-T4XJ:J>%"KYM?W9P9 M188CP=ON]OOJ\-/!E_$\#A^*[(*_2$NW4.6E%6- N2,'TF+/6NKYQD 0FY-. MEN8UJZ?_6ED\_<>?=^PB>CRYB /*;E!XL@=R:5M)4S?LWF#:D8M2JQ&&J($_ MPGQV0R(.8#8+'^^2,VHWN?SY6I% NDZ0M2;7@5Y7.M'LS&?G29&>ABGQ*8': MGR!LB397]4&P.Y$II%]WVI+@?4=_2V" BYNB55\;!G&5_)8@OR+/9_/'*'DE M1+T\=]OAN6F&05LJ.OI)X+9XR,A?!47@[(E=8FB=-U*"K5NH=0+51K SNM%Z M9>0DCNA';6]ZW;CB*6FQIO4]BYNC^Y^U-J;6B -'C!OFQ)$?*VJ_=F0$&!TE M:NQ7MO#+1H\/_/M2XUXPZ$AH1!,O,98#A3CT O-;&(?S8JZ"L]4$.C\,7YNH MC5<'3:$P*#/ -^]%"VNS"116*^I- M11D;K+&D+78V(AAFI:SH)]#JNFTAR<(F3I(L5]U-*:FPXVM J@%)XHB2Q#>H MIM$!^*46312CEGG@?,(AYK2;K.!UZU9)A:V)K-X ^W8+/'MUI;*T)-A+RSY[ M\4F:A>UJ!*)W0WBT'0(CV._;@,T!3TNV;B*2W(OJLK"97W85(6Z+_1(,6'E* M66T.ZXPMJR08T\F75;T-XVE9DEDU N4T0+Q_0<<;)+LMW+EWJSU06_%1,OQA MM$ ]?,'7@PD6^)L]QLT->2Q2?\9X/BW2I=%HGTP T(+/IT[L L%@X.NM;YD- M_I]J;KAA96/49^+Z_GCXST&M ]=]81<#^POB\$\#RFL/5=MWP,./RS7+"?:@ MEHCOX7$',Y>FPEX1WQ4B7,!,\G+'4$_S#LD$^DWR^JX5J^H1F"1&#:=+0B5: MU&U:\E8OU_3CIW:YII)F6:&I7UTFR6*P^E#Y%47=)=9>WAQGG(\?"2M6%4\Y M.WPA'4_N,\)?))6/3 T9UM65&F'A2 (!@.FK'%C%EZ'W$$:LQ'*1,BBA.N[2 MH=V2K:UE&0;HJZZ$S:LD]GMJJTZ*=M\VG,*Z2+BJ,V--(5ZZ#:C M?SS0[!;ZOA>]F_N%2T+712+1_N(F]K0@5U1;=\\D>B+?Z!%GIG!X]>]QBW89 MZ\*VU1L0J/#_(EYZ]YRL;RK+CK9IB](3I3=A&>N;Q';M?DQQL17CY3V&N1>5 M+)\7.66_"EI=\' 1YX3BF%_$?E0$_*76\C>R2+!U>MR*_=':4O8=U@X]\;SQ M+?'PX4Y6M\3;-U$C^Q"&#Z+:A ]A9P;N9OT/PX=(;=C_@'[2%3]!^^.A[J3; M\]79W3SI-BU ]AH,_Z7L-E9H2Y">MNADVQPD0I";X5&I-1\*U[8V$#L;O: M"X/S)#V:LX&6K4Z,WR@/E'%V:AQ/&MN44)IWN$9_6S%GK2FC4S/7HN#),8G) M),Q903+8-/9#Y[FJJJ=1U=6(];6Y64T@"'B*4])B50Z?A#$):ASQ**[PH>"1 M-<>O%<^*8A8&7;@Q.P)4V"DI;HC2P/X1C!';JNT!W'7\V!ZNJVY&93_NO"W7 MEE#_RIRD&=[+E=+/8,+&;@X2U8MS(BG0 MWYNK<:6;L01-W5""PICD.K#\C-*VOPDGM0O<5]\T)=-.F&.)I%3"_%7Q$ 1M M*F[IACU#)A6I"':><-.54UPF$B^MH%4PSN@_:C4K+N+:]*K8B1KU@ER84.

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